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SUMMARY
(1) Three methods for the production of an "activated" (if-hydroxylated 
or if-hydroperoxylated) derivative of cyclophosphamide were investigated:
(i) Photooxidation of cyclophosphamide by polymer-bound Rose Bengal was 
unsuccessful. No products could be detected by high performance liquid 
chromatography and no change in alkylating activity during incubation was 
observed.
(ii) Incubation of cyclophosphamide with rat liver microsomes followed by 
deproteinisation with ethanol to produce i*-ethoxycyclophosphamide was 
partially successful. The product was purified by flash chromatography 
but was too unstable for further concentration and characterisation.
(iii) Ozonisation of cyclophosphamide produced both i*-hydroperoxycyclo- 
phosphamide and l+-ketocyclophosphamide. The latter was easily purified by 
fractional crystallisation and the former by flash chromatography. Both of 
these derivatives were used in the enzyme studies in this project.
(2) The compounds used in these enzyme studies were : cyclophosphamide,
^-hydroperoxycyclophosphamide, ¿*-ketocyclophosphamide, phosphoramide
mustard and nitrogen mustard. All cyclophosphamide derivatives were fully
characterised and checked for purity by melting point determination, nuclear
1 13magnetic resonance spectroscopy ( H and "o), infra red and mass spectro­
scopy and high performance liquid chromatography. Their behaviour in thin 
layer chromatographic systems and in a chemical assay for alkylating activity 
was also measured.
(3) The spontaneous production of the primary cyclophosphamide metabolite, 
4-hydroxycyclophosphamide from i*-hydroperoxycyclophosphamide in aqueous 
solution was demonstrated by changes in alkylating activity and thiol­
binding properties of the product.
(U ) Normal rat hepatic plasma membranes were prepared and the adenylate 
cyclase activity characterised. The effect of cyclophosphamide derivatives 
on basal (Mg^+ ions present) and glucagon and fluoride-stimulated activity 
was investigated. Only if-hydroperoxycyclopho6pharaide was found to 
produce any significant difference in enzyme activity and inhibited basal 
activity by 50% at a concentration of 5 mM. Glucagon stimulation was 
totally abolished and fluoride stimulation only partially inhibited at this 
concentration.
(5) Guanylate cyclase of normal rat hepatic cytosol was characterised and 
the effects of cyclophosphamide derivatives on its activity was 
investigated. Phosphoramide mustard was found to stimulate O0% at 30 mM 
concentration) and ^-hydroperoxycyclophosphamide to inhibit (50% at 30 mM 
concentration) the basal (Mn ion6 present) activity of the enzyme. All 
derivatives were found to inhibit the carcinogen (N-methyl-N'-nitro-N- 
nitrosoguanidine)-stimulated guanylate cyclase activity with varying 
effectiveness. Using a carcinogen concentration of kO pM, 50% inhibition 
of enzyme activity was observed with 4-hydroperoxycyclophosphamide (1.97 
mM), phosphoramide mustard 06.72 mM), l*-ketocyclophosphamide ( 17 .70  mM), 
cyclophosphamide (18.20 mM) and nitrogen mustard ( >30 mM).
(6) The possible mechanisms of action of cyclophosphamide derivatives 
on the cyclase enzymes and possible relevance of these results to 
cyclophosphamide chemotherapy and its mode of action are discussed.
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INTRODUCTION
1CHAPTER 1 
INTRODUCTION
PART 1 CYCLIC NUCLEOTIDE METABOLISM
1.1 Cyclic Nucleotides
Naturally occurring 3'»5'~cyclic nucleotides are nucleotide mono­
phosphates whose phosphate group is cyclised by esterification to the 
ribose ring at the 3' and 5' positions. They have the structure shown in 
Fig. 1.1. Cyclic AMP and cyclic GMP are purine nucleotides that are 
generally thought to influence or regulate numerous cell functions and 
biological events. Other cyclic nucleotides, such as cyclic CMP and 
cyclic IMP, have been found in extremely low concentrations but nothing is 
known of their function or importance in biological processes.
The intracellular level of the cyclic nucleotides is governed by the 
enzymes catalysing their synthesis and degradation. A cyclase enzyme, 
acting on the corresponding nucleotide 5'-triphosphate, produces the cyclic 
nucleotide and pyrophosphate. A phosphodiesterase, acting on the cyclic 
nucleotide, produces the corresponding nucleotide 5'-monophosphate 
(reaction 1).
5'-NTP ------------ > cyclic NMP ------------- > 5'-NMP (1)
CYCLASE
♦
PPi PHOSPHODIESTERASE
Fig. 1.1 The Structures of 3'^'-cyclic Nucleotides
Fig. 1.1 Continued
The main figure shows the structure of cyclic AMP; other 3* 15'— 
cyclic nucleotides differ only in their base composition (insets).
The ribose ring, of 3'i5,-cyclic nucleotides is twisted slightly 
out of a planar orientation by the cyclic phosphate ring which is in 
a "chair" conformation. The plane of the base ring structure lies at 
right angles to the approximate plane of the ribose ring.
2It follows, therefore, that the concentration of a specific cyclic 
nucleotide may be controlled by alteration in the activity of a specific 
cyclase or phosphodiesterase.
In the following account I have restricted the discussion, so far as 
possible, to mammalian systems. The effects of calcium ions on the various 
processes discussed has been described separately in Section 1.10. The 
relevance of cyclic nucleotide metabolism to cancer has been discussed 
in Section 1.11.
1.2 3',5'-cyclic AMP
Cyclic AMP is the most abundant cyclic nucleotide, intracellular 
concentrations being in the range of 0.1 to 1.0 pmoles/kg in animal tissues
(1). It was originally discovered as a component of the mammalian 
hormonal system whereby adrenaline could stimulate liver glycogenolysis.
The role of cyclic AMP in such systems is that of the well documented 
"second messenger", mediating the response of the cell to a hormonal 
"signal" (1). Cyclic AMP has many diverse effects upon different 
organisms and cell types, some of these being summarised in Table 1.1.
The mechanism of cyclic AMP action is quite well understood and involves 
the interaction of cyclic AMP with a protein kinase.
1.3 Cyclic AMP-dependent Protein Kinase
Cellular processes regulated by cyclic nucleotides originate with 
binding of the nucleotide to a specific receptor protein. These sites of 
binding in eukaryotic organisms are protein kinases. Cyclic AMP-dependent 
protein kinase (A-PK) was first discovered by Walsh e_t al. (2) in skeletal 
muscle. Studies from several laboratories indicate that A-PK consists of 
two types of subunit , a regulatory (R) subunit which binds cyclic AMP,and
TABLE 1.1 Effects of 3'.Ij'-cyclic AMP
PROCESS SITE and ACTIVITY
Membrane permeability (i) Ions (synapse, neuromuscular junction,
adrenal medulla, retina)
(ii) Water (kidney, toad bladder, skin,
antidiuretic hormone)
Steroidogenesis Corpus luteum, adrenal cortex, Leydig cells
Secretory responses Hypothalamic releasing factors, salivary 
gland, exocrine pancreas, thyroid, insulin, 
gastric HC1
Triglyceride, cholesterol Adipose tissue, liver, steroid-producing cells
ester hydrolysis
Inhibition of lipogenesis Liver, adipose tissue
Movement of intracellular Melanophore dispersion, sperm mobility, cell
structures process maintenance, (fibroblasts)
Glycogenolysis, stimul- Liver, adipose tissue, muscle
ation and inhibition
Gluconeogenesis Liver, kidney
Gene transcription Microorganisms (lac operon), enzyme induction 
in foetal liver
Protein synthesis and General inhibition of protein synthesis,
translation selective protein synthesis (adrenal cortex), 
stimulation in microorganisms (tryptophan 
synthesis)
Motility and aggregation Slime mould aggregation
Reproduced from ref. (9)
3a catalytic (C) subunit which catalyses phosphorylation of substrate 
proteins by ATP (3)» The holoenzyme (RC) is a tetraraer containing two R 
and two C subunits. The mechanism of action of cyclic AMP is that it binds 
to the R subunit and causes dissociation of the inactive holoenzyme to 
yield fully active C subunit (reaction 2).
r2c2 + 2 cyclic AMP ^  ^ R2.cyclic AMP2 + 2C (2)
INACTIVE ACTIVE
Mr = 186,000 110,000 38,000
The association constant, Ka, for cyclic AMP ranges from 0.01 to 0.08 
pM, and binding of cyclic AMP and subsequent activation of A-PK are directly 
related to the concentration of cyclic AMP (if).
There are two isoenzymes of A-PK, type I and type II, which differ 
only in the R subunit. Type I is characterised by its high affinity binding 
site and its inability to self-phosphorylate the R subunit. Mg.ATP 
decreases the affinity of the type I A-PK for cyclic AMP by 10-fold and 
increases the affinity of the type II A-PK for cyclic AMP by 6-fold. The 
biological significance of the two isoenzymes is not clear but it may be 
that the type I enzyme is involved in cell proliferation and tissue growth 
and the type II is involved in cell differentiation (5) with a possible 
role in cancer (Section 1.11).
A-PK catalyses the transfer of the y-phosphate group of ATP to serine 
and threonine residue hydroxy groups of several enzymes and structural 
proteins, thereby affecting their biological functions in a variety of 
ways but it is not known which of these are true physiological substrates
(4).
If
The initial phosphorylation of a protein molecule may only be the first 
step in a series of reactions ultimately leading to an expression of 
activity. For example, the action of cyclic AMP in glycogenolysis in liver 
occurs by a "phosphorylation cascade" involving three phosphorylations 
(Fig. 1.2). The phosphorylated active form of phosphorylase catalyses a 
reaction which results in the expression of the glycogenolytic action of 
adrenaline since it is this enzyme which catalyses the conversion of 
glycogen to glucose 1-phosphate (Fig. 1.2) (6).
The phosphorylation of phosphorylase kinase is, however, rather more 
complicated than the scheme in Fig. 1.2 suggests, and involves multisite 
phosphorylation (7). Phosphorylase kinase is composed of four subunits 
and has the structure (a0y6), ; the y subunit contains the active site of 
the enzyme and the 6 subunit contains the calcium binding site. The 0 
subunit is phosphorylated quickly by A-PK (which is necessary for 
activation) and its dephosphorylation (and hence its deactivation) is 
enhanced by the slower phosphorylation of the a subunit, which therefore 
serves a regulatory role. Dephosphorylâtion of the a subunit also occurs 
and serves to inhibit the rate of deactivation, thus in this system, A-PK 
serves the dual role of (i) activating the enzyme by phosphorylâting the 
0 subunit and (ii) determining the time that deactivation may start by the 
slower phosphorylation of the a subunit. This mechanism ensures that for 
a period of time, determined by the different kinetics of a and 0 subunit 
phosphorylation, there is no competition between A-PK and 0 subunit 
dephosphorylation, prolonging the activation of phosphorylase kinase and 
facilitating the conversion of inactive phosphorylase to active phosphory­
lase. Such enzymatic regulation by multisite phosphorylation occurs in 
vivo and may be the rule rather than the exception (8).
Fig. 1.2 Cascade Activation of Glycogenolysis
ADRENALINE
I
I
Adenylate cyclase activation 
I
ATP — ^ ^  cyclic AMP
I
A-PK.b.--2k— ^ A-PK.a. + A-PK
7  I
(RC) (C) | (R-cyclic AMP)
4Phosphorylase kinase.b. =3Phosphorylase kinase.a.
I
4Phosphorylase.b. ~~ . . . . = )  Phosphorylase.a.
I
I
Glycogen _ > Glucose 1-P
KEY
—  ■ -  > Phosphorylation reaction
----> Activation
A-PK Cyclic AMP-dependent protein kinase
R Regulatory subunit
C Catalytic subunit
.a. Active form
.b. Inactive form
5Not all reactions of A-PK are of an "activating" nature, and it should 
be noted that the action of A-PK on glycogen synthetase serves to de­
activate this particular enzyme. This has been noted in view of the 
previous discussion of A-PK and glycogenolysis. It can be seen that A-PK, 
in this case, serves two functions, (i) it activates glycogenolytic enzymes 
and (ii) it deactivates the glycogen synthesising enzyme.
This system may at first sight seem to be extremely unselective. A 
rise in intracellular cyclic AMP concentration leads to an activation of 
A-PK which then acts by phosphorylating several types of proteins with 
various effects. However, selectivity may be exhibited by the presence or 
absence of such proteins. This would be governed by the control of 
expression of the genes for these proteins. Hence, the cellular response 
to a rise in cyclic AMP levels would depend upon the particular cell, its 
stage in the cell cycle and other effects influencing gene expression such 
as induction or repression.
Another degree of selectivity is achieved at the hormonal level by the 
receptor component of the adenylate cyclase system.
1 .It Adenylate Cyclase 
(i) Structure
Adenylate cyclase catalyses the conversion of ATP to cyclic AMP and 
pyrophosphate (1). It is a membrane-bound enzyme whose activity is 
controlled by a number of regulatory sites (Fig. 1.3) (10). The protein 
constituents, structured within the lipid framework of the cell membrane, 
are of at least three types. At the outer membrane is the receptor 
component (S) which contains a specific binding site. At the inner 
membrane surface are the catalytic (C) and the nucleotide regulatory (N)
Fig. 1.3 The Structure of Adenylate Cyclase
OUTER
SURFACE
COMPONENTS
INNER
SURFACE
COMPONENTS
Peptide hormones Catecholamines ( a-adrenergic)
Catecholamines ( p-adrenergic) Adenosine ( R site)
Other biogenic amines Opiates
+
PPi
Redrawn from ref. (10)
6components (11). The latter contains a GTP binding site and is 
responsible for mediating the effects of hormones and GTP on the activity 
of C. Much of the work on adenylate cyclase has involved investigations 
of target analysis (12) where high energy radiation is used to produce 
ionisation of the target molecule. The energy imparted is so high (1500 
kcal/mol) that a single "hit" anywhere in a protein molecule destroys its 
function. The analysis of the radiation inactivation curves (exposure vs. 
log. activity/original activity) leads to a value for the size of the 
"functional unit" under investigation (13)* The usefulness of such a 
method is that the measured "functional unit" may be the catalytic unit
(C) if this activity alone is measured, or the entire cyclase complex if 
cyclase activity is measured in the presence of hormone and GTP. Thus 
values for the size of various subunits may be calculated. For such 
studies the enzyme is preincubated with the appropriate ligand(s). The 
"ground state" target sizes are measured by irradiating the enzyme sizes 
obtained are presumed to represent precursor forms antecedent to those 
obtained after preincubation of the enzyme system (10).
Using this method, Schlegel at al. (12) have investigated the 
adenylate cyclase system of hepatic plasma membranes. One of their major 
conclusions was that the adenylate cyclase system increases in molecular 
size with increasing complexity of regulation, Table 1.2. This was taken 
to indicate the binding of regulatory proteins (R and N) to the enzyme
(C). Furthermore, the large target sizes discovered from ground state and 
hormone-binding studies (Table 1.2) indicated that multimeric complexes 
probably exist of the R and N components and that these break down to 
smaller units in the process of combining with the C subunit. Rodbell
(1 1 ) has postulated the possible structure of such multimeric components, 
Fig. 1.1«. It is possible that such structuring of the cyclase system is
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Fig. 1.<♦ A model for the coupling of the receptor-nucleotide regulatory
units (RN) to the catalytic unit (C) of adenylate cyclase and the 
role of hormone and GTP in this process. Redrawn from 
ref. (1 1).
GTP
iSL
R - receptor protein 
N - nucleotide binding protein 
C - catalytic unit
H - hormone or agonist
7necessary for the activity of the catalytic units when Mn.ATP is used 
as a substrate. That such structures are needed for further coupling to 
the C component may explain the effects of other effectors such as 
membrane lipids (14). Such oligomers of the RN components can be used to 
explain the kinetics observed with adenylate cyclase systems. In Fig. 1.4 
the GTP-binding site is drawn to indicate that binding of GTP cannot occur 
until binding of the hormone has occurred. Differences in the number of 
active RN "monomers" compared with the catalytic until could explain the 
effects observed for glucagon binding and the degree of activation by 
hormone (15)*
The proposed functional units, R, N and C have since been isolated 
by Citri and Schramm and reconstituted in their work on the action of a 
hormone receptor (16).
(ii) Hormonal Interactions - The R Component
A large number of hormones and neurotransraitters activate adenylate 
cyclase in the course of eliciting their physiological response (Table 
1.3). For each of these effectors, there exists a specific receptor 
(R component) containing a binding site for the hormone in question (1) 
(10). Cells may contain one or many such receptors on their surface.
Using the information of Kaslow e£ al. (19) that the N peptide has 
a molecular weight of 42,000, the results of Schlegel et al. (12) Table
1.2  suggest that the hepatic glucagon receptor has the corresponding 
molecular weight of 60,000. Their radiation inactivation data (19) 
suggest the Mr = 120,000 and they therefore conclude that this is due to 
the activity of a larger "functional unit" ((RNC^) which is measured and 
corresponds to two R components (Table 1.2). These results are in­
compatible with the previously reported data of Houslay ejt al. (31).
T A B U  1.3 Selected examples of hormone-cyclase interactions
STIMULATORY HORMONES INHIBITORY HORMONES
Adrenaline a-Adrenergic agonists (i)
Nor-adrenaline Cholinergic agents (i)
Glucagon (liver) Opiates (i)
Adrenocorticotrophic hormone Adenosine (adipocytes)
Leutenising hormone ADP (platelets)
Thyroid stimulating hormone Prostaglandins PGE^ PGE^ (adipocytes)
Parathormone Nicotinic acid (adipocytes)
Vasopressin Dopamine (adenoma)
Calcitonin (kidney) Angiotensin II (liver)
(i) Demonstrated with neuroblastoma x glioma hybrid cells
8Various physical factors in the sample preparation, however, were 
different. Dried samples were used instead of frozen and a rather low 
activity C32P] ATP used as substrate. Although they reported that the 
target size of the glucagon receptor plus that of the cyclase measured in 
the presence of sodium fluoride added up to the total measured glucagon- 
stimulated unit, no analysis of the contribution of the N unit could have 
been included. No mention was made of "ground state target sizes" 
considered by Schlegel et_ al. (12) to be critically important. From their 
data a value of i* 1,000 may be calculated for the molecular weight of the 
receptor component.
Other systems have also been studied in a similar way, notably, the 
turkey erythrocyte adenylate cyclase which is different from the liver 
enzyme basically due to the N component. In this system, the hormone 
receptor has been calculated to have a molecular weight of approximately 
90,000.
(iii) The Regulatory N Component
The regulatory component of the adenylate cyclase system (termed the 
N, G/F or G component) mediates the effects of hormone receptors, GTP, or 
its various analogues, F ions and cholera toxin on the catalytic 
component.
To explain the stimulatory and inhibitory effects of hormones,
Rodbell has postulated the existence of not only different R components but 
also different N units. Ns units which couple with Rs components of 
stimulatory hormones and Ni units which interact with Ri components of 
inhibitory hormones (1 1), both acting through the same catalytic component.
Work on elucidating the mechanisms involved in cyclase stimulation 
and inhibition has been aided by the ability to isolate and manipulate 
such components by detergent extraction from cell membranes (16) (17)
9and the isolation of various murine lymphoma i&9 variants. The Sk^ variant
which can be selected because cyclic AMP produced within wild-type Sk9  
cells in response to catecholamine or prostaglandin PGE1 is cytocidal, 
lack the N component completely (19)- Other S49 mutants have been utilised; 
unc cells have N units but these fail to interact with R units, and these 
N units have been shown to have different physical characteristics (20). 
fd Cells have normal N and C units but only 10 to 20% of the R units relative 
to wild-type cells (2 1).
Reconstruction experiments by Kaslow et_ al. (19) using the eye mutant 
and several other cell types, revealed that a complete cyclase system 
(R, N and C) took on the characteristics of the cyclase system from which 
the N component originated. Citri and Schramm (16) using similar methods 
and turkey erythrocyte and eye membrane extracts, found that in the 
presence of hormone all the R components were in the RN complex form. This 
is in agreement with the mechanism shown in Fig. 1.i», which postulates 
that the hormone-RN interaction reveals the GTP binding site of the N 
component.
The observation that GTP was required for hormonal activation of 
adenylate cyclase and that the non-hydrolysable analogue Gpp(NH)p gave
clone, eye , is deficient in adenylate cyclase activity (18). Cyc cells,
Gpp(NH)p
OH OH OH
9and the isolation of various murine lymphoma S49 variants. The S49 variant 
clone, eye , is deficient in adenylate cyclase activity (18). Cyc cells, 
which can be selected because cyclic AMP produced within wild-type S49 
cells in response to catecholamine or prostaglandin PGE^ is cytocidal, 
lack the N component completely (19)» Other S49 mutants have been utilised; 
unc cells have N units but these fail to interact with R units, and these 
N units have been shown to have different physical characteristics (20). 
pd Cells have normal N and C units but only 10 to 20# of the R units relative 
to wild-type cells (2 1).
Reconstruction experiments by Kaslow et al. (19) using the eye mutant 
and several other cell types, revealed that a complete cyclase system 
(R, N and C) took on the characteristics of the cyclase system from which 
the N component originated. Citri and Schramm (16) using similar methods 
and turkey erythrocyte and cyc membrane extracts, found that in the 
presence of hormone all the R components were in the RN complex form. This 
is in agreement with the mechanism shown in Fig. 1.4, which postulates 
that the hormone-RN interaction reveals the GTP binding site of the N 
component.
The observation that GTP was required for hormonal activation of 
adenylate cyclase and that the non-hydrolysable analogue Gpp(NH)p gave
P -------OH GppffflOp
OH OH OH
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consistent activation (22) led to the idea that a GTPase activity was to 
be found in the adenylate cyclase system. Furthermore, using a system 
designed to measure the hydrolysis of GTP, under conditions which minimised 
the "background" hydrolytic activity found to be present in the turkey 
erythrocyte membranes used, it was found that catecholamines interacting 
with the f}-adrenergic receptor increased this activity (23). It was also 
discovered that the hormone, upon binding, causes release of bound GDP
GTPyS was found to be an analogue which would stimulate adenylate 
cyclase activity consistently, would not be released by hormone binding 
to its receptor and, therefore, inhibited the GTPase activity of the 
enzyme system. From these results the regulatory role of both hormone 
and GTP were understood (Fig. 1.5). The hormone stimulates the enzyme by 
facilitating the release of GDP. Binding of GTP then activates the cyclase 
and the GTPase reaction results in the formation of inactive enzyme with 
tightly bound GDP.
The discovery that the stimulatory action of cholera toxin on 
adenylate cyclase was by inhibition of the GTPase reaction (25) led to the 
selective labeling of the N component by using cholera toxin and [^P]NAD 
( 26 ) .
Cells deficient in N by functional criteria were also found to lack
(or GppiNH)^) (24).
OH OH OH
the toxin labelled protein. In avian erythrocytes N is a heat stable
Fig. 1.5 The Regulatory GTPase Cycle
GDP Pi
ACTIVATION - DEACTIVATION BY GTP AND HORMONE
(a) Hormone binding facilitates the release of GDP allowing GTP binding 
to activate the enzyme.
(b) GTPase reaction inactivates the enzyme. GDP is tightly bound.
Cholera toxin stimulates adenylate cyclase activity by its inhibition 
at this stage.
EFFECT OF GTP ANALOGUES
(c) Gpp(NH)p replaces GTP in stimulating the enzyme. It is not 
hydrolysable so stimulation is consistent, however
(d) hormone can facilitate its release (2**).
(e) GTPyS activates the cyclase system. It is not hydrolysable and 
cannot be released by hormone action.
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protein of Mr = 42,000 (19)- Addition of detergent extracts containing N 
to membranes from cells genetically deficient in N (eye ) reconstitutes 
the ability of hormones, guanine nucleotides,F” ions and cholera toxin to 
activate the cyclase (1 1).
Although the N peptide of Mr = 42,000 has been identified in avian 
erythrocytes, it also exists as an oligomer of Mr = 126,000 (26). Cholera 
toxin has been found to ADP-ribosylate other peptides in membranes of other 
cells including S49 mouse lymphoma (19) and rabbit liver (27). Three 
major proteins have been observed with molecular weights of 45*000« 35*000 
and 52,000, in purified extracts of the N protein but the protein of 35,000 
Mr has not been observed to be labelled by cholera toxin and [^P]NAD
(27). Neither the 35,000 nor the 52,000 proteins appear to be necessary 
for measured activities of N but may be related to each other in that N 
may exist as complexes of different subunit composition with different 
functional properties (27). It has been noted, however, that in the A9 
mouse and 380-6 hamster transformed lung fibroblasts, cholera toxin and 
[^PjNAD labels an Mr = 52,000 peptide but not an Mr = 42,000 one (28).
The 52,000 peptide appears to be the functionally active form of the 
N component in such cells.
(iv) Adenylate Cyclase Reaction Sequence
Fig. 1.6 shows the reaction sequence of adenylate cyclase, and 
summarises much that has already been discussed. Structure I represents 
the cyclase components as they might appear when isolated after EDTA 
pretreatment or as they actually exist in isolated S49 membranes structure. 
It shows the effect of Mg^+ ions, which would presumably be the "natural 
state", with N tightly bound to C. Under such conditions the catalytic 
unit is active. Such activity represents the "basal activity" of the 
enzyme, although the C component can act alone, on the unnatural sub-
Fig. 1.6 Reaction Sequences for Adenylate Cyclase
Modified from ref. (21)
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strate, Mn.ATP. Structures III to V represent the GTPase cycle which 
occurs in the presence of GTP and agonist. Structure IV is the active 
unit. In structure V, GDP inhibits the cyclase but is released by agonist 
binding to R, returning to structure III. Structure VI shows the complex 
formed in the presence of F ions. Similar complexes exist with guanine 
nucleotides and analogues.
1.5 Cyclic AMP - Phosphodiesterase
Cyclic nucleotide phosphodiesterases (PDE) catalyse the irreversible 
hydrolysis of the 3'-bond of cyclic nucleotides to produce the non-cyclic 
nucleotide monophosphate. The action of PDE is the only catabolic process 
known for the cyclic nucleotides. PDE is not only responsible for "quenching" 
a cyclic nucleotide "signal" but also constitutes a potential mechanism for 
modulating the intracellular levels of cyclic nucleotides. Some confusion 
may arise when discussing PDE's because of the highly heterogeneous 
nature of these enzymes. The individual enzymes differ with respect to 
tissue distribution, subcellular location, physico-chemical properties, 
substrate specificities, kinetic characteristics and susceptibility to 
activators and inhibitors. However, on DEAE-cellulose ion exchange 
chromatography, three PDE's are resolved. Fraction I is predominantly 
active with cyclic GMP and fraction II has a relatively low affinity for 
both cyclic AMP and cyclic GMP. Fraction III has a predominant action on 
cyclic AMP and may therefore be termed cyclic AMP-phosphodiesterase 
(A-PDE).
Most tissues seem to have two forms of A-PDE with different 
affinities for cyclic AMP. However, since this conclusion is based on the 
non-linearity of Lineweaver-Burk plots, it could also demonstrate one 
enzyme exhibiting negative cooperativity (32).
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In human lung, A-PDE exhibits a Km for cyclic AMP of 0.5 pM and 
demonstrates negative cooperativity effects. It is predominantly membrane 
bound and probably corresponds to the Mr = 200,000 protein isolated by 
agarose gel filtration (32). Multiple forms of A-PDE have been shown to 
exist (33) and four active forms have been found in Walker carcinoma cell 
lines of apparent molecular weights of 10 ,^ U30,000, 350,000 and 225,000
(35)* These forms are apparently interconvertible and are composed of 
subunits of Mr = 15,000. A-PDE isolated from monocytes and lymphocytes 
is thought to be prototypical (35)« The lymphocyte enzyme demonstrates 
an extremely high substrate affinity (Km = 0.2 pM) but can be resolved into 
two species, one with a molecular weight of ¿»5,000 daltons (3*6 S) and 
the other of 98,000 daltons (6.0 S) which may be a dimer of the first. The 
monocyte enzyme is monomeric and is identical to the lymphocyte lower 
molecular weight enzyme, of lower affinity (Km = 0.5 pM).
Interestingly, physical manipulation of lymphocytes and "ageing" by 
storage of the homogenate causes the lymphocyte enzyme to convert to the 
lower affinity, lower molecular weight enzyme form identical to the 
monocyte enzyme (32).
It has been shown that many hormones can effect A-PDE activity and 
thus alter the level of cyclic AMP (32). The effects of insulin have been 
studied most but the biological significance of its actions on A-PDE is 
not known. It has been shown to increase the Vmax of A-PDE without 
affecting the high affinity particulate form of the enzyme (36). Since 
cycloheximide has no effect on this stimulation, it must be concluded that 
protein synthesis is not required (37)* Cyclic AMP itself and dibutyryl- 
cyclic AMP were found to mimic the effect of glucagon, activating A-PDE. 
Thus, it seemed, cyclic AMP was acting as a mediator for this hormone.
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Over a longer period of time, it was found that noradrenaline and 
dibutyryl-cyclic AMP induced low Km and high Km A-PDE of C-6 glioma cells 
(38). For this to occur, both protein synthesis and RNA production were shown 
to be necessary.
PDE activity has also been shown to be dependent upon the redox state 
of the cell. Since it is inhibited with consequent reduction in Vmax, by 
NADH (39) and is therefore dependent upon the nutritional state and 
hormonal control of the cell.
1.6 3*,3'-Cyclic GMP
The intracellular levels of cyclic GMP are in general ten times 
lower than the level of cyclic AMP, and range from 0.01 to 1.0 pmoles/kg 
in animal tissue (40). The biological role of this cyclic nucleotide is 
still poorly understood, most information on the subject being restricted 
to the knowledge that some physiological compounds can effect its 
concentration. It has become increasingly clear, however, that a similar 
system to that regulating the levels and effects of cyclic AMP also exists 
for cyclic GMP.
1.7 Cyclic GMP-dependent Protein Kinase
A class of protein kinases has been found in mammalian tissues which 
are preferentially activated by cyclic GMP (41). These cyclic GMP- 
dependent protein kinases (G-PK) have been found in lung (42), cerebellum 
(43)i and femoral artery (44), and these tissues have also been shown to 
contain high cyclic GMP levels (4). In contrast to A-PK, G-PK is a 
predominantly soluble enzyme. The Ka for cyclic GMP is 0.01 to 0.12 pM 
which is similar to that of A-PK for cyclic AMP, and ATP is the phosphoryl
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donor. Unlike A-PK, dissociation of the enzyme complex does not seem to 
be necessary for activation (reaction 3).
R2°2 + 2 cyclic GMP ^  — > R^.cyclic GMP2 (3)
INACTIVE ACTIVE
Mr = 165,000 165,000
Evidence to show that subunit structure exists comes from SDS-poly- 
acrylamide gel electrophoresis, where, in the presence of a reducing agent 
the Mr = 165,000 holoenzyme can be resolved into a polypeptide of Mr =
74,000 to 81,000 (45). This suggests that the holoenzyme is a dimer of 
identical subunits, each of which can bind a molecule of cyclic GMP. Like 
A-PK, G-PK is self-phosphorylating and such activity appears to inhibit 
the enzyme, A-PK is also capable of inhibiting G-PK by this mechanism. 
Arginine residues are also necessary for inhibiting G-PK activity : 
activation of G-PK can be achieved by the action of either 2,3-butanedione 
(an arginine blocking agent), or trypsin (hydrolysing at the arginine 
site), in the presence of mercaptoethanol which yields active monomers 
(46).
A-PK and G-PK appear to be very similar enzymes with respect to 
physical characteristics, cyclic nucleotide binding, ATP binding, amino- 
acid composition (70 to 90% homology), self-phosphorylation and substrate 
protein specificity. Two major differences are their relative activities 
and the existence of different modulator proteins for each.
Although G-PK is capable of phosphorylating most of the proteins 
regarded as substrates for A-PK (Section 1.3) its activity is much lower. 
The only proteins to be phosphorylated to any comparable degree are
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histones (47)* A-PK phosphorylates serine residues 32 and 36 of histone 
protein H2B, whereas G-PK preferentially phosphorylates serine residue 
32 (47).
In mammalian tissues there are two separate modulator proteins of PK 
activity; inhibitory modulator of A-PK and stimulatory modulator of G-PK
(4). The activities of these modulators is different in various tissues 
and represents a way of controlling the specificity of A-PK and G-PK.
The stimulatory modulator of G-PK acts by reacting with substrate histone 
molecules, rather than on G-PK directly, rendering them a better substrate. 
This modulator is also required for G-PK maximal phosphorylation of 
ribosomal proteins and appears to operate through polyanionic interactions 
rendering the substrate a better phosphate acceptor. Other polyanions 
such as DNA, polydeoxyribonucleotides, polyglutamate and heparin are 
also capable of stimulating G-PK phosphorylation of histones (47).
1.8 Guanylate Cyclase
(i) Guanylate cyclase catalyses the conversion of GTP to cyclic GMP and 
pyrophosphate in the presence of a divalent metal ion (48). It is widely 
distributed throughout mammalian tissues and can be distinguished from 
adenylate cyclase by its subcellular distribution, substrate specificity, 
cation requirements and its response to activating agents and detergents.
(ii) Subcellular Distribution
Guanylate cyclase is found in both the particulate and soluble 
fractions of cells. The relative activities of these forms of the enzyme 
varies with the tissue and species used. In rat lung, spleen and liver 
80 to 90£ of the total guanylate cyclase activity is found in the soluble 
fraction, whereas adenylate cyclase is predominantly particulate (48).
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Treatment with non-ionic detergents increases the enzyme activity in both 
particulate (3 to 10-fold) and soluble (1.5 to 2-fold) fractions (t+9). In 
mouse intestinal mucosa, the activity is predominantly particulate, 
approximately 90% of the total after treatment with detergents (<f0).
While in liver, particulate activity is only 20% of the total (1*9 ).
Several subcellular membrane fractions have been associated with guanylate 
cyclase activity including Golgi, endoplasmic reticulum and other 
organelles (50) (51). The soluble and particulate forms seem to represent 
different structures, this view being supported by the difference in 
properties between the two (52), Table 1.<*. These results could be 
explained by the existence of multiple forms of the enzyme (ie. different 
proteins or components) or a different distribution of factors affecting 
these properties (52). Garbers has shown that antibody prepared against 
particulate guanylate cyclase from sea urchin sperm inhibited mammalian 
particulate guanylate cyclase but had no effect on the soluble form (53)» 
This apparent demonstration of antigenically distinct forms has been 
refuted. Zwiller et^  al. (5M have demonstrated an antigenic similarity 
between particulate and soluble forms of rat brain guanylate cyclase. 
Furthermore, immunological studies suggest that the soluble guanylate 
cyclase is derived from the membrane-bound enzyme (55)» Goldberg and 
Haddox (56) have suggested the possibility of the soluble form of the 
enzyme being the result of an artifactual release of guanylate cyclase 
from the particulate fraction into the cytosol during sample preparation,
(iii) Guanylate Cyclase Activity
Guanylate cyclase is most active when Mn.GTP is used as substrate, 
whereas Mg.GTP and Ca.GTP result in less than 10% of the observed Mn^+- 
stimulated activity (<»8). Mg.GTP, however, must be regarded as the
TABLE 1.4 Some properties of soluble and particulate guanylate cyclase
from rat heart, lung and liver
PROPERTY SOLUBLE PARTICULATE
Apparent molecular weight ca. 150,000 ca. 300,000
Km for GTP 12 to 65 pM 50 to 100 pM
(sigmoidal kinetics)
Metal-nucleotide sites 1 2 or more
Ka for free Mn2+ ca. 0.2 mM ca. 0.2 mM
Activity with Mg2+ ca. 10% of Mn2+ ca. 10% of Mn2+
Effect of Ca2+ generally stimulates generally inhibits
Effect of detergents stimulates J>0 to 100% stimulates 300%
50# inhibition by ATP ca. O.L mM 1 mM
Cyclic AMP formation not detectable not detectable
50% inhibition by p-
chloromercuriphenyl 10 to 100 nM 1000 to 10000 nM
Reproduced from ref. (52)
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natural substrate due to the usually low intracellular concentration of 
Mn^+ ions (56). Copper has been found to inhibit plasma membrane 
guanylate cyclase activity in rat liver (57)1 while other divalent cations 
such as cadmium, zinc and mercury also inhibit the particulate enzyme 
(1*8), their effects being reversed by either of the thiol compounds 
glutathione or dithiothreitol (DTT).
There are a number of cellular metabolites which have been found to 
be inhibitory to guanylate cyclase. These include phosphoenolpyruvate, 
oxaloacetate, ATP, ADP, ITP, dGTP (48), AMP (58), and pyrophosphate (56). 
The intracellular concentration of these compounds is probably too low 
to have any physiological significance with regard to guanylate cyclase 
activity, with the possible exception of ATP. As well as inhibition, 
however, it has been noted that in rat renal cortex, ATP increased the 
activity of particulate guanylate cyclase but had no effect on the soluble 
form. It is possible that metal ions may act by chelating such inhibitors 
as well as by acting as a substrate/cofactor and binding to a separate 
activating site on the enzyme (50).
The importance of -SH groups for the activity of guanylate cyclase 
has been demonstrated. Inhibition of the rat liver enzyme by p-chloro- 
mercuriphenyl suphate is reversed by DTT (61). Furthermore, the 
inhibition of guanylate cyclase by arsenite which can be potentiated by 
equimolar concentrations of 2,3-dimercaptopropanol but completely reversed 
by its excess has been considered evidence for the existence of juxtaposed 
-SH groups on the enzyme (70).
Table 1.lf lists some properties of guanylate cyclase. In general, 
the soluble form has been shown to be of lower molecular weight (150,000 to
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1*50,000) compared to the particulate cyclase (300,000 to 600,000) and 
to express a higher affinity for substrate.
(iv) Hormonal Effects
Hardman and Sutherland showed that glucagon, insulin and adrenaline 
had no effect on guanylate cyclase activity (1*8) although there have been 
some reports of stimulation by insulin which have not, however, been 
corroborated (52). The action of acetylcholine and the a-adrenergic 
effects of noradrenaline increase cyclic GMP levels and may stimulate 
guanylate cyclase, but only in the presence of calcium ions (52), and 
may not, therefore, be a direct stimulation of the enzyme. Liang and 
Sacktor found that several catecholamines in low concentration activated 
guanylate cyclase and that neither a nor (3 blockers prevented this 
effect (63)« Although some neurotransmitters (noradrenaline, acetyl­
choline, histamine and glutamic acid) are capable of causing the release 
of cyclic GMP at nerve terminals, the distribution of guanylate cyclase 
does not parallel the distribution of nerve terminals using these trans­
mitters (62). There have been reports of other hormone activators of 
guanylate cyclase, such as secretin and pancreozymin and inhibitors such 
as the catecholamines adrenaline and noradrenaline (61) ( ( A) but these 
early reports are largely uncorroborated and have been considered to have 
probably resulted from (i) nonenzymic formation of cyclic GMP (65) (ii) 
contaminants in preparations (66) and/or (iii) alterations in the redox 
state of incubations and free radical formation (52).
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(v) Non-physiological Activators
Although guanylate cyclase does not seem to be activated by any 
hormones, there is a wide variety of nonhormonal (and non-physiological) 
compounds capable of stimulating the enzyme. These include certain lipids 
hydrogen peroxide, various oxidising agents and nucleophilic nitrogen 
compounds. Recent evidence suggests that although the precise mechanism 
of this stimulation is unknown, cellular processes involving alterations 
in the redox state of the cell and the formation of free radicals may be 
the general mechanism by which such stimulation can be modulated.
Soluble guanylate cyclase undergoes spontaneous, time-dependent 
"auto-activation", apparently involving an oxidation, in that oxygen is a 
requirement and thiol compounds completely block this process (67) led to 
the idea that hydroxyl radicals may be involved in this process, an idea 
which will be returned to later.
(vi) Activation By Nucleophilic Nitrogen Compounds
Sodium azide has been shown to activate guanylate cyclase in some 
tissues but not in others (52) (68). Mixing of responsive and non- 
responsive tissues revealed the need for a protein "activating factor" 
in unresponsive tissues (which was present in responsive tissues) and 
also that certain inhibitors should be absent for sodium azide to be 
active (52) (68). This explained the previously reported time lag and 
protein dependency of activation (68). Purification of the activator 
protein from rat liver by DEAE-cellulose chromatography revealed a heat- 
labile, protease and a-chymotrypsin-inactivated protein which co­
chromatographed with, and could be replaced by, the enzyme catalase (69). 
Peroxidase, cytochrome b^ and cytochrome c reductase can also substitute 
for the activating factor. The inhibitory compounds present in some
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tissue preparations were purified from rat heart and lung and identified 
as haemoglobin and myoglobin (52).
The effect of catalase and other activator proteins on sodium azide 
results in the production of nitric oxide which is a potent activator of 
guanylate cyclase (?1). It is apparent that the effects of other nitrogen 
containing activators are mediated through the production of nitric oxide. 
Activation by azide, hydroxylamine and possibly some others is enzymatic, 
as described, and requires the presence of hydrogen peroxide or oxygen.
The formation of nitric oxide from several other activators is 
spontaneous under the appropriate conditions and does not, therefore, 
require the activator protein. Nitrite, nitroglycerin, nitroprusside, 
nitrosamines and nitrosoureas are all capable of activating guanylate 
cyclase (52), an activation which is inhibited by haemoglobin and myoglobin. 
Some nitroso compounds such as diraethyl-nitrosamine, N-nitrosopiperidine 
have been found to give rise to nitric oxide and N-methyl-N-nitrosourea, 
only on photoirradiation a process which accelerates its spontaneous 
release from other nitroso compounds, including MNNG (N-methyl-N'-niiro- 
N-nitrosoguanidine) (72) a potent guanylate cyclase activator (73)*
DeRubertis and Craven (73) showed that MNNG is the most potent of 
the nitroso compound activators, increasing basal Mn2+ levels by 36-fold 
at 1 mM concentration.
Using electron spin resonance techniques, Nagata £t^  al. (72) 
demonstrated the production of free radicals by MNNG and found that the 
radicals produced in liver cytosol were different from those produced in 
solution unless sulphydryl compounds and ferrous (iron (II)) chloride 
were included in the solution. Under the latter conditions, Nagata ¿st 
al. concluded that an iron-nitric oxide-thiol complex was formed with an 
unpaired electron mainly localised on the iron moiety, giving rise to the
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free radical electron spin resonance signal observed. In liver cytosol 
incubated with MNNG, similar radicals were observed, presumably similar 
in structure, and iron-nitric oxide-thiol protein complexes were suggested. 
Considering the importance of thiol groups to guanylate cyclase activity 
it is perhaps not difficult to envisage an iron-nitric oxide-cyclase 
complex being involved in cyclase activation. This idea is supported by 
the observation that ferrous chloride enhances the activity of guanylate 
cyclase activated by sodium azide (69).
Although heat-treated liver supernatant and MNNG gave rise to free 
radical formation, the enzymes xanthine oxidase and diaphorase were found 
to give rise to free radicals without the need of ferrous chloride (72). 
Other thiol-containing enzymes including urease, aldolase and alcohol 
dehydrogenase gave no radical formation.
The iron-nitric oxide-thiol protein complexes formed may be similar, 
or at least analogous, to the iron-nitric oxide complexes observed with 
amino acids, imidazole ( 7 k ) hydroxy groups, phosphates and cysteine (75)»
A proposed structure is:
OH
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(vii) Activation By Hydroxyl Radical
An alternative pathway for guanylate cyclase activation is suggested 
by the observation that superoxide dismutase activates the enzyme in the 
absence of sodium azide (7b). Catalase, inhibitors of superoxide disrautase, 
such as cyanide ions or thiols, and hydroxyl radical scavengers such as 
catecholamines, hydroquinone or butylated hydroxyanisole prevent this 
activation.
Nitrate reductase, which catalyses the formation of superoxide anion 
(O^  ) from molecular oxygen, enhances the activation produced by super­
oxide dismutase. This activation therefore requires both superoxide anion 
and hydrogen peroxide probably leading to the formation of hydroxyl radicals 
(reaction *♦), which are necessary for the activation of the
°2~ H2°2 — ^  .H + OH" + °2
superoxide hydrogen hydroxyl hydroxyl molecular
anion peroxide radical anion oxygen
guanylate cyclase enzyme.
Under the appropriate conditions, catecholamines and Mn^+ ions may 
give rise to hydroxyl radical production (52) which probably explains the 
stimulatory effect of these agents in some preparations. Such a mechanism 
would be highly unlikely to have any physiological significance.
(viii) Fatty Acid Activation
Highly specific structural requirements must be fulfilled if fatty 
acids are to serve as activators for guanylate cyclase, presumably because 
only those fatty acids which are substrates for fatty acid cyclooxygenases 
seem to be capable of activating the enzyme (77). Fatty acids are
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metabolised to highly reactive hydroperoxide and endoperoxide intermediates 
by this enzyme.
The prostaglandin endoperoxides PGG^ and PGH^ have been shown to be 
potent activators but their effects are dependent upon the presence of 
molecular oxygen. The fatty acid hydroperoxides, 15-00H-20:4, 12-00H-20:4, 
and 13-OOH-18:2 also stimulate guanylate cyclase in a concentration 
dependent manner.
1 S - 0 0 H - a 0  4  i OOH
C H 3 (CH 2  )a C = C H C H gC H O tC H 2 >2 C H  C H 'C H g ^ C O O H
ia - O O H - a O :4  i O OH
CH^iCH s ) ^ O H :H C H g C = C H C H 2 CH=CH CH gCH =CH (CH a  I ^ O O H
1 3 - O O H - 1 B ; a  ! O O H
C H 3 (CH 2 )4 C = C H C H 2 C H = C H  ( C H g ) 7 C O O H
(ix) Physiological Relevance Of Guanylate Cyclase Activation
Fig. 1.7 summarises the pathways for guanylate cyclase activation 
already discussed and Table 1.5 shows the changes which occur in some of 
the properties of the enzyme upon its activation.
The most important alteration observed is the ability of the cyclase 
to use Mg^+ ions equally as effectively as Mn^+ ions which may not be 
present in high enough concentration under physiological conditions to 
have any effect. It may be considered, therefore, that the extremely low 
activity of guanylate cyclase in the presence of only Mg^+ ions results in 
a negligible physiological role until or unless it is activated.
Another important change in the activated enzyme is its ability to 
utilise ATP as a substrate for the production of cyclic AMP. Activated 
guanylate cyclase may be an important route for the production of both 
cyclic AMP and cyclic GMP and this may have important consequences in the 
regulation of intracellular levels of both nucleotides (78).
Fig .  1.7 Free Radical Formation and Redox Regulation of Guanylate 
Cyclase
TABLE 1.5 Alteration in properties of guanylate cyclase with activation
PROPERTY EFFECT OF ACTIVATION
Km for GTP unaltered or increased
Requirement for Mn^+ ions decreased
Effect of Mg^+ ions as sole cation as effective as Mn^+ ions
Stability more labile
Effect of Ca^+ ions decreased
Cyclic AMP formation ca. 5 to of cyclic GMP formation
Reproduced from ref. (52)
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Oxides of nitrogen are common environmental pollutants and the 
formation of nitroso compounds from dietary precursors may explain the high 
guanylate cyclase activities observed in lung and intestinal mucosa 
respectively (52). Since the concentration of nitric oxide required for 
activation is approximately 1 pM or less, concentrations of nitrite, 
nitrate, amines and other potential precursors are sufficiently high in 
tissues that humoral and/or physiological alterations in redox states could 
influence nitric oxide formation and guanylate cyclase activity (52).
Cyclic GMP formation and the production of hydroxyl radicals has been 
reported in leukocyte phagocytosis, fatty acid oxidation, prostaglandin 
synthesis and platelet aggregation. The altered formation of hydroxyl 
radicals could explain some of the observed effects of hormones and other 
agents on cyclic GMP production.
1.9 Cyclic GMP Phosphodiesterase
Like A-PDE activity, cyclic GMP phosphodiesterase (G-PDE) activity 
commonly occurs as a function of two distinct proteins separable by DEAE- 
cellulose chromatography (Section 1.5). One of these proteins can also 
hydrolyse cyclic AMP and has a low affinity for cyclic GMP (Km cyclic 
GMP = 20 pM) and is therefore inhibited by cyclic AMP. The other protein, 
separated as fraction I, has a high affinity for cyclic GMP (Km = 0.3 pM) 
with little or no activity with cyclic AMP (79)-
Hormonal effects on G-PDE activity have been reported (32). For 
example, insulin can increase the activity of the enzyme and raise the 
intracellular cyclic GMP levels in cultured cells. Thyroxine and 
glucocorticoids decrease G-PDE activity in the soluble fraction of the 
thyroid and in homogenates of liver and muscle respectively. The role of 
G-PDE and that of hormonal regulation is not known.
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1.10 Calcium and Cyclic Nucleotide Regulation
(i) Intracellular concentrations of Ca^* ions can be altered by the action 
of hormones and neurotransmitters and this provides another mechanism by 
which cyclic nucleotide metabolism may be controlled.
Ca^+ ions have direct effects upon the activity of adenylate and 
guanylate cyclase. The effects of calcium upon adenylate cyclase are some­
what obscure (21) and it may act at a distinct site on the cyclase complex 
or it may interact with Mg^ + ions, either at the binding site or in the 
form of the non-productive substrate Ca.ATP. Even in the presence of 
excess Mg2+ ions, Ca2+ ions inhibit adenylate cyclase in many tissues, 
including liver membranes (80). Maximum inhibition is produced with 1 mM 
Ca^+ in the presence of millimolar Mg2+. This effect results in a decreased 
Vmax for the enzyme with no change in the Km for ATP. Inhibition can be 
reversed to some extent with Mn^+ ions presumably because they act at a 
separate binding site, and this inhibition is completely reversed by 
EGTA. Levitski £t_ al. (81) proposed the existence of allosteric binding 
sites for free Ca^+ ions in turkey erythrocyte membrane adenylate cyclase 
which are distinct from the Mg^+-binding site. This conclusion has been 
questioned by Cech et al. (21) and criticized as a misinterpretation of 
their results. The data of Rodan et_ al. (82) suggests a competitive 
binding of Ca^+ ions to the Mg^+-binding site of the enzyme.
In contrast to their effect on adenylate cyclase, Ca2+ ions have 
been demonstrated to increase the activity of guanylate cyclase in 
millimolar concentrations (83) but are less effective than Mn2+ ions.
In the presence of Mn^+ ions, guanylate cyclase can be inhibited or 
stimulated by Ca2+ ions depending upon their concentration (&), but 
higher concentrations of Ca*"+ ions are required than would be expected to
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exist intracellularly under physiological conditions.
As well as these "direct" effects of calcium ions, other actions of 
Ca^+ ions can be mediated by a regulatory protein, calmodulin.
(ii) Calmodulin
Calmodulin is an endogenous, calcium-binding protein first discovered 
as a PDE-activating protein (85)* It has since been characterised as an 
acidic protein with a molecular weight of 16,723 and has the ability to 
bind four calcium ions per molecule with a dissociation constant of k to 
18 pM (86). It has been calculated that under physiological conditions, 
calmodulin may be found binding 3 Ca^+ ions and 1 Mg2+ ion (87). The 
binding of calcium converts the protein to a more helical configuration 
which is apparently necessary for its binding to calmodulin-sensitive 
enzymes. The activation of enzymes by calmodulin therefore requires two 
steps (Scheme 5)»
Ca2+ + Calmodulin Ca -Calmodulin* (i)
INACTIVE ACTIVE
Ca^+-Calmodulin* + E v ~ ^  Ca -Calmodulin*-E (ii)
INACTIVE ACTIVE
Scheme (5)
Calmodulin is found in all subcellular fractions although it seems 
to be mainly cytosolic and in most tissues, organs and species so far 
examined (87). It has been found to activate a number of enzymes 
including ATPase, phospholipase A2, PDE, adenylate and guanylate cyclases 
and protein kinases and may have a role in the control of intestinal 
secretion, disassembly of microtubules and smooth muscle contraction. In
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some tissues therefore, calmodulin may modify the biosynthesis and bio­
degradation as well as the actions of cyclic AMP and cyclic GMP.
(iii) Calmodulin-dependent Phosphodiesterase (CaM-PDE)
There is evidence that at least one of the multiple forms of PDS 
(Section 1.5) is activated or stimulated by Calmodulin. The hydrolysing 
activity of CaM-PDE is mixed, but seems to have a higher affinity for 
cyclic GMP than cyclic AMP. CaM-PDE often parallels the concentration of 
calmodulin in many tissues (e.g. brain, liver, kidneys, adrenals) although 
some tissues which contain much calmodulin possess little or no CaM-PDE 
activity (e.g. testes, lung, adrenal medulla, lymphoblast) (87). At 
saturating concentrations of Ca^^-Calmodulin* (Scheme 5) the Km for cyclic 
nucleotides was reduced 20-fold for both cyclic AMP (Km = 180 pM) and 
cyclic GMP (Km = 8 pM), with no change in Vmax (79)* Cheung, however, 
has reported both increased Vmax and decreased Km upon activation of bovine 
brain cyclic AMP-PDE activity by Calmodulin (88). Under saturating 
concentrations of Calmodulin, half maximal velocity (Vmax/2) was found 
at if pM Ca2+ for CaM-PDE activity and no time lag has been reported for 
Ca2+ ion-activation in the presence of Calmodulin.
Endogenous protein stimulators of CaM-PDE have been found in 
adipocytes, retina, testes and brain (79) with molecular weights ranging 
from 1000 to 95*000. These seem to act by binding to the activated Ca“^*- 
Calmodulin* complex (Scheme 5) preventing its binding to Calmodulin- 
sensitive enzymes. One other inhibitory binding protein (Mr = 5^0,000) 
has been found, however, which predominantly inhibits the Ca^+- 
independent PDE activity of bovine retina.
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(iv) Calmodulin-dependent Cyclases
Calmodulin-dependent guanylate cyclase activity has been demonstrated 
in Tetrahymena (89) but little is known of this enzyme in mammalian 
tissues.
There appear to be two forms of adenylate cyclase present in animals, 
one is inhibited by Ca^+ ions, the other is stimulated by Ca^ + and seems 
to be restricted to neuronal tissues. Ca^+-dependent adenylate cyclase, 
has however been reported in adipocytes and adrenal cortex (90). Ca^+-
stimulated adenylate cyclase from brain tissue is calmodulin-dependent 
(CaM-AC) and shows differential distribution within this tissue; medulla, 
thalamus and hypothalamus having high CaM-AC activity, cerebrum, and 
cerebellum intermediate and pons having low CaM-AC activity (87).
Catecholamine stimulation of brain adenylate cyclase is Ca2+- 
dependent. Although the release of Calmodulin from membranes has been 
shown to decrease the responsiveness of this adenylate cyclase to dopamine 
in the corpus striatum, dopamine increases adenylate cyclase activity in 
the presence of EGTA (87)«
Calmodulin has been reported to increase the Vmax of CaM-AC without 
affecting the Km for ATP (91)» In contrast, however, Brostrora et al.
(92) have reported that Calmodulin does not change the Vmax but decreases 
the Km for ATP of rat brain fluoride or GTP-stimulated cyclase activity. 
The kinetic basis of Calmodulin activation is therefore not at all clear.
The degree of activation of adenylate cyclase by Calmodulin is not 
large and its mode of action is not known. The presence of Calmodulin in 
the cell does not necessarily mean that the adenylate cyclase is 
sensitive to its effects and both sensitive and Calmodulin-insensitive 
adenylate cyclase may be present in the same cell (21). Studies of CaM-AC
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have been complicated by the nature of the adenylate cyclase complex 
(Section 1.4) but future radiation inactivation studies of CaM-AC should 
reveal much of its site of action within the complex and its interaction 
with the various modulatory ligands of adenylate cyclase activity.
(v) Calmodulin-dependent Kinases
Several kinases have been found to be stimulated by Calmodulin 
which are involved in stimulating glycogenolysis in skeletal muscle.
Ca^+-dependent phosphorylation of various membrane proteins have been 
reported in lung, spleen, skeletal muscle, vas deferens, heart and adrenals 
and shown to be Calmodulin-dependent. Furthermore, Calmodulin may be 
involved in the Ca^*-stimulated release of neurotransmitters (87).
1.11 Cyclic Nucleotide Metabolism and Cancer
(i) It has been observed that cyclic nucleotides play an important part 
in cellular proliferation and differentiation. The intracellular 
concentration of cyclic AMP changes during the cell cycle and is lowest 
at mitosis (93) is inversely related to growth rate (94) and is higher in 
contact-inhibited cells than in less dense populations (95)* The action 
of cyclic GMP appears to be antagonistic to those of cyclic AMP in many 
cases and its concentration has been shown to increase in proliferating 
cells (96). Cyclic GMP induces nucleic acid synthesis under the 
appropriate conditions (97) and counter acts the growth-inhibitory effects 
of cyclic AMP (98). Such observations led Goldberg et al. (99) to propose 
the "yin-yang" hypothesis of biological control. This general theory of 
cyclic nucleotide action applied to systems where the action of cyclic AMP 
could be either inhibitory or stimulatory, and cyclic GMP antagonistic to 
that of cyclic AMP, states that it i6 the ratio of cyclic AMP to cyclic GMP
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levels which is important. Furthermore, Beridge (100) has pointed out the 
importance of Ca^+ ions and proposed that these gave the primary "signal" 
for cell proliferation and division, cyclic GMP levels rising as a result 
of Ca^+ ion interactions with guanylate cyclase. If cyclic AMP levels were 
high enough, however, differentiation of the cell would be favoured. Cyclic 
AMP promotes the expression of differentiated properties of many cells and 
processes, such as those discussed in Section 1.2, and addition of cyclic 
AMP to cells accentuates the properties that are typical of that cell type.
It has been a useful generalisation that cyclic AMP inhibits and cyclic 
GMP promotes cell growth and that cancer cells have low cyclic AMP and 
high cyclic GMP levels (101). This holds true for some but not all 
cancerous tissues, nor indeed for many cell systems studied derived from 
normal tissue (102). No single alteration in cyclic nucleotide metabolism 
has so far been identified to distinguish neoplastic from normal tissue. 
Although cyclic GMP has been shown to stimulate nucleic acid synthesis 
in lymphocytes (103) and seems to be the signal for proliferation in 
such systems, cyclic AMP has also been shown to induce DNA synthesis in 
cultured thymocytes (10<*). Various tumours have also been found to have 
elevated cyclic AMP levels (105) and changes toward the increased ability 
to accumulate cyclic AMP during carcinogenesis have been observed (106).
With such conflicting evidence available it would be difficult to 
conclude that cyclic nucleotides play no part in the regulation of 
cellular proliferation and/or carcinogenesis. It is most probable, however, 
that different cell types respond to cyclic nucleotides in fundamentally 
different ways (102) and thus explain the difficulty encountered in 
formulating a generalisation of cyclic nucleotide action. It has also 
been suggested that there may be greater similarities than seems evident
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and that apparent discrepancies in observations may be accounted for, at 
least in part, by differences in experimental design (102).
(ii) Guanylate Cyclase
Guanylate cyclase activity has been shown to differ in foetal, 
neonatal and adult rat heart (107). Increased activity was observed 
(approximately 2.5-fold) in foetal and neonatal tissue, suggesting a 
possible role for cyclic GMP in these highly active, proliferative tissues. 
At the same time corresponding to the decline of DNA synthesis in these 
cells, the cyclase activity was also found to "return" to "normal" adult 
levels of activity (107). This would correlate well with a DNA synthesis- 
inducing effect for cyclic GMP.
Kimura and Murad have found that particulate guanylate cyclase activity 
was increased and soluble decreased in both foetal and regenerating rat 
liver and that this phenomenon was also expressed by the hepatoma 392<*A 
(108). Soluble activity in the cancer tissue was found to be decreased by 
2-fold and particulate increased by 9-fold. Earlier studies on Morris 
hepatomas showed a marked decrease in cyclase activity, its presence being 
undetectable in some cell lines (109). A similar decrease has been 
reported in renal cortical tumour tissue (110). In contrast to these 
reports, guanylate cyclase activity has been observed to be increased in 
ethionine-induced hepatomas (111), in both acute (childhood), and chronic 
(adult), lymphocytic leukaemia lymphocytes (112) and in 10-raethyl- 
choranthrene-induced rat prostate sarcoma (113). A consistent finding, 
however, is that the enzyme is located to a greater extent in the 
particulate fraction and has a reduced responsiveness to activators, 
particularly azide and hydroxylamine. It is not certain whether this 
reflects a property of the cyclase or the protein activator required for
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such stimulation (Section 1.8(vi)). It is interesting to note that 
many carcinogens have been shown to generate free radicals (111*) and 
are involved in binding of the carcinogen to nucleic acid bases. The 
effects of certain free radicals and the redox state of the cell on guany- 
late cyclase activity is well known (Section 1.8). Many carcinogens have 
been reported to activate soluble guanylate cyclase activity in a variety 
of tissues including phorbol myristate acetate (a lymphocyte mutagen) 
in lymphocytes (115) hydrazine (a carcinogen in tobacco smoke) in a variety 
of tissues including lung (116) butadiene diepoxide (117) streptozotocin 
(an antibiotic and nitrosourea derivative) (118) and a wide range of 
others including the nitroso compounds in many different tissue types
(73) 019) (120).
Further interest has arisen from the report of Vesely and Levey 
(121) that the guanylate cyclase stimulated activity induced by N*-nitro- 
N-nitroso-N-propylguanidine can be inhibited by a variety of anticancer 
agents. These include antimetabolites (methotrexate and 6-mercaptopurine), 
antitumour antibiotics (adriamycin and actinomycin D) and alkylating 
agents (cyclophosphamide, uracil mustard, isophosphamide, chlornaphazine 
and 1-propanol-3,3'”ifflinodimethane sulphonate). All act in an "irregular" 
dose-response manner (see Fig. 8.2F). It is possible that chemical 
carcinogenesis in some instances is mediated by activation of guanylate 
cyclase. The resultant rise in cyclic GMP levels, stimulating DNA 
synthesis and cellular proliferation. It is also conceivable that some 
anticancer agents may act by preventing or reversing this. Some anti­
cancer drugs are known carcinogens themselves and Vesely and Levey found 
that five of the forementioned drugs (6-mercaptopurine, chlornaphazine,
1-propanol-3,3'-iminomethane sulphonate, isophosphamide and uracil mustard)
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could stimulate basal guanylate cyclase activity, but only by 1.6 to 3»0- 
fold and at very high concentrations (50 to 100 mM) (121).
(iii) Adenylate Cyclase
Adenylate cyclase studied in various tumour systems has been found to 
exhibit properties different to the enzyme found in normal tissues. Some 
reports suggest an elevated basal activity in hepatomas (109) while others 
have reported lower levels (122). Decreased adenylate cyclase activity 
has also been reported for chick embryo fibroblasts transformed by Rous 
sarcoma virus with a corresponding change in Km for ATP from 0.25 mM to
1.0 mM (123). This change in Km was not observed when a different strain 
of virus was used, implying a different mechanism for altering cyclase 
activity (123). Adenylate cyclase with decreased activity has also been 
found in lymphocytes of patients with either acute or chronic lymphocytic 
leukaemia (112) and in rat prostate sarcoma (113) whereas adenylate cyclase 
activity in thyroid carcinomas is no different to normal tissue (12<*) and 
cyclase activity above normal has been found in renal cortical tumours
(125). A finding similar to that for guanylate cyclase in transformed cell 
lines, is that adenylate cyclase in such tissues is less responsive to 
activating ligands, and in particular to hormones. Lowered glucagon 
stimulation was reported in hepatomas, but increased responsiveness to 
adrenaline in these tissues was also observed (102). Adenylate cyclase 
shows decreased responsiveness to parathormone in renal cortical tumour 
(125), and to isoproterenol, as well as prostaglandin PGE and PGF^ in 
leukaemic lymphocytes (112). Klein et al. (126) have shown that the 
histamine stimulation of parathyroid adenoma adenylate cyclase can be 
abolished by cimetidine.
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Adenylate cyclase activity of rat heart is increased in foetal life, 
an opposite effect to that found for guanylate cyclase, and there is 
evidence for the delayed development of the glucagon receptor (127). It 
seems a general phenomenon that adenylate cyclase hormone receptors are 
less effective in rapidly proliferating tissue. This could occur by
(i) alteration in the binding sites or receptors for the hormones or
(ii) alteration in the N peptide (Section 1.4 (iii)). Variants of the 
S49 murine lymphoma have been found with both alterations of receptor 
binding sites (21) and in N peptides (19) (20) (Section 1.4).
It is interesting to note that cholera toxin, which stimulates 
adenylate cyclase, when given in only one injection, has been demonstrated 
to produce almost complete inhibition of proliferation for up to 4 days 
in intra-peritoneal YAC lymphoma cells in mice without any noticeable 
noxious effects on the animals (128).
Manipulation of adenylate cyclase may therefore be another method 
or "target" for chemotherapy. Tisdale and Phillips (129) have shown 
a reduced response to fluoride ions by adenylate cyclase from Walker 
carcinoma cells (approximately 1.2 to 1.5-fold increase). Neither of the 
alkylating agents chlorambucil (bifunctional) nor 5-aziridinyl-2,4- 
dinitro-benzamide (cB1954, monofunctional) had any effect on either basal or 
fluroide-stimulated enzyme activity although the carcinoma is responsive 
to the cytostatic actions of these compounds. A CB1954-protective agent 
had no effect alone but in combination with CB1954 stimulated basal 
activity to the level expressed by fluoride ions. Fluoride ions had no 
effect on this stimulated activity (129).
36
(iv) Protein Kinase
An increase in the total activity of cyclic AMP-dependent protein 
kinase (A-PK) has been reported in thyroid adenoma (124). Rapidly growing 
hepatomas with high cyclic GMP levels were found to have increased cyclic 
GMP binding activity (109). In liver neoplasia there appears to be a 
shift towards a less responsive protein kinase system (130) and the 
lack of steroidal response in adrenal cortical carcinoma was thought to be 
due to a "defect" in the protein kinase system in this tissue (131). In 
various hepatoma cell lines, a decreased capacity to bind cyclic AMP 
was found, and in HTC hepatoma cell line, this was found to be due to the 
presence of C component of A-PK in the cytoplasm (109) (Section 1.3). 
Although A-PK in the prostate sarcoma was reported to have a slightly 
higher affinity for cyclic AMP (Km cyclic AMP; prostate = 0.11 pM, 
tumour = 0.08 pM) the same responsiveness to cyclic AMP was found (113)- 
Cyclic GMP-dependent protein kinase (G-PK) however, was much more 
sensitive to cyclic GMP in tumour tissue than in normal prostate (Km 
cyclic GMP; prostate = 4.85 pM, tumour = 0.88 pM) (113)-
Studies like these and the observation by Fossberg at al_. (132), that 
there was a raised type I/type II ratio of A-PK isoenzymes in renal 
cortical tumours, led Russel to propose that type I A-PK was responsible 
for stimulatory effects on cell growth (5). ChoChung (133) has more 
recently proposed protein kinase to be involved as a key step for signaling 
tumour regression. He suggests the existence, from various lines of 
evidence, of a cyclic AMP ternary complex of A-PK type II isoenzyme, 
phosphorylated at a serine residue. This complex, he proposes, is capable 
of translocating to the nucleus of the cell where the R subunit would bind 
to an acceptor site, releasing active catalytic components. These would be
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capable of interacting with chromatin proteins and trigger tumour cell 
regression. It is reasoned that if it is this ternary complex and its 
translocation which is the property of differentiated cells which stop 
proliferating, then hormone-dependent tumours that retain the properties 
of differentiated cells should undergo regression with the proper cyclic 
AMP stimulation (133)-
Tisdale and Phillips have demonstrated that the bifunctional alkylating 
agent, chlorambucil, activates A-PK in Walker carcinoma cells sensitive to 
the effects of this compound (WS cells) (13^). CB195^ and merophan also
activated A-PK in WS cells but N-ethyl-chlorambucil had no effect. The 
degree of activation by 5 chlorambucil was equivalent to 100 vgA>l»
dibutyryl cyclic AMP. Chlorambucil was also found to increase A-PK 
activity in HeLa and Chinese hamster cells (135) and this correlated well 
with the rise of cyclic AMP levels in these cells.
Cyclic AMP binding in Walker cells was observed to decrease as 
resistance to CB1954 or chlorambucil was increased (in special resistance- 
developed cell lines) and this was found for both low and high Km binding 
sites (136).
Of the cyclophosphamide metabolites tested, only 4-hydroperoxy- 
cyclophosphamide (HP) inhibited cyclic AMP binding in Walker cells to any 
extent (137) although similar effects were observed for the i»-hydroxy- 
it-methyl-cyclophosphamide derivative. Since l*-ketocyclophosphamide (KP) 
was ineffective it was apparent that the presence of an oxygen atom alone 
in the Qk position was not sufficient to elicit a response. Cyclophos­
phamide (CP) and cytoxyl alcohol (Section 1.11») were also ineffective in 
inhibiting binding activity. HP produced competitive binding (Ki = 0.19 
mM) corresponding to an interaction with the low affinity (high Km) site.
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Furthermore it was found that HP activated the protein kinase in Walker 
cells with a linear relationship for binding and activation, suggesting 
that HP bound to the kinase cyclic AMP binding site, causing dissociation 
of the holoenzyme (137)* CP, KP, chlorambucil and phosphoramide mustard 
had no effect on kinase activity.
(v) Phosphodiesterase
Cyclic AMP phosphodiesterase (A-PDE) and cyclic GMP phosphodiesterase 
(G-PDE) have been found with a 5 to 10-fold greater activity in 
leukaemic lymphocytes compared with lymphocytes, spleen, thymus or lymph 
node PDE from normal mice (139)* This increased activity was not due to 
the action of a calcium-dependent activator protein, although present, and 
was accompanied by an increase in the Vmax of the enzyme. The PDE's 
isolated from leukaemic lymphocytes were similar to those isolated from 
normal cell6 with respect to pH optima, stability to freezing and thawing 
and their sensitivity to the inhibitors chlorpronazine, papaverine and 
isobutylxanthine but were found to be more heat-resistant (139)»
The specific activities of adenylate cyclase and A-PDE have been found 
to increase as the density of cultured cells (chick embryo fibroblasts) 
is increased (32). In contact-inhibited cells intracellular cyclic AMP 
levels are increased corresponding to an increase in the ratio of 
adenylate cyclase : A-PDE activities at higher cell densities. The growth- 
promoting effect of trypsin may be due to its protyolytic action on 
membrane-bound A-PDE (32).
The low Km form of A-PDE has been observed to have a high activity 
in leukaemic (106) hepatoma (109) and human breast cancer (138) cells.
The presence of at least two forms of A-PDE, with high and low affinities 
for cyclic AMP, has been demonstrated in several experimental animal
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tumours including Walker 256 rat mammary carcinoma, ADJ/PC6 plasma 
cytoma, sarcoma 180, NK and TLX5 lymphomas (140). The apparent Vmax of 
the low Km form A-PDE in Walker 256 and ADJ/PC6 cells, naturally sensitive 
to alkylating agents, contributed a higher percentage to the total 
measured Vmax than in any of the other, naturally resistant, cell lines.
The alkylating agents chlorambucil and C31954 produce an increase in 
cyclic AMP levels in sensitive Walker 256 cells (141). This effect has 
been found to be produced by an inhibition of A-PDE activity which can 
also be produced by the alkylating agent merophan (142). A comparable 
increase in cyclic AMP levels was found with the PDE inhibitor amino- 
phylline at a concentration which produced the same degree of growth 
inhibition (141). The N-ethyl derivative of chlorambucil had no effect.
In chlorambucil-resistant (WR) cells of the Walker 256 carcinoma, 
increasing resistance was found to be accompanied by a decreasing activity 
of low Km form A-PDE (140) not due to the presence of an endogenous 
inhibitor. The apparent Vmax of this form of the enzyme has been shown to 
decrease in increasingly resistant WR cells. Furthermore, a change from 
high molecular weight to low molecular weight forms was demonstrated as 
Walker cells achieved resistance to chlorambucil, with no change in the low 
affinity form of the enzyme (34).
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PART 2 CYCLOPHOSPHAMIDE 
1 .1 2  O r i g i n s
Cyclophosphamide (2-[bis(2-chlorethyl)amino]tetrahydro-2H-1,3,2- 
oxazaphosphorine-2-oxide,C P ) is one of the most effective and widely 
used drugs in clinical cancer chemotherapy and immunosuppression (143)- 
It is effective against more different types of human neoplastic disease 
than any other chemotherapeutic compound (144). It is an alkylating agent 
and kills dividing and non-dividing cells by covalently binding to 
essential cellular components.
The development of "mustard gases" for use as chemical warfare agents 
led to the production of nitrogen mustard compounds during World War II.
The observation that lymphoid tissues and rapidly dividing cells were 
particularly susceptible to the toxic effects of such compounds suggested 
that lymphoid tissues would be a good "target" for chemotherapy using 
nitrogen mustards. The first synthetic compound found to possess anti­
tumour activity in humans was methylbis (P-chloroethyl)amine, (nitrogen 
mustard, HN2) which was used to treat Hodgkin's disease and caused liaited 
regressions in certain lymphosarcomas (Fig. 1.8).
This success led to the production of many congeners of bis-f-chloro- 
ethylamines but none proved to be more effective than HN2. The observation 
by Gomori et al. in 1948 that the activity of the enzyme phosphamidase was 
localised in certain tumours led Friedman and Seligman to develop 
phosphoramide mustards (Fig. 1.8) as latent derivatives of nitrogen mustards. 
It was postulated that phosphamidase would cleave the P-N bond of these 
phosphoramide mustards thus releasing the cytotoxic nitrogen mustard moiety
within the cell
<♦1
CP was synthesised by Arnold and Bourseaux as a "transport form" of 
nor-HN2 (Fig. 1.8) using the same rationale. CP does indeed require 
metabolic activation but this is not brought about by a phosphamidase- 
mediated release of nor-HN2.
1.13 Metabolism
The metabolic pathways for CP activation, deactivation and degradation 
are shown in Fig. 1 .9. The pathway of activation involves hydroxylation 
of CP to produce 4-hydroxy-CP (OHCP) which tautomerises to aldophosphamide 
(AP) with which it is in equilibrium. Spontaneous elimination of 
acrolein from AP produces the active species, phosphoramide mustard (PM). 
The major deactivating pathway ¿n vivo is the production of 4-keto-CP 
(KP) and carboxyphosphamide (CarbP) both of which appear as urinary 
metabolites.
1.14 Microsomal Hydroxylation
(i) Brock and Hohorst ( 11*5 ) demonstrated that the liver was the primary 
site of activation of CP, although the production of alkylating 
metabolites was detected when lung and kidney tissue was used instead of 
liver. Activation by the liver was found to require NADPH and oxygen 
and Cohen and Jao (11*6) confirmed the idea that CP activation was mediated 
by the mixed function oxidase system. The mixed function oxidase system 
is well known for its involvement in the metabolism of steroids, prost­
aglandins and drugs including carcinogens. One of the major purposes of 
the system appears to be the detoxification of xenobiotics ( 147) by 
converting the compound to a more polar derivative, usually by hydroxy­
lation, rendering it more water-soluble and thereby more susceptible to
Fig. 1.8 The Structure of Nitrogen Mustard Compounds
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Fig- 1-9 The Metabolism of Cyclophosphamide
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excretion via the renal tubules. In some cases, however, these oxidative 
processes may have the opposite effect and produce a reactive (or 
pharmacologically active) species from an inactive compound. This is true 
for many drugs including parathion, tremorine, prontosil and CP which 
express their action only through the production of pharmacologically 
active metabolites.
Cytochrome P-450, which is tightly bound to microsomal membranes, plays 
an important part in the oxidative metabolism of a wide variety of 
xenobiotics by acting as the oxygen-activating enzyme as well as the site 
of binding. Its involvement in CP metabolism has been demonstrated by the 
production of a type I spectrum for cytochrome P-450 in the presence of CP 
providing evidence for CP binding to the cytochrome (148). The mixed 
function oxidase reactions obey the equation shown in reaction 6, where
RH + 02 + NAD(P)H + H+ — >  ROH + H20 + NAD(P)+ (6)
RH is the substrate for the hydroxylation.
The mechanism for the action of cytochrome P-450 is probably similar 
to that described by White and Coon (149) Fig. 1.10. In hepatic microsoraes 
a flavoprotein (NADPH-Cyt.P-450 reductase) containing both FMN and FAD 
catalyses electron transfer from the electron-donating, reduced pyridine 
nucleotide (usually NADPH) to the cytochrome. This process involves binding 
of the substrate to cytochrome P-450 in the resting ferric state, followed 
by uptake of an electron from the associated flavoprotein and oxygen 
binding forming an oxyferro complex. Uptake of a second electron leads to 
the elimination of water leaving the oxylide radical bound to iron. The
£*&;. 1 .10 Proposed Mechanism of Action For Cyt. P-430 in Substrate
Hydroxylation
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dissociation of the hydroxylated product and the restoration of ferric 
P-450 is the final step and perhaps the least understood part of the 
mechanism in the reaction sequence (149)*
It is not, therefore, surprising that CP activation is carried out 
predominantly in the microsomal fraction of rat (146) and mouse (150) 
liver and requires NADPH for full expression of activity, although NADH 
can be utilised (146), but not to any great extent. The extent of 
activation by other tissues corresponds to their microsomal content (143), 
and the optimum pH has been reported as 7«3 (148). Kinetic data for
the metabolism of CP by rat and mouse liver varies widely. For example, 
for CP the Km varies from 0.48 to 7.0 mM and Vmax varies from 0.7 to
65.7 pmoles/g liver/Hr (144).
Activation is inhibited by carbon monoxide which binds to cytochrome 
P-450 and by other compounds which interrupt microsomal electron transport 
such as p-hydroxymercuribenzoate and cytochrome c (146) (148) (150). Many 
other compounds have been reported to affect metabolic activation of CP
(144) of these SKF-525A (2-diethylaminoethyl-2,2-diphenylvalerate) is the 
most potent competitive inhibitor (Ki = 4.1 pM). H xobarbital (146), ethyl 
morphine (148) (competitively), and nicotinamide (148) (noncom petitively), 
inhibit CP transformation as measured by a retardation in the appearance of 
alkylating activity during CP incubations with microsomal fractions. 
Steroids (146), atropine and adrenaline (150), also inhibit while 
chloramphenicol has been 6hown to retard CP transformation in humans (151). 
Reduced in vitro activity has also been observed in microsomal preparations 
which had previously been stored in a froaen state (148).
Activation can be stimulated by pretreatraent of the experimental 
animals with phénobarbital which induces the production of microsomal
kk
enzymes. Furthermore, a sex difference has been reported, male rats 
metabolised CP at a much faster rate than did female rats (1^6). This 
probably correlates with the difference in microsomal content of the liver 
between the sexes.
(ii) Activation
The importance of aldophosphamide (AP) as a key intermediate of CP 
metabolism was first suggested by Connors et_ al. (151)* Sladek (152) 
had already implicated this compound as the primary metabolite of CP, 
having demonstrated that the activation of CP generated material which 
gave a positive test for aldehydes. Isolation of AP (Fig. 1.11) from 
an in vitro incubation mixture of CP with mouse liver microsomes and from 
the plasma of CP-treated patients (15^ ) supports the metabolic scheme 
(Fig. 1.9) in which the first product of metabolism is l*-hydroxy-CP 
(OHCP) (Fig. 1.11). AP is formed spontaneously from this hydroxylated 
intermediate with which it is in equilibrium. Qualitative and 
quantitative analysis by thin layer chromatography has demonstrated the 
existence of OHCP and AP in both synthetic and biological sources (153)« 
The presence of i*-ethoxy-CP in ethanol-deproteinised samples was also 
shown. Isolation and mass spectral identification of ¿»-ethoxy-CP from 
microsomal incubations of CP treated with ethanol supported the existence 
of OHCP and an imino intermediate, iminophosphamide (151) (11*3) which may
IMINOPHOSPHAMIDE
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be formed by the elimination of water from OHCP, and is thought to be in 
equilibrium with OHCP (143)- The N=C double bond would be very polar and 
addition of an alcohol or thiol across the bond may, therefore, be expected 
to occur readily. Evidence for the existence of iminophosphamide has been 
obtained by treatment of synthetic OHCP with sodium borodeuteride to 
produce CP which is monodeuterated at CA (1A3)*
Sladek (152) identified AP by reaction with semicarbazide to produce 
the corresponding semicarbazone. Struck e_t a^. (158) treated synthetic 
OHCP with semicarbazide in aqueous solution and subsequently isolated and 
identified the semicarbazone of AP, identical to the product of Sladek 
implying the conversion of OHCP to AP. Further evidence for this is that 
acrolein which is eliminated from AP, can be found as a spontaneous 
decomposition product of synthetic OHCP (15A). AP has also been identified 
in the plasma of patients receiving CP chemotherapy and in microsomal 
incubations of CP after reaction with cyanide to yield the cyanohydrin 
derivative (155) which cam also be produced by addition of cyanide to 
solutions of OHCP (155)* Conversion of AP to OHCP is also possible, 
evidence of which has been provided by the extensive oxidation of alco- 
phosphamide (Fig. 1.11) the product of which is A-keto-CP (KP). Initial 
oxidation produces AP which tautomerises to OHCP which is then further 
oxidised to KP (156). Voelcker et_ al. (157) have reported the equilibrium 
of the O H C P A P  interconversion reaction to be in favour of OHCP (OHCP : 
AP = 1.69).
By use of a A-deuterated analogue (CP-A-d^) Connors et^  al. (159) were 
able to differentiate between initial hydroxylation at either the CA or C6 
position. As well as confirming initial CA hydroxylation, Connors £t al. 
showed that there was a virtual absence of any isotope effect between the
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rate of hydroxylation of CP and CP-^-d^- This indicated that cleavage of 
the C-4-D bond is not the rate-determining step in CP 4-hydroxylation.
(iii) ¡3-elimination
Colvin et al. (160) were the first to identify phosphoramide mustard 
(PM) as a biologically active metabolite of CP by chromatography and 
mass spectrometry of incubation mixtures of CP with mouse liver microsomes. 
Connors et al. (1fj1) suggested its mode of formation by spontaneous 
^-elimination of acrolein from AP (reaction 7).
Struck et al. (161) isolated and identified PM as a blood metabolite in 
mice treated with CP and PM has also been detected in plasma and urine of 
patients receiving CP chemotherapy (162).
The production of acrolein during the metabolism of CP has been 
demonstrated by Alarcon and Meienhofer and its biological effects have 
been much studied (143). Furthermore, the liberation of acrolein from 
"activated" derivatives of CP and isophosphamide (an isomer of CP), has 
recently been utilised in a fluorimetric assay for such compounds by 
condensation of acrolein with m-aminophenol (163)*
U7
(iv) Side Chain Hydroxylation
The action of microsomal mixed function osidase on CP also produces 
CP hydroxylated at the a-carbon of the 2-chloroethyl side chain (Fig.
1.9) (161). This compound spontaneously decomposes to yield N-dechloro- 
ethyl-CP (monochloroethyl-CP) and chloroacetaldehyde, both of which have 
been detected as blood metabolites of CP (161). Monochloroethyl-CP has 
also been isolated from microsomal incubation mixtures of CP (151).
Although this product is apparently inactive as a cytostatic agent, chloro­
acetaldehyde may play an important part in the immunosuppresive actions
of CP (1<*3) (see Section 1.15(ii)).
1.15 Deactivation Reactions
(i) Urinary Metabolites
Carboxyphosphamide (CarbP) and KP (Fig. 1.11) are detoxification 
products derived from oxidation of AP and OHCP respectively (152) (Fig.
1.9) . These two compounds are the major urinary metabolites of CP KP 
accounting for approximately 15# and CarbP about 50# of administered CP 
0<t3) (157).
CarbP was found to be produced from either OHCP or AP by incubation 
with the cytosolic fraction of mouse liver cells, or with purified aldehyde 
oxidase (150). Conversion of OHCP to CarbP is presumably achieved via AP 
since this is the most likely precursor and substrate for the enzyme.
KP was isolated and identified from the urine of CP-treated dogs by 
Hill et al. (16A) and the identification confirmed by chemical synthesis 
of KP. It has since been reported in the urine of CP-treated rabbits, 
sheep and man (1A4). Since KP can be produced by the dehydrogenation of 
OHCP, the cytosolic enzyme alcohol dehydrogenase has been implicated for 
this conversion (152).
The spontaneous production of nor-HN2 (Fig. 1.8, 1.9) from PM has 
been reported after administration of CP (11+5) to rats. It has been 
detected both in plasma and as a urinary metabolite (17U) in humans.
Nor-HN2 is capable of cyclisation to N-2-chloroethyl aziridine under 
refluxing for 48 hours (165). Even so, the presence of the latter compound 
in vivo has been reported after CP administration (145)* Other detoxi­
fication products have been isolated which arise from this pathway. For 
example hydroxylation of N-2-chloroethylaziridine followed by cyclisation 
of the remaining 2-chloroethyl group to the aziridine structure again, and 
further hydroxylation yields the products shown in Fig. 1.9 culminating in 
production of bis(2-hydroxyethyl)amine (166).
Nor-HN2 is also capable of dimerisation to give N-N'-bis(2-chloro- 
ethyl) piperazine (PZ) or reaction with CO^ to yield 3-(2-chloroethyl)-1, 
3-oxazolidine (OZ) both of which have been found as urinary metabolites
(167) (168) (Fig. 1.9)« Although the dimerisation of nor-HN2 to form PZ 
is not certain in vivo (167), OZ may be produced from nor-HN2 and carbon 
dioxide in blood. In aqueous solution in the presence of bicarbonate ion 
at neutral pH, OZ is spontaneously produced from nor-HN2 via a carbonate 
ion intermediate (168). Both PZ and OZ are undoubtedly inactive products
( 168)  .
(ii) Enzymic Oxidations
Alcophoshpamide (Fig. 1.11) has been found as a product of CP 
metabolism, Connors et al. (151) observing its formation from CP by a 
fraction of liver cells, possibly by the action of phosphorodiamide 
esterase. It has also been observed as a blood metabolite in mice which 
had been treated with CP (161). It has also been proposed that alcophos- 
phamide may arise from AP by reductase activity (161).
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As has already been stated, chloroacetaldehyde is produced by side- 
chain oxidation of CP. Isophosphamide (IP), an isomer of CP, undergoes 
side-chain hydroxylations and much work has been done investigating the 
products of this reaction.
In the case of IP, side chain hydroxylation is not such a minor 
metabolic pathway as found in CP metabolism (166). Slower ring 
hydroxylation is probably due to stereochemical hindrance of the C4 
position by the chloroethyl side chain of the N3 atom. Chloroacetaldehyde 
may be converted rapidly in vivo to chloroacetic acid and metabolites of 
this compound have been isolated from the urine of patients treated with 
IP, namely S-carboxy-methylcysteine and thiodiacetic acid (Fig. 1.9)
(166). There is evidence which suggests that these compounds are also 
present in CP biotransformation. Other metabolites of chloroacetic acid 
may enter the general metabolic scheme of the cell, leading to production 
of carbon dioxide (Fig. 1.9)«
(iii) Sulphydryl Reactions
The reaction of OHCP with thiols (Section 1•18(iii)) may be 
considered a deactivation reaction although it is reversible and may 
therefore serve only to "delay" activation. Various other thiol reactions 
are 6hown in Fig. 1.9» AP and acrolein have been shown to be capable of 
binding to thiol groups but the involvement of these reactions in the 
actions of CP is unknown.
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(iv) Hydrolytic Products
In isotonic saline at room temperature, CP is quite stable (165)- 
In unbuffered solution, CP slowly hydrolyses to nor-HN2 and phosphoric 
acid ester of N-propanolamine and inorganic phosphate. Under conditions 
which lead to acid-catalysed hydrolysis, CP is converted to cytoxylamine 
(Fig. 1.11). This compound has been found in the serum of rats and the 
urine of humans administered CP, and apparently has anti-tumour activity 
in vitro. Decomposition of CP by cleavage of the exocyclic P-N bond has 
also been shown, over a long period of time (2 weeks).
If CP is refluxed for several hours, internal alkylation of the 
endocyclic N atom can occur. This leads to the formation of various 
intermediates (143) (165) of which the most abundant is a dioldiamine:-
This pathway is also believed to occur to some extent on acid hydrolysis 
and is thought to account for some loss of activity in the NBP test 
(Chapter 3). The dioldiamine product has also been observed in high yields 
when cytoxyl alcohol (Fig. 1.11) was hydrolysed in water (143)»
Cytoxyl alcohol has been synthesised and could theoretically be 
a metabolite of CP after endocyclic P-0 bond cleavage. It has not, however, 
been observed, possibly due to its rapid hydrolysis in biological fluids. 
Unlike CP, cytoxyl alcohol is active against L1210 cells in mice.
HCI • N
HO
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1 . 1 6  C h e m is try
The biological activity of CP and its metabolites is due in part to 
their chemical reactivity. Alkylating agents are electrophilic reactants 
which combine with electron rich or nucleophilic centres. They have the 
ability, therefore, to substitute alkyl groups for the hydrogen atoms of 
certain organic compounds. The overall, unimolecular reaction which these 
agents exhibit (reaction 8) can be resolved into two processes. The
x" ♦ RY — ---3» RX + Y~ (8)
NUCLEOPHILE ALKYLATING
AGENT
first, rate-determining step is a slow, reversible, heterolytic bond 
fission or ionisation of the alkylating agent (HY) to yield a carbonium 
ion (R+) (reaction 9)» This is followed by a much faster bond formation 
between carbonium anion and nucleophile, completing the first-order
RY -----=» R+ + Y' (9)
SLOW
R+ + X~ -----3» RX (10)
FAST
nucleophilic substitution (SN!) reaction (reaction 10). Some alkylating
agents such as primary and secondary alkyl halides (e.g. methyl iodide, 
isopropyliodide) undergo second-order nucleophilic substitution (S^ 2) 
involving the formation of a transition state (reaction 11).
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RY + X -- >  Y”  R == X --;> Y + RX (11)
TRANSITION
STATE
2-chloroethylamines such as the nitrogen mustard derivatives tend to 
undergo an S^ l type of reaction producing a cyclic aziridinium (ethylene- 
immonium) ion in the step equivalent to reaction 9 (reaction 12).
CH.
(12)R2N-CH--CH2-C1 --- ^ Cl
^CH2
2-CHLCROETHYLAMINE AZIRIDINIUM ION
Phosphoramide mustards such as CP have been shown to undergo such 
reactions by selective deuterium labelling of the side chain (170). Using 
PM labelled only at the p-carbons (Fig. 1.11) Colvin et_ al. found that 
upon reaction with ethanethiol, the product contained deuterium atoms 
distributed uniformly in the a and p positions. This result is explained 
best in terms of aziridinium ion formation, where a and P carbon atoms of 
the side chain are equivalent. Reaction of this symmetrical ion with 
ethanethiol produced scrambling of the label due to the equivalence of the 
a and P carbons. Direct displacement of the chlorine atoms in the 2- 
chloroethyl side chain by Sfj2 reaction (reaction 11) would not have produced
such scrambling
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Cyclisation of the reactive aziridinium ion (reaction 12) is affected 
by the basicity of the nitrogen atom, and is therefore influenced by the 
substituents of the nitrogen mustard derivative. Strongly electronegative 
substituents have the effect of reducing the rate of cyclisation, and this 
is generally true of fully substituted phosphoramide mustards (esterdi- 
amidates, triamidates, diesteramidates) the phosphoryl group being 
inherently electronegative. In phosphoramidic acid mustards such as PM 
(Fig. 1.11) the hydroxyl group is ionised at physiological pH and its 
electron-repelling effect actually enhances the basicity of the nitrogen 
atom. This increases both the rate of cyclisation to the reactive 
intermediate and (therefore) the alkylating activity (H+3)* CP, however, 
shows no alkylating activity in the NBP test, whereas other esterdiamidates 
show at least some activity.
Since ionisation is important for reactivity, it is not surprising 
that the pH of the medium may influence alkylation. Alkylation would be 
much reduced at a pH below the isoelectric point since ionisation would be 
repressed, decreasing the negative charge on the molecule. Alkylation would 
be enhanced at a pH above the isoelectric point since ionisation would be 
favoured (reaction 13)-
9*
PM, HN2 and nor-HN2 are strong alkylating agents at low pH but only 
PM and HN2 retain some reactivity at physiological pH (7.1* )• This is 
due to the fact that nor-HN2 is active when protonated at low pH but is 
converted to ethylenimine at higher pH (reaction 1*0.
The ethylene iaines derived from PM and HN2 cannot be neutralised by the 
loss of a protein and so retain their charge at physiological pH. OHCP has 
very little alkylating activity at pH6.0 and no measureable activity at 
physiological pH (Table 1.6) as compared to PM. OHCP, like HN2, is a more 
potent alkylating agent under conditions of low pH.
Another method of assessing the chemical reactivity of CP and 
derivatives is by estimation of the rate of chloride ion liberation. Such 
liberation occurs during alkylation (reaction 8), but the interpretation 
of such measurements is very difficult. The NBP assay is a direct measure 
of alkylation of the NBP molecule and requires no further considerations. 
Chloride ion liberation, however, occurs during intra-molecular alkylation 
(reaction 12) which may theoretically lead to inter-molecular alkylation.
It is also possible that intra-molecular alkylation may not lead to further 
alkylation but result in the formation of an ethylenimine as is the case 
with nor-HN2 (reaction 11»). Intramolecular cyclisations such as that 
occurring during CP hydrolysis (section 1.15(iv)) will also lead to 
chloride ion release without alkylation of "target" substrates. Even so, 
both NBP and chloride ion liberation assays have been used to quantitate 
chemical reactivity with biological activity for both CP and its metabolites.
TABLE 1.6 Alkylating activity of CP metabolites using the NBP test (161)
PH nor-HN2 PM OHCP
1*. 82 0.663 0.791 -
6.0 0.351 0.270 0.011*
6.88 0.052 0.2A3 -
7.A 0.016 0.11*8 0.000
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1.17 Biological Activity
As has been already discussed, CP is an inactive transport form which 
gives rise to active derivatives i_n vivo, a process known as "drug 
latentiation" ( I kU) . This process has the effect of reducing the general 
toxicity of the drug while preserving its chemotherapeutic potency and thus 
introducing a margin of safety. Since CP undergoes a complex variety of 
biotransformations, it is important to establish which of the major 
metabolites is responsible for the biological effects of CP and which may 
be the transport forms. The active form(s) must spontaneously react with 
the biological substrate and would therefore be expected to have a high 
chemical activity as well as a high jin vitro and i£ vivo cytotoxicity. The 
transport form would be expected to demonstrate low chemical reactivity and 
in vitro cytotoxicity but a high in_ vivo cytotoxicity. Oncostatic 
specificity, obviously a prerequisite for an anti-tumour agent, could be 
exhibited at any stage previously mentioned. CP has a relatively high 
oncostatic specificity. This has been evaluated quantitatively by 
determining the therapeutic index (TI) of the drug (171) which is the 
ratio of the LD^q (the concentration of drug required to kill 50# of the 
animals in the test; Lethal Dose^Q) to the CD (the concentration 
required to produce tumour regressions in 50# of the animals treated; 
Curative Dose^). For the potent cytotoxic agent nor-nitrogen mustard, 
the TI in Yoshida ascitic sarcoma of the rat is 2.5 whereas for CP it is 
175 (Table 1.7). It can also be seen from Table 1.7 that CP has a low 
chemical reactivity compared to that of nor-HN2, in terms of both alkylating 
activity and chloride ion liberation. These compounds therefore represent 
the extremes of activity of CP metabolites which show cytotoxic activity. 
With the exception of KP which is completely inert in terms of chemical
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reactivity and biological activity and acrolein which lacks alkylating 
activity, CP metabolites show gradation of activity between these two 
limits. OHCP demonstrates some alkylating activity at low pH (Table 1.7) 
although it exhibits none at physiological pH (Table 1.6). It has a 
demonstrable cytotoxic activity ¿n vitro, slowly liberates chloride ions 
and exhibits a high TI of 120. All other metabolites tested (172) had 
TI's below *♦. Correspondingly, PM, CarbP and nor-HN2 have relatively high 
alkylating activity (Table 1.7). This is an interesting observation since 
OHCP is the primary hydroxylated metabolite and all compounds tested with 
low therapeutic indices are produced after this in the metabolic scheme 
(Fig. 1.9) and has been considered evidence that OHCP is responsible for 
the oncostatic specificity of CP (171).
The use of deuterated analogues of CP has shown that isotope effects 
of 2.2 and 1.8 obtained for the formation of KP (e.g. the b - d ^ analogue) 
and CarbP (l»,6-d^  analogue) respectively caused no change in anti-tumour 
activity (173). This parameter was measured against advanced ADJ/PC6 
tumour in female BALB/C mice. However, in the same study, the 5-d2 
analogue in which ^-elimination of acrolein (section 1.4(iii)) was 
decreased by a factor of 5-3, showed a marked drop in anti-tumour potency, 
a 7 to 13-fold increase in CD^q. Furthermore, when the release of acrolein 
(or its analogous unsaturated aldehyde) was completely blocked by use 
of the 5,5-dimethyl-CP derivative, it produced a complete loss of 
biological activity (172). These data suggest that PM is the active, 
alkylating metabolite both ¿n vitro and _in vivo.
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1.18 Specificity
(i) It is still uncertain how CP attains its anti-tumour specificity and 
various proposals have been suggested on the basis of several lines of 
evidence. It is, however, generally accepted now that PM is the CP 
metabolite responsible for alkylating target macromolecules within the 
cell (15 1) (160) (1if3) and some evidence for this has already been 
presented. Struck et al. (161) have reported that high levels of PM 
relative to those of OHCP could be isolated from the blood of mice after 
administration of [1**C] CP. This has also been observed in patients treated 
with CP (171*). It has therefore been suggested that PM may be released 
from OHCP after its formation in the liver (161). A certain degree of 
selectivity may be afforded by the different reactivity of PM at different 
pH values. It is well known that some tumour cells have a reduced intra­
cellular pH value which may be as low as 6.8 (175)* From Table 1.6 it can 
be seen that PM demonstrates a 1.6-fold increase in activity at this pH 
value than at pH7.it, the pH to be found in normal cells. Such a small 
difference in alkylating activity is probably not responsible for the high 
oncostatic specificity of CP but could, nevertheless, be a significant 
factor. It can be seen from Table 1.7 that the therapeutic index for PM 
is very low (3*5) and this argues against the idea that it is the circulating 
level of PM in the blood which is responsible for selectivity. Furthermore, 
PM is less immunosuppressive than CP (176) and does not cause depilation 
(1^3), suggesting that these actions of CP are caused by some other 
metabolite(s).
Brock (172) has reported that the concentration of OHCP required to 
be cytotoxic to Yoshida sarcoma cells is 25-fold lower than the equivalent 
cytotoxic dose of PM (Table 1.7). This has also been reported for CP
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activated i£ vitro by microsomal incubation and tested for cytotoxic 
activity against murine L1210 leukaemia cells; the concentration needed 
was 20-fold less than that of PM required for cytotoxicity (1i*3)• The 
concentration of 'activated' CP required is very similar to the cytotoxic 
dose of OHCP O^).
¿♦-methyl-CP has been found to be more toxic but of a lower therapeutic 
index than CP (176). Since this compound is metabolised in a similar way 
to CP (177) and produces PM, its effect cannot be due simply to the 
release of this metabolite.
It has been suggested, therefore, that OHCP, AP or iminophosphamide 
acts as the transport form of PM, being capable of entering the cell 
where release of the active metabolite occurs.
(ii) Permeation
Permeation of metabolites into cells is an obviously important property 
since the active metabolite must be within the cell in order to exert its 
effects. Differences in the permeation rates of CP metabolites into normal 
or tumour cells could influence the specificity of CP action. It is well 
known that some molecules may enter cells via a carrier-dependent transport 
mechanism, HN2 transport has been shown to be mediated by a choline 
carrier (178). More recently, Byfield and Calabro-Jones (179) have 
demonstrated that many water-soluble alkylating agents exhibit carrier- 
dependent uptake (i.e. HN2) and that lipid-soluble alkylating agents are 
carrier-dependent. Unfortunately, these workers were unable to assess the 
mechanism of transport of PM due to its negligible effects upon the T- 
lymphocytes used in their assay. Draeger and Hohorst (180) have studied 
the permeation of CP metabolites into tumour cells, and their results show 
that nor-HN2 had the greatest uptake of the derivatives tested and reached
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its saturation after 20 minutes incubation. In contrast, CarbP showed very 
rapid kinetics, reaching saturation within 20 seconds. However, very little 
uptake of CarbP was observed and these results were interpreted as 
adsorption of CarbP to the cell surface rather than uptake into the cell.
CP and HP showed very nearly the same saturation kinetics and saturation 
value (=5 nmol/mg protein) which was about half that observed for nor-HN2.
These workers have also shown (180) that while CP can be excluded 
rapidly from tumour cells, HP shows a certain degree of retention within 
the cells during sequential washings. They found that retention was greater 
at 37°C than at 0°C, for HP and that temperature had no effect on the 
efflux of CP from the cells. The stronger retention of HP was suggested 
to result from binding of this derivative to cellular components, although 
no loss in its alkylating activity was detected. Thus a reaction other 
than alkylation was responsible. It was suggested that retention of HP in 
the cells may have been due to a reaction between protein sulphydryl groups 
and OHCP, which is released spontaneously from HP (157)»
(iii) Sulphydrvl Binding
The reaction between OHCP and thiols is thought to occur via an 
iminophosphamide intermediate (H»3) (151)• Various sulphydryl compounds 
have been found to react reversibly with OHCP (169). Protein binding 
studies have shown that OHCP can bind to the thiol groups of bovine serum 
albumin yielding a quite stable product (153) capable of being isolated by 
Sephadex column chromatography. The reaction is shown in Fig. 1.12, and 
results in an equilibrium between bound OHCP and free OHCP which is capable 
of spontaneous decomposition to yield PM, via AP, through tautomeric 
equilibrium. Thus, the release of active alkylating material (PM) is 
dependent upon the two equilibria of thiol binding of OHCP and its 
tautomerisation to AP. The concentration of AP is established by the OHCP/
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thiol equilibrium and therefore the reaction rate of release of PM is 
inversely proportional to the concentration of free thiol compound (169).
This alteration in the rate of production of the alkylating metabolite by 
thiol compounds may enhance the stability of the metabolites in the plasma 
(171). It has also been suggested that such reactions could facilitate the 
entry of metabolites into cells, direct their movement to specific sites 
inside the cells and delay the release of alkylating phosphoramide 
mustard. The oncostatic specificity of CP would therefore be due to the 
particular reactions of OHCP (171)« This is supported by the estimated 
cytotoxic specificity for OHCP in vitro (Table 1.8) and also by the very 
high TI exhibited by OHCP in vivo (Table 1.7).
(iv) Selective Detoxification
The detoxification of OHCP and AP by enzymic oxidation to KP and CarbP 
respectively, (section 1.15(i))» has been suggested by Sladek (181) and 
Connors et_al. (151) to be responsible for the selectivity of CP. Cox et 
al. (182) have shown that the ability of tissue soluble-enzyme fractions 
to "detoxify" biochemically prepared AP, AP analogues and PM varied with 
the tissue used. The range of deactivating ability obtained was; 
liver »  kidney »  intestinal mucosa > tumour > spleen = bovine serum 
albumin solution. This finding supports the idea that normal tissues contain 
more of the enzymes necessary for deactivation than does tumour tissue.
Only spleen contained less deactivating activity than the Walker ascites 
tumour cells used in the study. They have also correlated the deactivating 
ability of these tissues with NAD+-dependent aldehyde dehydrogenase 
activity. Cox et^  al. (177) have also pointed out that although <»-methyl-CP 
is metabolised in a similar way to CP and produces PM, it cannot form 
metabolites analogous to KP and CarbP. 4-methyl-CP has a lower therapeutic
TABLS 1.8 Cytotoxic specificities for selected CP metabolites
COMPOUND CYTOTOXIC 
SPECIFICITY (a) 
(in vitro)
THERAPEUTIC 
INDEX (b) 
(TI)
OHCP 160 120
PM 1.3 3-5
nor-HN2 <♦.1 2.5
HN2 12 U.U
(a) (cytotoxic activity/alkylating activity) x 10.
Alkylating activity in nor-HN2 e 
(b) See Table 1.7
quivalents/mol./min.
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index than CP, indicating that its metabolites are less selective in their 
toxicities toward normal and tumour tissues. This further lends weight to 
the hypothesis that active CP metabolites are not released into normal 
cells to the same degree found in tumour cells due to the high activity 
of deactivating enzymes in the former. The primary CP metabolites OHCP and 
AP are metabolised to non-alkylating derivatives more rapidly in normal 
tissue than in tumour tissue. As a result, tumour cells are subject to the 
full cytotoxic effect of PM, released from activated CP, whereas normal 
cells are only minimally affected.
Hohorst et al. (1?1) however, do not agree with this hypothesis. The 
enzymatic deactivation of primary CP metabolites, they argue, appears to 
contribute little to the specificity of CP in vivo. It is also unable to 
explain the specificity of OHCP i l l vitro (estimated by relating the in 
vitro cytotoxicity, Table 1.7, to alkylating activity) (Table 1.8). It is 
suggested that if in vitro cytotoxicity of these compounds is only related 
to their alkylating activity, then all values for cytotoxic specificity 
would be approximately equal, and they clearly are not. Furthermore 
Gurtoo et al. (183) have evaluated the role of aldehyde dehydrogenase 
(ADH) in two strains of mice with differing phenobarbital-inducibilities 
for ADH and CP-activating enzymes. They conclude that there is no 
correlation between CP activation and ADH activity and that ADH is not a 
significant determinant in the metabolism of CP, in the binding of CP to 
macromolecules or in the chemotherapeutic activity of CP.
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1.19 Stereochemical Effects
Because CP contains a chiral phosphorus atom and therefore exists as 
a mixture of optical isomers (Fig. 1.13) it would not be unreasonable to 
suppose that there may be differences in the metabolism of the different 
isomers. U-hydroxylation introduces another chiral centre to the molecule 
and differences in the activities of the four resulting isomers of OHCP 
may also be expected.
Struck et^al. (1?6) found that for the i*-methyl derivative of CP, 
there was no difference in metabolism or activity between its cis and trans 
isomers. Cox et al. (18lf) have reported that (-) - CP derivatives were 
obtained from the urine of patients treated with racemic, (-) - CP. They 
found up to 83*0 91% of the (-) - isomer in some cases, which suggested 
stereo-selective metabolism of the R - (+) - isomer. Furthermore, when 
tested against plasma cytoma cells in mice, the S - (-) - isomer was found 
to be more effective. The reported TI's were; (-) - CP = 128.1, (+) - 
CP = 68.9, (-) - CP = 93.
The products of (+) or (-) - CP microsomal incubations were found to 
have equal toxicities against Walker tumour cells in_ vitro. Mass spectro­
metry of deuterated or non-deuterated enantiomers of CP metabolites after 
administration as pseudoracemates showed very little stereoselectivity of 
hydroxylation since the CP recovered in urine samples resembled that 
administered (185). The production of KP, however, was found to pre­
dominate from the (+) - isomer, whereas production of CarbP predominated 
from the (-) - isomer, but to a lesser extent.
An apparent species difference has also been reported (186). 
Stereo-selective metabolism was found in the rabbit but not in the mouse or 
rat, the S - (-) - isomer showing a ¡»-fold greater rate of metabolism in
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metry of deuterated or non-deuterated enantiomers of CP metabolites after 
administration as pseudoracemates showed very little stereoselectivity of 
hydroxylation since the CP recovered in urine samples resembled that 
administered (185)• The production of KP, however, was found to pre­
dominate from the ( + ) - isomer, whereas production of CarbP predominated 
from the (-) - isomer, but to a lesser extent.
An apparent species difference has also been reported (186). 
Stereo-selective metabolism was found in the rabbit but not in the mouse or 
rat, the S - (-) - isomer showing a l*-fold greater rate of metabolism in
Fig. 1.13 Structure of The Optical Isomers of Cyclophosphamide and
Hydroperoxy-CP
(a) R - ( + ) - C P S - ( - ) - C P
(b) R-Hydroperoxy-R-CP S-Hydroperoxy-R-CP
In all structures the ring is in the chair conformation.
In R-(+)-CP the jphosphoryl oxygen is axial to the ring and trans 
to the ring nitrogen's hydrogen atom, although the geometries about the 
exo and endo nitrogen atoms is almost planar.
The R-Hydroperoxy group is axial to the ring and the chloroethyl 
side chains assume varied conformations. R and S forms of 4-hydroperoxy-CP 
also exist in the S-(-)-CP conformation, ( not drawn).
(a) drawn using data from ref. (189).
(b) drawn using data from ref. (190).
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liver microsomal incubations. _In vivo differences were also reported for 
R/S isomer ratios of KP recovered in the urine. These were; R/S = 3*0 
(mouse), S/R = 3-8 to 11.1 (rabbit), no selectivity (rat).
Tsui flt al. (187) have demonstrated selective activation of CP isomers 
by microsomes from phenobarbital-induced mouse livers. Table 1.9 
summarises these results. It can be seen that these results indicate a 
slight difference in kinetic parameters for the two isomers of CP. These 
workers have also reported that no difference in TI's could be found for the 
isomers in screening tests against mouse L1210 lymphoid leukaemia.
Jarman et_ al. (188) report that there is no difference between the 
isomers of CP in the plasma half life of CP or in the urinary output of 
CarbP from CP treated patients. They have found that the production of 
urinary KP is greatly increased by administration of (+) - CP compared to 
the racemate, again suggesting stereoselective metabolism of the (+) - 
enantiomer regarding KP production. They also report that the enantiomers 
were found to be equally bound to plasma protein.
There is little evidence for any stereoselectivity between the isomers 
of CP other than urinary metabolite production. The increased production 
of KP during (+) - CP metabolism (and presumably an increased deactivation) 
appears to have little effect upon the therapeutic efficacy of CP (185).
1.20 Biological Effects
(i) Target Molecules
The biological effects of alkylating agents such as CP are considered 
to be brought about by the alkylation of target molecules within the cell. 
Since active CP metabolites react with nucleophilic centres (section 
1.16) such targets will include organic and inorganic anions, primary,
TABLE 1.9 Stereoselective microsomal activation of CP isomers
R - ( + ) - C P S - ( - ) - C P ( - ) - C P
Vmax ^ 13.8 -  1.0 20.0 -  1.5 16.3 - 1 .1
Km (mM) 0.37 - 0.02 0.56 - O.Oi* 0.i*5 - 0.02
Vmax, (-)-CP
= 1.34  -  0 . 1?
Vmax, (+)-CP
Km, (-)-CP
Km, (+)-CP
1.35 - O.H*
(a) ymol. nor-HN2 equivalents/g. liver/Hr.
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secondary and tertiary amines, heterocyclic-ring N-atoms and sulphides 
(191). Covalent bonding to compounds of low molecular weight is probably 
not important for the agent's cytotoxic effects since the products of 
such reactions are probably rapidly removed from the cell and excreted. 
However, such compounds afford some protection to the cell and may be 
important if in high (or low) enough concentration in only particular 
tissues. This effect has been put to good use in a tissue-protective 
role by the simultaneous adminstration of sulphydryl agents with C? 
(section vi) (169).
More critical to the functioning of the cell is the alkylation of 
macromolecules, where such alkylation interferes with their biochemical 
activity. Many structural proteins and enzymes react with alkylating 
agents, but at physiological dose levels the alkylation has been shown to 
be small compared with the number of enzyme molecules present, so that a 
serious enzyme inhibition does not necessarily result (192)»
The prime target for alkylation is thought to be nucleic acid at 
present the most satisfactory hypothesis is that DNA is most sensitive to 
alkylation and that inhibition of some aspect of DNA function is the 
primary cause of cytotoxicity. The most extensively alkylated site in 
nucleic acids is the N7 position of guanine, less extensively alkylated 
is the N1 position of adenine, N3 of adenine, N3 of cytosine and 06 of 
guanine (see Fig. 1.1) (192). Differences in the extent of alkylation of 
these sites between RNA and DNA are probably due to the availability of the 
site. In DNA, the N1 of adenine and N3 of cytosine are both involved in 
hydrogen bonding of base pairs. Whereas these are sites of extensive 
alkylation in RNA, they are much less extensively alkylated in DNA.
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Alkylation of these and other sites in nucleic acids may lead to the 
loss of the base from the polynucleotide chain. In DNA further breakdown 
of the chain may occur. Bifunctional alkylating agents such as PM may 
cross-link the two strands of the DNA helix. Loss of cross-linked residues 
would be more serious and may result in DNA scission. The cross-linking 
of adjacent guanine residues in the N7 position was thought to be the 
predominantly toxic reaction but the cross-linking of a number of nucleo­
philic centres also occurs. Interstrand cross-linking of DNA would result 
in an inhibition of mitotic division by inhibiting DNA synthesis and thus 
constitute an effective block to cell division. Cross-linking can also 
occur between DNA and protein. HN2-treated L1210 cells have been shown to 
acquire cross-linked DNA to alkylated residues of large non-histone 
proteins of the nucleus (195)*
(ii) Mutagenicity and Carcinogenicity
As well as being Cytotoxic, CP has been shown to be mutagenic and 
carcinogenic. CP, after metabolic activation, produces mutations in a 
variety of test systems (11*0. Gatehouse, however, has also reported 
mutagenic activity from the breakdown products of CP, formed during its 
storage in phosphate buffer (193). This may indicate that some breakdown 
products are similar to CP metabolites found i_n vivo. The most potent 
mutagenic derivative which seems to fit these criteria is nor-HN2.
CP and HN2 are carcinogenic in mice (190 and produce pulmonary 
tumours in mice in a dose-dependent manner. HN2 was found to be effective 
at concentrations 300 times lower than CP, reflecting the fact that only 
an active CP derivative is responsible for this action. No relationship 
has been observed between carcinogenicity and chemotherapeutic activity 
(190.
These effects are certainly produced by the action of CP metabolites 
on DNA, although the precise mechanism(s) is unknown.
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(iii) Teratogenicity
Binding studies of radiolabelled CP to nucleic acids and proteins 
of embryonic tissues in pregnant mice have suggested that the teratogenic 
effect of CP is exerted via the alkylation of DNA (196). The production of 
an active species from CP is dependent upon maternal metabolism since the 
embryo does not possess the microsomal enzymes necessary for CP activation. 
Previous in vitro studies, however, have indicated that unmetabolised CP
(197) and the urinary metabolic KP (198) have teratogenic activity. Recent 
studies indicate that PM is the metabolite responsible for teratogenic action, 
having a 10,000-fold greater activity than CP alone (199). HP was also 
shown to have similar activity to PM, presumably due to the formation of PM 
from this compound.
(iv) Immunosuppression
/
CP is known to suppress both the humoral and cellular immune responses 
in many animals including man (1^ 3) and is possibly the most potent 
immunosuppressive agent yet discovered. Contrary to most other effects 
of CP, alkylation does not seem to be important for this activity. PM has 
been found to have very little effect even at doses which induce 
haemopoietic depression. Of the CP metabolites tested for immuno­
suppressant activity, chloroacetaldehyde, a product of side chain 
hydroxylation, has been suggested as the mediator of this effect. The 
immunosuppie6sive action of CP has led to clinical usage in the treatment of 
non-malignant diseases, in two particular fields; (i) suppression of the 
immune response prior to organ transplantation, especially of bone marrow 
which has been highly successful in the treatment of acute leukaemia,
(ii) treatment of auto-immune diseases including rheumatoid arthritis.
The use of CP in the treatment of non-malignant diseases is limited because
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of various unfavourable side-effects. In particular, the carcinogenic 
action of CP has led to the occurrence of acute myelogenous leukaemia in 
some patients treated with CP for rheumatoid arthritis.
(v) Anti-tumour Activity
CP is effective against Yoshida sarcoma, Walker 256 carcinoma, L1210 
murine leukaemia and many other animal tumours including the virally- 
induced Friend and Rauscher leukaemias (143)* CP has been shown to be 
somewhat less effective against experimental epithelial tumours. PM has 
been shown to be effective against many of these but its activity relative 
to that of CP varies, depending on the tumour studied.
The wide spectrum sensitivity to CP seen in animal tumours is 
reflected in the large number of human tumours responsive to CP therapy. 
Lymphoid tissues are most sensitive to the effects of CP. In many 
instances consistent and satisfactory responses to CP therapy have been 
seen in which a significant prolongation of life and even cure have been 
obtained (143)•
CP is used mostly in combination chemotherapy regimens but has shown 
a dramatic response when used in Burkitt's lymphoma as a single agent. In 
early disease CP produces a >90% complete remission rate, with over 80% 
of children remaining long-term survivors. Treatment of advanced disease 
results in a 50% long-term survival rate.
One of the most widely used combination regimens is MOPP 
(Mechlorethamine/HN2, Oncovin/vincristine, Procarbazine and Prednisone) 
which is used against Hodgkin's disease. Substitution of CP for HN2 has 
no effect on the therapeutic response of this particular disease.
CP chemotherapy has shown good responses in the treatment of childhood 
acute lymphocytic leukaemia (40% response rate in previously untreated;
10% in previously treated patients) ovarian cancer, and breast carcinoma 
(35% overall response rate with CP alone, >50% in combination).
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PM has been used clinically (1*t3) and the main differences between 
it and CP were increased nausea and vomitting, lack of alopecia and 
few objective anti-tumour responses.
(vi) Side-effects
CP treatment has various side-effects due to the toxicity of CP 
metabolites. Cardiac toxicity is the dose-limiting effect of treatment 
with CP but heart failure only occurs at very high dose levels ( >100 
mg/kg in Hr). Gonadal damage (aspermia, amenorrhea) has been reported. 
Nausea is apparently caused by PM, since in clinical studies involving 
treatment with PM, this effect was greatly increased. Water retention 
(increased urine osmolality) alopecia (hair loss) a side-effect employed 
for non-mechanical sheep shearing (200) and teratogenic and carcinogenic 
effects have also been observed.
The latter have been discussed, however, the teratogenicity of CP 
has been shown to be decreased by administration of thiol compounds (201) 
or pyrithinoldehydrochloride (202) and the use of thiols to prevent 
teratogenic effects in pregnant patients treated with CP has been suggested 
(201).
Haemorrhagic cystitis is caused by the effects of CP metabolites in 
the urine on the mucosa of the urinary bladder. Cystitis occurs in the 
rat treated with CP, isophosphamide and, to a lesser extent, PM. Cox 
(203) has shown that diethyl-CP (H atoms replace the Cl atoms) also causes 
severe cystitis. Since acrolein is the only reactive metabolite of diethyl 
CP, it is most likely this compound which causes cystitis. Acrolein has 
been shown to be capable of binding to proteins and free thiol groups (20i*). 
Due to its high reactivity it is probably only present for a short 
duration and is largely excreted into urine as 3-hydroxypropylmercapturic 
acid (205). Binding to thiols has been used to prevent damage of the
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urinary bladder by local instillation of N-acetyl-L-cysteine (203).
Wrabetz et_ al_. (206) have shown that acrolein does not contribute to the 
cytotoxic action of CP.
1.21 Modification of CP Action By Modification of Its Metabolism
The modification (by stimulation or inhibition) of CP metabolism has 
been discussed (section 1.1U(i)). Changes in the rate of biotransformation 
of compounds where, unlike CP, the parent compound is the active species, 
would be expected to produce quantitative changes in therapeutic response. 
Sladek (207) however, has pointed out that where a metabolite rather than 
the parent compound is effective, as is the case for CP, no effective change 
may be expected by alteration of the rate of biotransformation.
Although the rate of activation of CP can be stimulated or depressed 
by pretreatment with various drugs which effect its metabolism in the 
liver, the response to activated metabolites which produce an all-or- 
nothing effect (e.g. tumour cell kill) depends on concentration of 
metabolite and its time of contact with the cell. _In vivo, the increased 
activation rate of CP due to pretreatment with liver enzyme-inducers 
(e.g. phénobarbital) is accompanied by an apparent increased disappearance 
rate of alkylating activity from blood and urine, and vice versa.
Altered blood levels are accounted for by alterations in the activation 
rate of the anti-tumour compound. An increase in the concentration of 
activated metabolite is observed early with lowered concentration observed 
later, when metabolism has been stimulated. The reverse is true when 
metabolism has been depressed.
Sladek states that this inability to alter the therapeutic efficacy 
of CP by modification of its metabolism, demonstrates the futility of 
trying to improve the efficacy of CP in patients by pretreatment with 
drugs which alter CP metabolism (207).
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
(i) Chemicals
The following compounds were purchased from Sigma (London) Chemical 
Co. Ltd. :
ATP, Bovine serum albumin (crystallised and lyophilised), cyclic 
AMP, cyclic GMP, dithiothreitol, EGTA, GTP, glucagon, glucose-6-phosphate, 
HN2 (hydrochloride), NBP (y-(p-nitrobenzyl)pyriaine), Triton X-100 and 
MNNG.
Sodium fluoride and sodium lauryl sulphate (SDS) were purchased from 
Hopkin and Williams and BDH Chemicals Ltd. were the suppliers of Folin 
reagent E, imidazole and theophylline.
Fisons Chemicals Ltd. supplied PPO and POPOP for scintillation 
counting and NADP and DTNB (5*5'-dithiobis(2-nitrobenzoic acid)) were 
obtained from Boehringer Mannheim, GmbH.
Cyclophosphamide was a gift from Boehringer, 4-hydroperoxycyclo- 
phosphamide was a gift from Dr M. Colvin, Johns Hopkins Oncology Centre, 
Baltimore, Maryland and phosphoramide mustard was a gift from the 
National Institutes of Health, Bethesda, Maryland.
Sensitox II (Chemical Dynamics Corp. NJ.) was a gift from Dr M. 
Jarman, Chester Beatty Research Institute, London.
(ii) Enzymes
Glucose 6-phosphate dehydrogenase (E.C. 1.1.1.49) type XI, Cobra 
(Ophiophagus hannah) snake venom and creatine phosphokinase from rabbit 
muscle, type I, wore obtained from the Sigma (London) Chemical Co. Ltd.
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(iii) Radiochemicals
Adenosine 5,~C«'-'^P]triphosphate, [adenine-U-1i*C]adenosine 3*»5*~ 
cyclic phosphate, guanosine 5,~[a-^P]triphosphate and [8-1i*C]guanosine 
3',5'~cyclic phosphate were purchased from the Radiochemical Centre, 
Amersham, Bucks, UK.
[a-^P]triphosphates were stored in dry ice and utilised within one 
week, [1l+C]cyclic nucleotide phosphates were stored at -25°C.
(iv) Chromatography Resins
All Dowex resins were purchased from Sigma (London) Chemical Co. Ltd. 
Aluminium oxide (neutral grade, activity grade I) was purchased from 
BDH Chemicals Ltd. Merck supplied kieselgel 60 (0.0+0 - 0.063*®, 230 - 
i+00 mesh) for use in 'flash' chromatography and kieselgel 60, f254 for 
thin layer chromatography.
(v) Apparatus
(A) Chromatography
"Econocolumns" were purchased from Bio-Rad Laboratories, polypropylene 
(i+ x 0.7 cm) for use in adenylate cyclase assays and glass (15 x 0.7 cm) 
for use in guanylate cyclase assays.
A Waters Associates model M-6000A HPLC was used with a C-18 pBondapak 
reverse-phase column and an Rl+01 differential refractometer for compound 
detection.
(B) Spectroscopy
1 3[ CjNMR spectra were obtained from a Bruker WH-90 spectrometer by
M i s s .  L.Y.  U a n .  Mass spectra were obtained from a Carlo Erba/Kratos
mass spectrometer by Mr. I . K a t a l .  All other spectra were obtained
1by myself. [ H]NMR spectra were recorded on a 220 MH^ Perkin Elmer R34 
NMR spectrometer, IR spectra on a Perkin Elmer 257 grating IR spectro­
photometer and UV/visible spectra were run on a Unicam SP1800 ultraviolet 
spectrophotometer. Routine absorbance measurements were made using a 
Unicam SP600 spectrophotometer.
71
(iii) Radiochemicals
Adenosine 5'-[a-^2P]triphosphate, [adenine-U-1!*C]adenosine 3*»5* — 
cyclic phosphate, guanosine 5'-[a-^2P]triphosphate and [8-1i+C]guanosine 
3',5'-cyclic phosphate were purchased from the Radiochemical Centre, 
Amersham, Bucks, UK.
[a-^P]triphosphates were stored in dry ice and utilised within one 
week, [1i>C]cyclic nucleotide phosphates were stored at -25°C.
(iv) Chromatography Resins
All Dowex resins were purchased from Sigma (London) Chemical Co. Ltd. 
Aluminium oxide (neutral grade, activity grade I) was purchased from 
BDH Chemicals Ltd. Merck supplied kieselgel 60 (0.0+0 - 0.063mm, 230 - 
kOO mesh) for use in 'flash' chromatography and kieselgel 60, f254 for 
thin layer chromatography.
(v) Apparatus
(A) Chromatography
"Econocolumns" were purchased from Bio-Rad Laboratories, polypropylene 
(4 x 0.7 cm) for use in adenylate cyclase assays and glass (15 x 0.7 cm) 
for use in guanylate cyclase assays.
A Waters Associates model M-6000A HPLC was used with a C-18 pBondapak 
reverse-phase column and an Ri+01 differential refractometer for compound 
detection.
(B) Spectroscopy
13[ CjNMR spectra were obtained from a Bruker WH-90 spectrometer by
M i s s .  L.Y. Lian.  Mass spectra were obtained from a Carlo Erba/Kratos
mass spectrometer by Mr. I . K a t a l .  All other spectra were obtained
1by myself. [ H]NMR spectra were recorded on a 220 MH^ Perkin Elmer R3*+
NMR spectrometer, IR spectra on a Perkin Elmer 257 grating IR spectro­
photometer and UV/visible spectra were run on a Unicam SP1800 ultraviolet 
spectrophotometer. Routine absorbance measurements were made using a 
Unicam SP600 spectrophotometer.
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(C) Centrifugation
The following centrifuges and rotors were used in the course of this 
work : BTL bench centrifuge, Sorvall superspeed RC2-3 (GSA and SS- Jk  
rotors), Beckman model L-2 ultracentrifuge (swing out Stf25.2 rotor) and 
the Spinco L-50 (*»0 and 30 rotors).
(D) Miscellaneous
A Gallenkamp melting point determination apparatus was used and a 
British Oxygen Company B.O.C. Mk. II ozoniser was employed to produce 
ozone. A Packard 21*25 Tricarb liquid scintillation counter was used to 
measure radioactivity.
(vi) Animals
All rats used were male Wistar, weighing approximately 250 to 300g.
2.2 The Assay of Adenylate Cyclase Activity 
(1) Introduction
Adenylate cyclase catalyses the conversion of ATP to cyclic AMP and 
pyrophosphate in the presence of magnesium ions. This reaction is 
stimulated by one or more cell-specific hormones in the presence of GTP.
In these studies, using plasma membranes prepared from rat liver as the 
enzyme source, the stimulatory hormone was the peptide, glucagon.
Adenylate cyclase activity was measured using radiolabelled substrate. 
The formation of cyclic AMP was estimated, after thorough purification 
on two separate ion exchange columns, by liquid scintillation counting.
The specific activity of adenylate cyclase in eukaryotic tissues is 
very low and only a small percentage, usually less than 0.05# of the 
substrate ATP undergoes cyclisation to form cyclic AMP in an in vitro 
assay system. Assay sensitivity and reliability is therefore largely
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dependent upon and proportional to the efficiency with which cyclic AMP 
is separated from ATP and its breakdown products. Such products can 
accumulate at a high rate due to the activity of other enzymes present in 
almost every membrane preparation, possibly as contaminants. Due to the 
presence of such enzymes, cyclic AMP as well as ATP may give rise to the 
accumulation of adenosine in the reaction mixture.
Adenosine has been shown to stimulate (208) or to inhibit (209) 
adenylate cyclase activity of various sources. Cyclic AMP phospho­
diesterase is capable of hydrolysing any cyclic AMP as it is produced by 
adenylate cyclase in_ vitro. Methyl xanthines and other inhibitors can be 
used to reduce product hydrolysis but these do not completely eliminate the 
problem. If radiolabelled ATP is used as substrate, then a 'cold trap' of 
unlabelled cyclic AMP may be utilised to advantage. In the presence of 
10 mM theophylline and 0.05 mM cyclic AMP, adenylate cyclase may be assayed 
in rat liver plasma membrane preparations with 95 to 98% recovery of 
cyclic AMP.
Many techniques for the purification of the radiolabelled product 
of adenylate cyclase assays have been previously reported. These have 
been assessed primarily with respect to convenience (i.e. the time involved 
and complexity of procedure) but also with respect to sensitivity. 
Sensitivity approaches a maximum as assay blank values approach zero.
A single step chromatographic procedure using neutral aluminium oxide 
has been described (210) (211) and although rapid, simple and convenient 
sensitivity is diminished due to high blank values. Q values (see 
section (10)) using this procedure have been reported as high as 100 to 
300 (212). Another system is that of Krishna et^  ¿1. (213) utilising an 
ion exchange column of Dowex 50 which separates the bulk of radiolabelled
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c y c l i c  AMP f r o m  t h e  s u b s t r a t e .  T h i s  i s  f o l l o w e d  b y  p r e c i p i t a t i o n  o f  
n u c l e o t i d e s ,  o t h e r  t h a n  c y c l i c  AMP, b y  t h e  n a s c e n t  p r o d u c t i o n  o f  b a r iu m  
s u l p h a t e .  A l t h o u g h  t h i s  r e p r e s e n t s  a h i g h e r  s e n s i t i v i t y  (Q  = 15 ) i t  h a s ,  
h o w e v e r ,  b e e n  r e p o r t e d  t h a t  Ba^ + i o n s  w i l l  c a t a l y s e  t h e  n o n - e n z y m a t i c  
p r o d u c t i o n  o f  c y c l i c  AMP an d  t h u s  a n o m a l o u s  a c t i v i t y  may b e  m e a s u r e d  (2 1 < * ) .
P o l y a c r y l a m i d e  B o r o n a t e  G e l  c o l u m n s  h a v e  b e e n  u s e d  i n  a d e n y l a t e  c y c l a s e  
a s s a y s  ( 215 ) b u t  t h e  u s e  o f  o n l y  o n e  i o n  e x c h a n g e  c o lu m n  o r  o n l y  t h i n  
l a y e r  o r  p a p e r  c h r o m a t o g r a p h y  may b e  a r g u e d  t o  p r o d u c e  an  a s s a y  w h i c h  l a c k s  
s p e c i f i c i t y  a n d  t h e  c h o s e n  p r o c e d u r e  i s  t h e r e f o r e  a  tw o  c o l u m n  e l u t i o n  
f i r s t  d e s c r i b e d  b y  S a l o m o n  e t  a l .  ( 2 1 2 )  an d  m ore  r e c e n t l y  p u b l i s h e d  i n  
g r e a t e r  d e t a i l  ( 2 1 6 ) .
( 2 )  E x p e r i m e n t a l  P r o c e d u r e
I n i t i a l  s e p a r a t i o n  o f  c y c l i c  AMP f r o m  r e a c t i o n  m i x t u r e s  i s  a c h i e v e d  
u s i n g  a Dow ex AG50W-X<* ( 2 0 0  -  ¿*00 m e sh )  c o lu m n  e l u t e d  w i t h  w a t e r .  The 
f u n c t i o n a l  g r o u p  o f  t h i s  c a t i o n  e x c h a n g e  r e s i n  i s  a  s u l p h o n i c  a c i d  w h i c h  
r a p i d l y  e x c l u d e s  h i g h l y  c h a r g e d  a n i o n s  f r o m  t h e  c o l u m n .  N u c l e o t i d e s  a r e  
r e s o l v e d  b y  t h e i r  c h a r g e  c o n t e n t  a n d  t h e i r  m o b i l i t y  o n  t h e  r e s i n .  T h i s  
f i r s t  e l u t i o n  r e m o v e s  m o s t  o f  t h e  ATP i n  t h e  r e a c t i o n  m i x t u r e .
N u c l e o s i d e s  and  h e t e r o c y c l i c  b a s e s  a r e  r e t a i n e d  b y  t h e  Dowex c o l u m n .  
C y c l i c  AMP a n d  r e s i d u a l  ATP a r e  n e x t  e l u t e d  w i t h  w a t e r  d i r e c t l y  o n t o  
n e u t r a l  a l u m i n a  c o l u m n s  w h ic h  s t r o n g l y  a d s o r b  m u l t i v a l e n t  a n i o n s  ( 2 1 1 ) .
T h u s ,  t h i s  r e s i n  w i l l  s e p a r a t e  c y c l i c  AMP f r o m  t h e  n u c l e o t i d e ,  ATP, s u b ­
s t r a t e .  C y c l i c  AMP i s  e l u t e d  f r o m  t h e  a l u m i n a  c o l u m n s  w i t h  i m i d a z o l e  
b u f f e r  a l m o s t  i m m e d i a t e l y .
[ ^ P ] A T P  i s  u s e d  a s  s u b s t r a t e  i n  t h e  a s s a y  and  was  n o t  p u r i f i e d  
b e f o r e  u s e  a s  i t  was o b t a i n e d  f r o m  t h e  R a d i o c h e m i c a l  C e n t r e ,  Amersham, 
w h e r e  p u r i f i c a t i o n  i s  a c h i e v e d  e s p e c i a l l y  f o r  a d o n y l a t e  c y c l a s e  a s s a y s  o n
an  i o n  e x c h a n g e  c o l u m n .
75
'll*[ C]cyclic AMP is used as a column marker or internal standard to
determine the recovery of cyclic AMP from each column, this value being
32used to correct for any column loss of product [ P]cyclic AMP.
Although this assay system has been well documented, the column 
system was characterised before use to ensure that the chromatographic 
steps worked perfectly and to ensure the purity of the radiochemicals used.
(3) Elution Volume Determination
Elution volumes were determined by adding standards of [^PjATP and 
[ Cjcyclic AMP together with membrane protein and assay constituents to 
Dowex 50 columns (Fig. 2.1). At first, these columns were made as a slurry 
of Dowex resin and water but this was found to give irregular and 
irreproducibly sized columns. By drying the resin first, then weighing, 
columns of reproducible size were made.
(A) Dowex 50 Columns
After the addition of standards to the columns, portions of water 
(0.5 ml) were added and collected separately in scintillation vials for 
counting. After each addition, the columns were allowed to drain 
completely with no ill-effects to the column bed. This determined the 
elution profile of the Dowex 50 columns (Fig. 2.1C).
(B) Neutral Alumina Columns
(i) Standards were added to Dowex 50 columns and most of the ATP removed 
by the addition of water (2-5 ml) as determined by the elution profile for 
Dowex 50 columns (Fig. 2.1C).
(ii) The Dowex 50 columns were then placed above neutral alumina columns 
(0.6g in stoppered Pasteur pipette) and cyclic AMP eluted from the Dowex 50 
onto the alumina columns by the addition of water (1*.0 ml), again as 
determined by the elution profile for Dowex 50 columns (Fig. 2.1C).
Fie. 2.1 Slution Profiles of Columns Used In Th» Adenylate Cyclase Assay
A Dowex AG50X**, 5 ml slurry Dowex : water (1:1) 
B Dowex AG50XU, 2 ml slurry Dowex : water (1:1) 
C Dried Dowex used as column bed (2.5 g)
D Aluminium Oxide (0.6 g) column. Elution of cyclic AMP 
fraction indicated from column C 
Each result is averaged for two columnr,
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(iii) After removal of the Dowex 50 columns, portions of imidazole-Cl 
buffer (0.5 ml, 0.1 M, pH?.3) were run through the column and collected 
directly into scintillation vials for counting. This determined the elution 
profile for alumina columns (Fig. 2.1D). As can be seen from this profile, 
nearly all of the cyclic AMP was eluted in the first three ml and no 
radioactivity due to nuclide could be detected.
(4) Column Preparation
(A) Packing of Dowex 50 Columns
'Econocolumns' were packed with 2.5g of Dowex AG50W-XJ+ (200 - UOO 
mesh) which had been washed (deionised water, repeatedly) and dried 
(gently in a desiccator below 60°C) previously. HC1 (1M) was run through 
each column before use (~ 10 ml).
(B) Packing of Alumina Columns
Dry alumina (0.6 g) was added to glass wool-stoppered Pasteur 
pipettes. Imidazole-Cl buffer (1.0 M, pH7»3) was used to wash the columns 
(= 10 ml). Imidazole-Cl buffer (0.1 M, pH7*3) was then used similarly.
The columns were then ready for use.
(C) Column Recycling 
(i) Dowex 50 Columns
It was found that the best method of recycling the columns to obtain 
reproducible elution profiles was to first wash the columns with HC1 
(1.0 M, * 10 ml). When this was partly drained, the column bed was
resuspended by gentle agitation with a glass rod or by inverting the column 
2 to 3 times. HC1 (1.0 M, = 10 ml) was again passed through the columns 
after the column bed had been allowed to reform. The columns were then
ready for re-use.
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(ii) Alumina Columns
Alumina columns were discarded after use and therefore new columns 
were prepared for each assay.
(5) Assay Cocktail
(A) ATP, Cyclic AMP and GTP
Solutions of these compounds were made and their concentrations at pH
7.0 accurately measured spectrophotometrically. ATP and cyclic AMP were
-1measured at 259 nm., assuming a molar absorbance of 15,**00 1 mole Cm 
GTP was measured at 252 nm., assuming a molar absorbance of 13,700 1 mole
Small aliquots of each (<0.2 ml) were stored at -25°C. The required 
amount of each was thawed and diluted to the required concentration before 
use.
(B) Reagents
Stock solutions were prepared of all the reagents used in the assay 
and stored at 0 tol*°C (Table 2.1). These were added to a test tube, in 
the order listed in Table 2.1, containing the solid creatine phosphate 
and creatine phosphokinase, and made up to a total volume of 1.0 ml with 
water.
(C) [?2pJatp
The required amount of [^ 2P]ATP (2 to 8 x 10^ dpm per assay tube) 
was evaporated to dryness (this compound had been supplied in 50# 
ethanol solution). The appropriate amount of assay cocktail (Table 2.1), 
was then added to the dry test tube (10 per assay tube).
Activity of [^PJATP = 1 i^Ci per vl at t = 0
= 2.22 x 106 dpm
TABLE 2.1 Reagents for the preparation of assay cocktail
SOLUTION REAGENT
Conc.
(raM)
Vl of 
reagent
conc. in 
cocktail 
(mM)
Final conc. 
in assay 
(mM)
Creatine "N 
phosphate y  
Creatine I
solid
6. U mg 25 5
phosphokinasei 250 U 250 U/ml 50 U/ml
Tris acetate 1000 125 125 25
Mg acetate 1000 25 25 5
ATP 100 25 2.5 0.5
cyclic AMP 10 25 0.25 0.05
DTT 100 50 5 1
BSA 10 mg/ml 50 0.5 mg/ml 0.1 mg/ml
GTP 1 50 0.05 0.01
BGTA 100 50 5 1
[52P] ATP
Q
2-6 x 10 cpm/ 
ml
2-6 x 10^ cpm/ 
assay
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This was true for most batches of [^P]ATP obtained from Amersham, 
however, occasionally, a batch was received of only half this activity.
Approximately twice this amount was required per assay tube, and the
32appropriate correction factor for [ P] decay also applied :
Amount required (for n assays) = _____ ^ ______  pi
decay factor
(6) Assay Procedure (Step By Step)
Glass test tubes containing assay cocktail (10 pi), and test 
compounds (CP and derivatives) to a total volume of 25 pi were equilibrated 
to 30°C in a water bath (Table 2.2).
(A) The reaction was started by adding freshly-thawed and diluted plasma 
membrane suspension (1 to 8 pg protein) in 20 pi , preincubated for 15 
minutes with f^O (5 pi), hormone or fluoride (5 pi). Final reaction 
volume was 50 pi.
The reaction mixture was vortex mixed and then incubated for 15 
minutes at 30°C.
(B) The reaction was then stopped by adding stopping solution (100 pi) 
containing unlabelled ATP (1*5 nM), cyclic AMP (1.3 mM), SDS (2%) and again 
vortex mixed.
(C) After the reaction was stopped, [1i>C]cyclic AMP (approximately 20,000 
cpm) was added carefully to each tube (50 pi).
(D) All reaction tubes were next boiled in a water bath for 3 to 5 
minutes and cooled to room temperature afterwards. Thi6 procedure 
completely solubilised all membrane protein.
(E) At this stage in the assay procedure, the tubes may be stored for up 
to a few days at -20°C. After storage, test tubes were allowed to 
equilibrate to room temperature before use.
TABLE 2.2 Solutions used in the assay of adenylate cyclase
SOLUTION Reagent pi of Final cone
cone. reagent in assay
(mM) (mM)
Assay Cocktail - 10 -
t(Theophylline 33-33 15 10)
♦ACTIVATORS NaF 100 5 10
glucagon 100 nM 5 nM 10 nM
Plasma membrane - 20 -
Total assay volume 50 pi
Stopping solution 100 pi
t when included in assay.
♦ fluoride or glucagon was added to the plasma membrane preparation 15 min.
before the start of the assay.
CP and derivatives were included in the assay cocktail or replaced
theophylline.
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(F) Two types of blanks were prepared for the assay :
(i) No-enzyme blanks were prepared using Tris-DTT (Tris acetate, 10 raM, 
pH7.6, DTT, 1 mM) solution in place of the plasma membrane preparation.
(ii) Zero-time blanks were prepared by adding the stopping solution
to the assay cocktail before the addition of plasma membrane suspension.
(G) Standards of the radiolabelled compounds were prepared and counted. 
The [^P]ATP solution (10 pi of a 1/100th dilution in assay cocktail)
was added directly to a scintillation vial containing scintillant (20 ml) 
and imidazole-Cl buffer (290 pi).
Similarly, the [1+C3 cyclic AMP solution (50 v D  was added to a vial 
containing scintillant (20 ml) and imidazole buffer (250 pi).
Background counts were obtained using imidazole-Cl buffer (3-0 ml) 
in scintillant (20 ml).
(7) Chromatography
Water (300 pi) was added to each tube (total volume 0.5 ml) before 
applying the samples to the Dowex 50 columns.
(A) Elution of ATP
A rack of Dowex 50 columns was placed over a collecting tray, having 
been washed prior to use with water. The contents of each assay tube was 
decanted onto the columns and allowed to drain completely. Water (2.5 ml) 
was then run through each column and allowed to drain into the collecting 
tray. This fraction contained ATP and was therefore discarded.
(B) Elution of Cyclic AMP
The Dowex 50 columns were placed above a rack of freshly prepared 
alumina columns and water (**.0 ml total volume, in 1.0 ml portions) was 
allowed to drain through both columns and discarded.
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Scintillation vials containing scintillant (18 ml) were placed under 
each of the alumina columns and the Dowex 50 columns removed. Imidazole-Cl 
buffer (0.1 M, pH7.3) was run through the alumina columns and collected 
directly into the scintillation vials (3.0 ml total volume). This step 
eluted cyclic AMP.
The vials were stoppered, agitated to disperse the sample and produce 
a single phase solution, then counted using manually-set windows for 
dual label counting. Vials were counted for four minutes.
(8) Identification of Product
The identity of the radioactive product of the adenylate cyclase assay 
was determined by thin layer chromatography on PEI-cellulose plates in 
sodium acetate (60 mJi, pH5.^). Spots were visualised by UV and the plates 
then cut into 1 cm squares for counting. These squares were left overnight 
in Nuclear Chicago Solubiliser (0.7 ml of a 1:5 dilution) at U0°C in order 
to solubilise the adsorbed compounds, before counting in scintillant. 
Standards were prepared by spotting onto 1 cm squares of PEI-cellulose 
plates and were subjected to the same procedures as the samples after TLC.
Although the [^P]-labelled product of the adenylate cyclase assay
1J*system co-chromatographed with the added [ C]-labelled cyclic AMP standard 
on the Dowex-alumina chromatographic system, further confirmation of its 
identity was felt to be advisable. Using this method of TLC, the ATP in 
the assay cocktail was shown to co-chromatograph with ATP standard (Rf =
0.12). When either the assay cocktail or the cyclic AMP fraction collected 
from the alumina columns was subjected to TLC (after incubation) both [1i*C] 
and [^P]-labelled compounds were shown to co-chromatograph with a cyclic 
AMP standard solution (RJ = 0.25). When assay cocktail was used prior to
column chromatography, the area on the plate corresponding to ATP was also
32observed to contain the [ P]-label.
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Therefore, in summary, it has been shown that the [^P]-labelled 
product of the adenylate cyclase assay, as well as co-chromatographing 
with [ UC] cyclic AMP on the Dowex-alumina column system, also co­
chromatographs with cyclic AMP in the PEI-cellulose-sodium acetate TLC 
system.
(9) Calculations
Two methods for calculating the activity of only one isotope in a dual 
labelled sample are available.
(A) Absolute dpm
In order to calculate the absolute dpm, one must determine the 
efficiency of counting each isotope in each of the two channels used.
This can be done by accurately measuring a standard sample volumetrically
[1i+C] channel A [^P] channel B
[1UCD standard C C
[” pj standard P P'
Sample (assay) S S'
Background B B'
and then calculating the actual dpm, from the known specific activity, 
cpm is then obtained by counting the sample and the discrepancy between 
calculated and measured values (dpm and cpm respectively) may be assumed 
to be duo to the efficiency of the machine.
% efficiency obtained cpm 
calculated dpm
x 100
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The following equations can be used to calculate the absolute dpra 
of each isotope in a dual isotope sample :
(i) C32P] cpm ch A = [3PP] activity x [32P] efficiency A
(ii) [11*C] cpm ch A = S - [32P] cpm ch A
= S - ([32P] x C32PJ ch A)act. ell.
[32p]act. (dpm) =
[32p]eff. Ch B
[1ifC] . (dpm) = [1^ C] cpm ch A• ' act. _______________
....... ................... ...  Ch A
x 100
S - A) 
t1l,cW ch a
S - S' [32p]eff. Ch A
_[*P]eff. ch B
eff. ch A
x 100
(B) Relative cpm
Absolute dpm may not necessarily be used when correcting for 
"channel leakage". For clarity, it may be assumed that the background 
counts, B and B', have already been subtracted from all counts.
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(i) [1UC] counts in the [^P] channel
Correction factor F = _____ x 3
C
To be subtracted from cpm in ch B sample. S' 
(ii) [^P] Counts in the [1t>Cj Channel
Correction factor F' = _____  x S'
P'
To be subtracted from cpm in channel A sample, S.
(iii) Cyclic AMP Recovery
This is calculated as a percentage :
Scyclic AMP recovered = ____  x 100 (%)
C
The factor for multiplying sample cpm by in order to correct for 
recovery is :
C c
_____  which is modified to ______
S S-F'
(iv) Specific Radioactivity (Sr>R)
Where A is the concentration of ATP per assay tube in pmol.
SpR P' x 100
A
(v) Cyclic AMP Produced
This is equal to S'-F and is converted to pmol by dividing by SpR. 
The correction factor for % recovery is applied and the result expressed 
as a function of the membrane protein (E) per assay.
c (S' - F) x 1000
cyclic AMP x (pmol/ 1 5  min/mg prot)gross S - F' SpR x
The blank value (Z) is calculated similarly and, :
Z
(10) Q Values
4 is a measure of the purity of ["^P] ATP used and provides an
indication also of the performance of the chromatographic procedure.
Q values should be below 10 and typically about i».0 for this assay.
the assay.
Typically, Q values of 5 to 7 were obtained in these studies.
2.3 The Assay of Guanylate Cyclase Activity 
(1) Introduction
Guanylate cyclase catalyses the conversion of GTP to cyclic GMP and 
pyrophosphate, in the presence of divalent cations. The basal activity of 
guanylate cyclase is dependent upon the specificity of the enzyme for 
manganese, Mn^+, ions. This enzyme is stimulated by a wide range of
SpR x E x Z x 10
Q = ____________________________
P'
32note: P' is the direct cpm of a 1/100 dilution of [ P] ATP used in
physiological and non-physiological compounds ($2). In these studies, 
using the cytosolic fraction of rat liver as the enzyme source, MNNG was 
used as the enzyme activator (73)«
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Some laboratories measuring guanylate cyclase activity have reported 
methods of determining the cyclic GMP formed by competitive binding assays 
requiring either the availability of relatively scarce antibodies (217) 
or a sufficiently specific lobster-tail binding-protein (218). When using 
radiolabelled GTP as substrate, the product cyclic GMP must be separated 
before estimation by liquid scintillation counting. As is the case in the 
adenylate cyclase assay system, many techniques for this separation have 
been described.
Single column chromatography using aluminium oxide with (219) or 
without (210) suitable preparation and dual column chromatography either 
on first Dowex 50 eluted with water followed by aluminium oxide (220) (221) 
or on first aluminium oxide followed by Dowex 1 (222) have been utilised.
(2) The Development of The Chromatographic Step
The assay method of dual chromatography on Dowex 50 followed by 
alumina was investigated, applying the modifications of Nesbitt ejt al.
(223) and Wallach et al. (,22k) to the adenylate cyclase assay system of 
Salomon (216).
Elution profiles were determined by the method reported in section 2.2
(3) for the adenylate cyclase system.
The results from Dowex 50 elutions were very poor (Fig. 2 . 2 k ) . No 
separation of GTP from cyclic GMP could be seen and, therefore, an 
investigation of the effect of the column bed size was carried out (Fig. 
2.2). It can be seen that 'separation' is optimally carried out with a 
bed size of 8 cm (x 0.7 cm). This separation was, however, very poor 
and not as reported previously (220) (221).
Other types of Dowex resin are commercially available and two of these 
were investigated. Dowex 50X8, a resin with more cross-linking than
fig. 2 . 2  Elution Profiles of Dowex AG50X<* (200 - 400 mesh) Eluted 
With Water
Fig. 2.2 Elution Profiles of Dowex AG^OX^ (200 - ¿»00 mesh) Eluted
86
Dowex 50XU (8% instead of k%) gave similar results (Fig. 2.3A). Dowex 1X8 
(chloride form) is an anion exchange resin and was found to give adequate 
separation using water as eluant (Fig. 2.3B). However, the volume containing 
cyclic GMP was very large (6 to 8 ml) and the columns required a long time to 
run (retention volume for cyclic GMP was approximately V* ml). These 
findings are in agreement with those of Birnbaumer et_ al. who went on to 
modify the Dowex 50 chromatographic procedure to separate GTP and cyclic 
GMP to a much greater extent (225).
By applying the developments of Birnbaumer et_ al. (225) GTP and cyclic 
GMP were separated on Dowex 50 columns to an extent which compares favourably 
with the separation of ATP and cyclic AMP during this stage in the 
adenylate cyclase assay system (Fig. 2.4A, cf. Fig. 2.1).
The major modification introduced is the application of sample and 
subsequent elution of GTP from the Dowex 50 columns under acid conditions. 
Cyclic GMP is eluted onto alumina columns using water, the precise volumes 
required having been estimated from the elution profile.
Alumina elution was carried out basically as in the adenylate cyclase 
assay system but larger columns (1.0 g) were used, and cyclic GMP was 
eluted after an initial void volume of approximately U.O ml was first 
obtained. Elution profiles for alumina columns are shown for the unmodified 
Dowex 50 procedure (Fig. 2.3C, 2.3D) and the modified one (Fig. 2.4B).
This procedure gave consistently high recovery rates of cyclic GMP 
(70 to 80% recovered, compared to only 50 to 60% recovered in other 
systems) and very low blank values. Blank values in some systems are 
considerably higher, probably because of the poor separation obtained 
on the Dowex columns (in some systems up to 20% of the applied GTP may 
elute with cyclic GMP) (225).
Guanylate Cyclase Assays
i1 ig. -2.3 Elution Profiles of Columns Investigated For Application
recovered
50.
50-
GTP A
cyclic G”P A
OTP B
cyclic GUP F I B
12 16
D
V
Elution Volume (ml 1,
A Dowex AG50X8 : 4.0 X 0.7 cm column bed.
Eluted with water.
B Dowex AG1X8 : 4.0 X 0.7 cm column bed.
Eluted with water.
Aluminium oxide columns after application of cyclic GMP 
fractions from Dowex AG50X4 columns (8.0 X 0.7 cm) as shown 
in Fig. 2.2C.
C Eluted with Tris-Cl (0.1 M pH7.3).
D Eluted with water.
Fig. 2 . U Elution Profiles of Columns Used In The Guanylate Cyclase Assay
■ To alumina ■
IOC —
Relative
recovered
|Z
ÎC1- H2°
-- Collected fraction
Elution Volume (ml ).
A Dowex AG50WXU (200 - 1*00 mesh). 0.7 X 8.0 cm (3.0 ml) column bed, 
eluted first with HC1 (50 mM) then water. The 4 ml fraction indicated 
containing cyclic GMP was applied to alumina columns.
B Aluminium oxide, 1g column eluted with imidazole buffer (0.1 M pH7.3) 
after application of cyclic GMP fraction from Dowex column. The 3 ml 
fraction indicated was used to collect cyclic GMP in the assay.
Each result is averaged for 2 columns.
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(3) Column Preparation
Columns were prepared in precisely similar ways reported in section
2.2(1»).
(1») Assay Cocktail
Stock solutions were prepared and stored as previously stated, GTP
and cyclic GMP being stored in small aliquots after their concentration
was accurately measured spectrophotometrically. The assay cocktail was
made similarly (section 2.2(5)) but to a final concentration of 1.5 ml
32(Table 2.3)» The appropriate volume of [ P]GTP was dried under nitrogen 
and redissolved in the required amount of assay cocktail.
(5) Assay Procedure
Glass test tubes containing assay cocktail (50 pi) and 'test' 
compounds (25 pi) were equilibrated to 30°C in a water bath (Table 2 . k ) .  
During studies with MNNG, the enzyme solution was diluted to the required 
concentration of protein with MNNG solution which had been freshly 
prepared. The concentration of the MNNG solution was carefully calculated 
to yield the desired concentration of MNNG when used to dilute the enzyme 
solution. The enzyme-MNNG mixture was kept in an ice bath for 30 minutes 
before use. A similar procedure was followed with cyclophosphamide 
derivatives during pre-incubation experiments.
(A) The reaction was started by the addition of the enzyme solution to the 
assay cocktail. This had first been appropriately diluted with either
(i) buffer, (ii) MNNG or (iii) 'test' compound depending upon the 
experiment. 50 to 150 pg of protein were used per assay (in 25 p1). The 
reaction mixture was mixed thoroughly by vortex mixing and incubated at 
30°C for 15 minutes.
(B) The reaction was stopped by the addition of stopping solution (100 pi) 
containing SDS (2%) and EDTA (30 mM, pH7.6).
TABLE 2.3 Reagents for the preparation of assay cocktail in the assay of
guanylate cyclase activity
SOLUTION REAGENT
cone.
(mM)
Ul of 
reagent
cone, in 
cocktail 
(mM)
Final cone, 
in assay 
(mM)
Creatine
phosphate solid 11.52 mg 30 15
Creatine
phosphokinase 150 U 100 U/ml 50 U/ml
Tris-HCl 1000 150 100 50
MnCl2 J+00 30 8 U
GTP 60 60 2. It 1.2
cyclic GMP 90 90 5-V 2.7
Theophylline 33.33 900 20 10
BSA 10 mg/ml 30 0.2 mg/ml 0.1 mg/ml
«2°
[32p ]gtp
2<* 0
a
O.U-1.2x10° 
cpm/ml
2-6 x 10  ^cpm/ 
assay
TABLE 2.\ Composition of the reaction mixture in guanylate cyclase assay
SOLUTION VOLUME OF REAGENT (^ 1)
assay cocktail 50
test compounds 25
ENZYME 25
Total volume 100
stopping solution 100
[1i4C]cyclic GMP 50
Total volume 250
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(C) After the reaction had been stopped [1<+Cjcyclic GMP (approximately
20,000 cpm per assay tube) was carefully added (50 pi).
(D) All reaction tubes were boiled for 3 to 5 minutes and then cooled to 
room temperature. This step solubilised all protein present in each sample.
(E) As in the adenylate cyclase assay, the procedure may be interrupted 
at this stage and the assay tubes stored for a few days at -25°C. Stored 
tubes were allowed to equilibrate to room temperature before use.
(F) Suitable blanks were prepared of no-enzyme (Tris-HCl buffer in place 
of the enzyme solution) and zero-time (addition of stopping solution before 
the addition of enzyme).
(G) Standards were also prepared according to the method reported for the
1hadenylate cyclase assay, using [ C]cyclic GMP and assay cocktail 
containing [^PJGTP.
(6) Chromatography
To each sample was added HC1 (1.0 ml, 50 mM). Each tube was vortex 
mixed and then decanted onto previously prepared Dowex 50 columns.
(A) Elution of GTP
When the sample had drained completely, a further portion of HC1 
(1.0 ml, 50 mM) was applied to each column and also allowed to drain. A 
further portion of HC1 (2.0 ml), was applied and allowed to drain, after 
which H^O (1.0 ml) was also allowed to drain through each column. The 
eluant from this procedure contained the majority of the GTP in each sample, 
and was appropriately disposed of since this also contained radioactive 
material.
The Dowex 50 columns were placed above alumina columns and H^O (l».0 
ml) was allowed to drain completely through both columns. This eluted the 
cyclic GMP from the Dowex onto the alumina columns, together with residual 
amounts of GTP and was discarded.
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(B) Elution of Cyclic GMP
Imidazole-Cl buffer (4.0 ml, 0.1 M, pH7.3) was allowed to drain 
through each alumina column and was discarded. A further portion of the 
same buffer (3.0 ml) was passed through each column and collected directly 
into scintillation vials containing scintillant (18.0 ml), as this 
contained the eluted cyclic GMP (Pig. 2.AB).
(7) Discussion
Using this method of assay, recovery of [1i>C] cyclic GMP was 
consistently high (60 to 8C$) and Q vaues, although seemingly quite high 
(20 to 100) indicate a definite advantage over other methods where high 
blank values are routinely obtained. Blank values also varied with the 
batch of [^PjGTP used, a not unexpected effect, since the Radiochemical
Centre, Amersham, do not apply the purification techniques used for their 
32 32[ P]ATP to their [ PjGTP product. A purification column could have been 
employed but the time and effort involved were deemed to be too extravagant 
with regards to the small advantage to be gained.
2.1* The Measurement of Alkylating Activity Bv The NBP Test 
(1) Introduction
During the course of this work two assays utilising NBP (y(p-nitro- 
benzyl)pyridine) to measure the alkylating activity of CP and its 
derivatives have been used.
Friedman and Boger's modification (226) of the NBP assay for 
alkylating agents (227) was first used but its limitations soon became 
apparent. This is the most widely used chemical method for the estimation 
of CP and its alkylating metabolites in biological systems, because of 
its high sensitivity and low background. However, according to this method 
biological samples containing CP are deproteinised by treatment with
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hydrochloric acid and boiling. This step will also hydrolyse CP to nor- 
nitrogen mustard (nor-HN2) and is therefore a great disadvantage. The 
measurement of alkylating activity after initial acid hydrolysis has been 
referred to as total alkylating activity, potential alkylating activity, 
alkylating capacity and nor-mustard-like activity. This method also 
produces an unstable coloured compound which must be estimated at a precise 
time after mixing, making the assay rather tedious and difficult 
particularly since estimations must be made sequentially rather than 
simultaneously.
The modified method first published by Morita et_ al. (228) is a 
significant improvement. Perchloric acid (.2%, v/v) replaces hydrochloric 
acid for deproteinisation of biological samples; trichloroacetic acid, 
which is often used for this purpose cannot be used because it would react 
with NBP. Only when boiled for 20 minutes in perchloric acid will CP 
hydrolyse to yield nor-HN2. If the sample is kept cold (i.e. in an ice 
bath) then no hydrolysis will take place in the presence of perchloric 
acid. This provides a method for assaying, under identical conditions, 
the alkylating activity of CP or its derivatives directly (before or without 
prior acid hydrolysis) and also the potential alkylating activity (after 
acid hydrolysis). Furthermore, the extraction of the coloured complex into 
ethylene dichloride instead of ethyl acetate greatly increases the 
stability of the ion. When also covered with NaOH, no loss of colour is 
detectable for up to 3 hours. This is to be compared to a value of less 
than three minutes in the original assay.
A further modification to this assay has been recently published (229) 
but no reference to the method of Morita et^  a_l. has been made, from whom 
the basic assay procedure is derived. The modifications include a higher 
concentration of NBP in the assay, the replacement of NaOH with triethyl-
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amine and the elimination of the "ethyl acetate extraction of the pigment". 
This is claimed to give greater stability of the pigment complex and is 
also claimed to be more convenient. It is difficult to see, however, why 
the use of copious quantities of triethylamine could possibly be considered 
convenient. Although this method of alkalinisation has also been previously 
reported by Abel et_ a_l. (230) no clear advantage can be seen. The method 
of Morita et al_. has been followed here.
(2) Experimental Procedure
Either biological samples or solutions of pure compounds were used in 
the N3P test.
(I) Biological samples
The sample was first diluted 1:1 with perchloric acid (4#, v/v). This 
was kept in an ice bath and precipitated the protein present in the sample. 
Centrifugation was used to remove the protein and aliquots of the super­
natant fraction taken for analysis. Aliquots were diluted to a final 
volume of 2.0 ml in perchloric acid (2%, v/v).
(II) Pure compounds
Pure solutions of alkylating compounds were assayed by taking aliquots 
and diluting to 1.0 ml with ¡^O. Perchloric acid (4%, v/v) was added to a 
final volume of 2.0 ml. A convenient method was to use 50 yl aliquots 
of a 2 or 3 niM solution when using CP and its derivatives. For construction 
of the standard curves, using nitrogen mustard (HN2) a 1 mM solution was 
sufficient.
(III) Two estimations were made using the same compound or sample : the 
direct and the potential alkylating activity.
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(A) Potential Alkylating Activity
This was measured by first hydrolysing the alkylator in perchloric 
acid. This was done simply by placing the prepared sample, which was 
contained within a stoppered test tube, in a boiling water bath for 20 
minutes. After this period, the sample was removed and cooled in an ice 
bath.
(B) Direct Alkylating Activity
This was measured by keeping the prepared sample in an ice bath 
ensuring that acid hydrolysis did not take place. Such samples were kept 
on ice while others were being acid hydrolysed.
(TV) When all samples were at ice bath temperatures (s k°C) the pH was 
adjusted to ¿*.6 by the addition of acetate buffer (pH^.6, 0.2 M)/Na0H 
(1N) mix (2.0 ml). This mixture had been adjusted previously so that the 
NaOH neutralised the perchloric acid in the sample. This was found to be 
best achieved by mixing 1 vol acetate buffer to 2 vol NaOH. This was not 
the relative proportion given by Morita et_ al.
(V) N3P solution (0.5 ml, 5# w/v in acetone) was added to each sample. 
Efficient mixing during the previous procedure (IV) was found to be 
essential to achieve the correct pH before addition of the NBP. During 
this addition the solution became an opaque white.
(VI) Each sample was next boiled for 20 minutes. This step brings about the 
reaction of NBP with the alkylating material to yield a pyridinium ion 
(reaction 15).
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(VII) After boiling, the samples were cooled in ice,and acetone (2.0 ml) 
and ethylene dichloride (5*0 ml) added to each sample.
(VIII) NaOH (1N, 2.0 ml) was then added to each sample and the stoppered 
test tubes vigorously shaken. Under alkaline conditions such as these,
the NBP complex (ionised) is deprotonated and the solution becomes coloured 
blue in the aqueous phase. On shaking, the coloured complex is extracted 
into the organic phase and becomes coloured pink, probably due to charge
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transfer. At this stage, minimal light was allowed to reach the samples 
as although the colour is stable for up to 3 hours, in the dark, it was 
observed that the colour could be bleached by strong light, an observation 
not reported by Morita e_t al.
(IX) Samples were stored for at least 30 minutes in an ice bath and then 
centrifuged for 5 minutes at approximately 2500 g in a bench centrifuge. 
This step ensured the separation of the two phases.
(X) The upper aqueous layer was pipetted off carefully so as to not 
disturb the lower (pink) layer. The lower layer was then pipetted into a 
glass cuvette and overlaid with NaOH (1N). Careful pipetting was required 
as any mixing of the two layers resulted in an emulsion leading to spurious 
results.
(XI) The absorbance maximum of the pink complex was measured to be 540 nm 
(HN2) and the sample O.D. was read at this wavelength.
(3) Standard Curve
HN2 was used to construct a standard curve using this procedure. The 
value obtained for alkylating activity of HN2 did not change due to acid 
hydrolysis and, therefore, the standard curve was constructed using the 
direct measurement (Fig. 2.5B).
A curve was also constructed using the method of Friedman and Boger 
and was found to be in good agreement with that constructed by the method 
of Morita et al. (Fig. 2.5A).
Fig. ¿.5 Alkylating Activity Standard Curves for nitrogen rlustar::
(HN2) Using; NBP Test
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A Method of Friedman & Boger, blank subtracted.
B Method of Morita £t al. water used as blank.
Error bars represent minima and maxima from two ¡4 
separate experiments in each case. 1
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2.5 The Ozonisation of Cyclophosphamide
(1) Introduction
Although other methods for the synthesis of activated derivatives 
of CP exist (231) (232) the direct ozonisation of CP was considered the 
simplest. Furthermore, the starting material (CP) was available in 
abundance.
The method of Peter et_ al. (233) produces two derivatives of CP, 
4-ketocyclophosphamide (KP) and 4-hydroperoxycyclophosphamide (HP). KP 
is reported to be produced in about 50% yield and HP in about k0% yield. 
Many difficulties were encountered during the course of this synthesis 
but most of these were overcome by the detailed experimental procedure 
and useful advice given to us by Peter (23^ *) and the later availability of 
HP to utilise as a standard, kindly donated by Colvin (section 2.1).
(2) Experimental Procedure
The apparatus required for this experiment is shown in Fig. 2.6A.
This arrangement was arrived at after some experimentation.
(A) The Ozoniser
The ozoniser is a water-cooled device which produces a silent electric 
discharge through gaseous oxygen. This produces ozone (0^ ) and the 
quantity of ozone produced can be controlled by varying the flow rate of 
oxygen through the device. The ozoniser was calibrated by constructing 
a standard curve of ozone output versus oxygen flow rate. This was done 
by placing acidic potassium iodide solution (5# w/v, 25 to 100 ml) in 
the reaction vessel and bubbling ozone through it for a measured length 
of time (usually judged so that the colour change observed was not too 
large). The iodine thus liberated was then estimated by back titration
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with sodium thiosulphate (0.1 N) and the amount of ozone then calculated 
according to reaction 16.
( i )  0 3 + 2KI + h 2 o ---->• Z2 + 2K0H + o r\j
( 1 6 )
( i i )  I 2 + 2NaS20 ---- >• 2NaI + Na2S4°6
Thus for every mole of ozone, 2 moles of sodium thiosulphate will be 
used. Values of ozone (mg/ml) were calculated and plotted against the 
flow rate of oxygen ( l/min) as registered on the built-in flow meter of 
the ozonisor (Fig. 2.6B).
This was compared to a similar curve constructed from the 
data supplied by the British Oxygen Company. The experimental curve 
demonstrates a saturation effect, probably due to ozone not being absorbed 
but passing through the reaction mixture at high flow rates. This had no 
relevance to the ozonisation, however, because the flow rate required was 
not on this portion of the curve. Flow rate was adjusted to give l»5 mg/min 
of ozone (1 mmole O^/min) or 0.8 l/min).
(B) The Reaction Vessel
Various reaction vessels were tried, all of which gave different 
values of ozone absorbed by a solution of potassium iodide within them.
This was probably due to the fact that saturation of the solution was not 
occurring. The best vessel design was that described by Peter (23**) and 
consisted of a glass column (21 cm x 3 cm int. dia.) with a sintered 
glass partition (D2). When oxygen wa6 allowed to flow from underneath this 
partition, liquid could be poured into the column from above and would 
maintain its position above the partition. The sinter had the effect of
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producing many fine bubbles of gas which percolated through the solution. 
Thus a large surface area was created at the gas/liquid interface.
(3) Ozonisation Of Cyclophosphamide
A scaled down version of the original synthesis (233) was used.
CP (5.0 g), water (20 ml), acetone (10 ml) and hydrogen peroxide (3-3 ml) 
were placed in the reaction vessel while oxygen (low flow rate) was passed 
through it. This prevented any seepage of the reaction mixture through 
the sinter. The flow rate was then adjusted accordingly (to 0.8 l/min) 
and the reaction vessel and acetone/I^O mixture (Fig. 2.6A) placed in an 
ice bath. The acetone/water mixture (1:2) was found to be necessary to 
prevent the precipitation of CP in the reaction vessel due to the 
evaporation of solvent.
The ozoniser was then turned on and ozone left to percolate through 
the reaction mixture for 2.5 hours. This time was found to be optimal 
by taking samples every 30 minutes for 6 hours and running thin layer 
chromatograms (section A.2). Before being allowed to enter the fume 
cupboard, the gaseous extract was first allowed to pass through an 
ammonia solution to deactivate any alkylating material should any have 
been carried away from the reaction vessel and secondly through a solution 
of potassium iodide to remove any remaining ozone. After ozonisation 
oxygen was allowed to flow through the apparatus to purge the system of 
any ozone.
(1*) Extraction of Reaction Products
After ozonisation, a precipitate of KP and some CP was removed by 
filtration from the reaction mixture, and acetone removed from solution by 
rotary evaporation at 0°C. It was essential to keep the reaction mixture 
cold to prevent the thermal decomposition of HP.
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The mixture was left to stand in ice for 2 hours, after which a 
further precipitate of KP was removed by filtration. The filtrate was 
extracted with dichloromethane (4 x 50 ml) and the organic layer dried by 
the addition of molecular sieve. The organic phase was concentrated to 
an oily residue, under cooling with ice/water, by rotary evaporation.
Dichloromethane (8.4 ml) was added and the solution left to stand 
overnight at -25°C. At this stage most of the remaining KP was 
crystallised out and was removed from the solution by filtration. The 
filtrate was again concentrated to an oily residue, after the KP had been 
washed with dichloromethane and the washings added to the filtrate. The 
residue was redissolved in dichloromethane (0.5 ml) and portionwise 
addition of diethylether (5.0 ml) should have precipitated HP. However, 
the precipitation of HP from the reaction mixture is extremely difficult 
and it was found that the addition of diethylether served to precipitate 
any remaining KP in the solution. When this was removed by filtration, 
the remaining filtrate was only slightly contaminated with KP as 
determined by TLC visualised with NBP 6pray (section 2.14).
Chloroform extractions were performed on the filtrate and the extracts 
combined together and reduced to about 10 ml by rotary evaporation under 
ice cooling. This sample was used for column chromatography during which 
HP was purified.
(5) Column Chromatography
A medium pressure column chromatographic technique was employed to 
purify HP, which has been termed "flash chromatography" (235)* A 
kieselgel 60 column (1" x 6") was used with ethyl acetate as eluant.
This eluant was determined by prior TLC in several solvent systems. The 
column was pressurised using nitrogen and a flow rate of 1-2" of solvent
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through the column/minute was used (approximately 20 to '*0 ml/min). All 
chromatographic work was undertaken in a cold room (= f»°C).
Fractions (10 ml) were collected after application of the chloroform 
extract (5.0 ml). Fractions containing HP (determined by TLC) were combined 
and the solvent removed by rotary evaporation.
2.6 Incubation of Cyclophosphamide With Rat Hepatic Microsomes
(1) Introduction
A similar system to that described by Cohen and Jao (146), Sladek 
(148), and Connors et al. (151) was used to produce OHCP from CP by 
incubation of CP with rat liver microsomes. Due to the instability of OHCP, 
an ethoxy-CP derivative is produced during the extraction from the medium.
(2) Experimental Procedure
The incubation conditions were as described in Table 2.5.
To the substrate (0.2 ml) in a 25 ml conical flask (37°C, shaking 
water bath), the incubation mixture (previously kept in an ice bath) was 
added in three portions (i) 3 ml (ii) 3 ml (iii) 4 ml at 15 min intervals, 
with oxygen blown over the surface of the incubating mixture continuously. 
The total incubation time used was 45 min and the reaction was stopped 
at this time by the addition of ethanol (40 ml).
(3) Extraction of Metabolites
The addition of ethanol had two effects: (i) it precipitated the 
protein present in the sample, (ii) it reacted via any OHCP present to 
produce the 4-ethoxy-CP derivative. After the ethanol had been added, the 
protein was removed by centrifugation.
The supernatant fraction was reduced to 1 to 2 ml by rotary 
evaporation using an ice bath for cooling. The pH was adjusted to 4.0
TABLE 2.5 Additions to the nicrosomal incubation system for CP
activation
ADDITION CONCENTRATION
microsomes 3 ml (= 3g liver)
NADP+ 2.7 pmoles
Glucose 6-phosphate 55
MgCl2.6H20 ^9.5 "
G 6-P dehydrogenase 3*5 units
Tris-HCl (0.1M, pH7.4) 7.0 ml
CP 10 pmoles
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by the addition of HC1 (1N) and extraction accomplished using alcohol- 
free chloroform (3 x 20 ml). This extract was dried using molecular 
sieve, and again reduced by rotary evaporation and subjected to chemical 
analyses primarily by NBP test (Chapter 6).
2.7 The Assay of Phosphodiesterase Activity
The method of Butcher and Sutherland (236) was used to measure the 
activity of cyclic AMP phosphodiesterase. This was carried out at 25°C 
for 30 min the latter 10 min in the presence of excess Cobra snake venom, 
which produces adenosine and phosphate from the 5'-AMP product of the 
phosphodiesterase reaction. The phosphate thus produced was assayed by 
the method of Fiske and Subbarow (237).
2.8 Protein Determination
The method used to determine protein concentrations in all samples 
was that of Lowry et al. (238). Colour produced is the result of :
(i) biuret reaction of protein with copper ions in alkali and (ii) 
reduction of the phosphomolybdic-phosphotungstic reagent by the tyrosine 
and tryptophan present in the treated protein.
BSA (lyophilised) was used as standard and the standard curve obtained 
was shown to be linear with respect to BSA concentration (100 pg = 0.305 
O.D.). The intensity of the blue colour was read at 680 nm and sensitivity 
was found to be 5 to 100 pg protein. Sample dilutions were manipulated 
to give a reading in the midrange of the standard curve (30 to 70 pg) 
before assignment of unknown protein concentrations were made.
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2.9 The Assay of Free Thiol Groups By 5-5'-dithiob_is(2-nitrobenzoic acid) 
The method of Ellman was used to estimate thiol group concentrations
(239). This involved the reduction of 5-5'“hithiobis(2-nitrobenzoic acid) 
by thiolate anion to yield a coloured anion (reaction 17).
t = 13600 A l/cm
Colour intensity was read at 1*12 nm.
Ellman's reagent was prepared in phosphate buffer (0.1 M, pH7) to a 
concentration of 10 mM. Tubes were prepared containing buffer mixture 
(H^O : phosphate buffer, 0.1 M, pH8.0 = i»:1, 3*0 ml) Ellman's reagent 
(20 yl).
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2.9 The Assay of Free Thiol Groups By 9~5>~dithiobis(2-nitrobenzoie acid) 
The method of Ellraan was used to estimate thiol group concentrations 
(239). This involved the reduction of 5~5'-dithiobis(2-nitrobenzoic acid) 
by thiolate anion to yield a coloured anion (reaction 17).
Colour intensity was read at 1*12 nm.
Ellman's reagent was prepared in phosphate buffer (0.1 M, pH7) to a 
concentration of 10 mM. Tubes were prepared containing buffer mixture 
(H^O : phosphate buffer, 0.1 M, pH8.0 = l* :1 , 3*0 ml) Ellman's reagent 
(20 vl).
RS“ (17)
n o 2 f  i\io2
c = 13600 Al/cm
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CP or derivatives were incubated at 1 to 10 aM concentration with 
L-cysteine (10 mM) in phosphate buffer (0.1 M, pH7.0) under appropriate 
conditions (Chapter 9). Aliquots (50 yl) were taken at various times 
after the addition of compounds (to start the incubation) and added to 
the prepared tubes. These were usually read immediately.
Using cysteine as a standard, this assay was found to be linear with 
respect to concentration, between 0 and 500 nmoles (gradient = 1.33 O.D. 
units/pmole).
2.10 The Isolation of Rat Liver Plasma Membranes
The method of Pohl et_ al. (80) is a modification of the method of 
Neville (2W) for producing a plasma membrane fraction from rat liver.
This was used initially but found to be very difficult due to various 
ambiguities in the reported method. Plasma membranes were produced by this 
method and found to have low activities of associated marker enzymes 
(section 7.2). Therefore, another method, combining that of Pohl £t^  al. 
and Emmelot et al. (2<+1) was used and this method is described here.
(1) Six rats were killed by cervical dislocation and their livers removed 
and placed immediately in ice-cold NaCl (0.85# w/v). Typical liver 
weight of combined livers was U0 to 60 g.
(2) The livers were finely chopped using scissors and then gently homogenised 
(loose-fitting 0.6 mm teflon pestle and glass homogeniser) in approximately
8 to 10 g fractions of liver in bicarbonate buffer (30 ml, 1 mM). This 
was achieved by delivering 6 to 8 passes of the pestle by hand. All 
homogenates were pooled and made up to 800 ml with bicarbonate buffer.
(3) The homogenate was then filtered through (a) 2 layers of cheesecloth 
and then (b) 1* layers of cheesecloth.
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(if) The filtrate was centrifuged at 500 g for 5 min and then slowly 
accelerated to 1,500 g which was maintained for a further 10 min. (Glass 
centrifuge bottles of 250 ml capacity were used in a Mistral centrifuge).
(5) The upper white layer of fat was removed. The supernatant fraction 
was carefully removed by pipetting. The remaining pellet of cell debris, 
plasma membranes and nuclear material was resuspended in 800 ml of bi­
carbonate buffer and re-centrifuged, following the procedure described in 
(if) above.
(6) Two layers were formed in the pelleted sediment which consisted of :
(i) tightly packed cell debris, etc., in a red lower layer, and
(ii) loosely packed plasma membranes in a light-tan upper layer.
(A) Most of the supernatant was pipetted off carefully and bicarbonate 
buffer (3*0 ml) added to each centrifuge bottle.
(B) Using a bent (90°) glass rod, the plasma membrane layer was very 
carefully resuspended.
(C) The resuspended plasma membranes were carefully pipetted off, leaving 
the pellet of nuclear and cell debris. The plasma membrane fractions were 
combined.
(7) The plasma membranes were re-homogenised and made up to 500 ml with 
bicarbonate buffer.
(8) This homogenate was centrifuged at 1,000 g for 10 min (2 x 250 ml 
glass bottles).
(9) After discarding the turbid supernatant, the pellet was resuspended 
in bicarbonate buffer (50 ml) and again centrifuged at 1,000 g for 10 min 
(SS3*f rotor, Sorval).
(10) The pellet formed was resuspended in a small amount of bicarbonate 
buffer and re-homogenised. This was then added to sucrose (62 ml,
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69 - 0.1%, w/v) in a 250 ml measuring cylinder and made up to 110 ml by 
the addition of H^O. The resulting solution was mixed thoroughly and 
adjusted to kk -  0.1% (w/v) sucrose by the addition of either sucrose or 
H^O. This was measured accurately using a refractometer.
(11) This was distributed between 3 centrifuge tubes of a swing out
rotor (25.2). Sucrose (i»2.3 - 0.1% w/v) was then carefully layered on top, 
forming a discontinuous sucrose density gradient.
(12) The gradient was centrifuged at 107,000 g (25,000 rpm), for 150 min 
(L2-50 centrifuge).
(13) A small pellet was formed in each tube together with a 'float'. This 
floating material was carefully removed and resuspended in bicarbonate 
buffer by passing through a ^20 guage needle (10 ml).
(1A) The combined fractions were centrifuged at 12,500 rpm for 20 rain in 
an SS3A rotor.
(15) The pellet thus formed was resuspended (by needle aspiration as in (13)) 
in bicarbonate buffer (3*0 ml).
(16) Aliquots (100 of this suspension were stored under liquid nitrogen. 
These were thawed prior to their use in adenylate cyclase assays and 
correspond to 'crude' (not 'purified') plasma membranes.
2.11 The Isolation of Rat Liver Cytosol
A simple rat liver cytosolic fraction was prepared for experiments 
with guanylate cyclase.
Rat liver (prepared as in step (1), section 2.10, using only 1 rat) 
was homogenised in Tris-HCl (5 mM, pH7.6), and sucrose (0.25 M) then 
centrifuged at 750 g for 10 rain. The supernatant fraction was re­
centrifuged at 60,000 g (30 rotor, 26,000 rpm) for 60 min. Aliquots 
(200 pi) were stored under liquid nitrogen or -80°C. These were thawed 
prior to their use in guanylate cyclase assays.
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2.12 Preparation of Rat Liver Microsomes
Male Wistar rats were fed phénobarbital (0.5 g/i) ad libitum in 
their drinking water for 10 days prior to the preparation of microsoraes.
Microsomes were prepared by the method of Connors et_ al. (15 1). 
Centrifugation and initial homogenisation were performed in KC1 (0.15 M) 
with the microsomal pellet being ’washed' at least once (i.e. with at 
least two high-speed centrfiguations). Final resusper.sion of the micro­
somal pellet was in Tris-HCl (0.2 M, pH7.U) to a dilution of 1 g wet 
weight liver per ml. Microsomes were used immediately for incubation 
experiments with CP.
2.13 Scintillation Counting
(1) A toluene-Triton X-100 scintillant was used containing both primary 
and secondary scintillators for maximum efficiency. These were PPO (5-5 
g/1) and dimethylPOPOP (0.15 g/l) respectively. The emulsifying agent 
Triton X-1CO was used to produce a stable emulsion when samples from 
cyclase assays were added to scintillant. The efficiency and reproducibility 
of counting relies on the production of such a stable emulsion and this 
in turn is affected by (i) sample size, (ii) salt concentration, (iii) 
temperature and (iv) the ratio of toluene : Triton X-100.
Sample size was usually 3*0 ml in all cases and contained imidazole-Cl 
buffer (0.1 M, pH7.3)* The scintillation counter was refrigerated to 
reduce background noise from its photomultipliers and so the toluene :
Triton X-100 ratio was adjusted to allow for all these factors. A 1:1 
ratio (18 ml) was found to be necessary to maintain a  stable emulsion.
Any less than this resulted in a stable emulsion at room temperature but a 
two-phase system resulted when such a scintillant was placed in the cool 
environment of the counter (using toluene : Triton X-100 = 2:1).
106
(2) Using a gain of 75 (10% gain selected) the window settings of the 
scintillation counter were investigated throughout their range to find the 
best possible settings for dual isotope counting P] and [1i*C] of the 
quenched (3.0 ml imidazole-Cl buffer) samples. By selecting a window of 
0 - 900, all counts due to [1i*C] could be collected. A second window was 
selected 900 - 00 within which no counts due to [ *C] could be detected 
and which could be used to measure counts due to [^P]. These have been 
referred to as the [1*C] channel and the C^P] channel respectively.
2.1** Thin Layer Chromatogranhy (TLC)
(A) Production of TLC Plates
Plates for TLC (2" x 8") were produced by mixing silica gel 60 (f25**) 
with water (30 g in 60 ml) and spread using a layer thickness of 0.02 mm 
after degassing the solution in a closed vessel connected to a water- 
powered vacuum pump. After heating to 100°C for 1 hour, the plates were 
cooled and stored ready for use.
Various solvent systems have been used and wherever possible, the 
sample was applied in the particular solvent system. Standards were run 
when available, the importance of this must be stressed in the case of 
cyclophosphamide and its derivatives since the presence of water vapour 
can drastically influence the Rf values obtained (23**).
(B) Visualisation
Visualisation of CP and related compounds was achieved primarily by 
NBP reagent spray. For the hydroperoxy derivative, a peroxide spray was 
also employed. Iodine vapour was also used for all TLC plates before 
applying a spray reagent (the plates being left to decolourise before 
spraying). This was done by placing the TLC plate in a tank containing
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solid iodine and pre-saturated with vapour. This visualised nitrogen- 
containing compounds.
(I) NBP Spray
This was used to visualise any alkylating material on the TLC plate.
The plate was first sprayed with a solution of ethanolic NBP (5%, w/v).
After heating to 100°C for 5 rain (to visualise good alkylating agents) 
or 15 to 20 min (to visualise weakly alkylating agents) and subsequent 
cooling to room temperature, the plate was sprayed with ethanolic KOH 
(3% w/v). This method produced a temporary blue spot where alkylating 
material was present (157).
(II) Peroxide Spray
This spray visualised any peroxide present (263).
Spray Reagent I
KI solution (10 ml, k%, aqueous), was mixed with acetic acid (Z*0 ml) 
and a pinch of zinc powder added.
Spray Reagent II
Fresh starch solution (1$).
The zinc was filtered off and the TLC plate sprayed with solution I. 
Peroxides appeared as yellow spots due to iodine liberated, within 5 minutes. 
For better visualisation, solution II was sprayed onto the treated plate, 
which yielded blue spots.
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2.15 The Photooxidation of Cyclophosnhamide By Polymer-bound Rose Bengal
(A) Introduction
There is evidence that hydroxylation of CP by rat liver microsomes 
involves singlet oxygen. The ozonisation of CP to produce HP is also 
considered to involve this species. Sources of singlet oxygen are 
available for chemistry, and its photosensitised formation using various 
dyestuffs is the method of choice for most synthetic and mechanistic 
applications. The use of such systems to produce an activated CP 
derivative was suggested to us by Jarman (Dr M. Jarman, Chester Beatty 
Research Institute, London).
Sensitox is a polymer-bound Rose Bengal which is a well known UV 
sensitiser for the formation of singlet oxygen from the gaseous element. 
Sensitox II is especially developed for use in aqueous solvent systems. 
Immobilised Rose 3engal has been used successfully in the photooxidation 
of various aliphatic saturated and unsaturated compounds.
(B) Experimental Procedure
CP (60 mg) and Sensitox II (30 mg) were incubated in either H2O 
(10 ml) or a H20/acetone (7:3) mixture in the presence or absence of ^2^2 
(0.3 ml) under oxygen aspiration as shown in Fig. 2.7.
The apparatus was immersed in an ice/water bath and illuminated for 
up to 6 hours with a concentrated 100W white light source. Oxygen 
aspiration maintained saturation of the solution and prevented the 
sedimentation of the Sensitox II polymer beads.
Periodically, aliquots were taken, centrifuged (bench centrifuge,
3 minutes) to remove the Sensitox II and analysed by TLC (silica gel 
60, ethyl acetate) NBP test (section 2 .U ) or HPLC (section 2.1).
The experiment was also carried out at both low ($° to 15°C) and 
medium temperatures (30° to 35°C).
Fig. 2.7 The Apparatus Used To Investigate The Photooxidation of CP
By Polymer-bound Rose Bengal (Sensitox II)
109
2.16 Safety Precautions
(1) Radioactivity
For all work involving the use of radioactive substances, the usual 
precautions were taken. These included working in gloves and within 
designated bench space, including trays, wherever possible. All cyclase 
assay columns were run within a large tray in case of spillage. For 
work involving the use of [^P] nuclide, perspex screens were used which 
were very effective at stopping the g particles emitted, as determined 
by the use of a radioactivity monitor.
(2) Hazardous Chemicals
Many of the alkylating substances used are classified as carcinogens 
(HN2, HP, PM) or potential carcinogens (CP) and care was taken when 
using all such compounds. That such care is necessary is indicated by the 
study of Falck e_t al. (2*»2). In hospitals where patients were treated with 
anti-cancer agents, including cyclophosphamide, not only did the urine 
concentrates of patients exhibit mutagenicity in an Ames test but their 
nurses also showed this effect.
Cyclophosphamide and 'inactive' derivatives (i.e. KP) were handled 
within a fume cupboard with the fans switched off. This was to prevent 
ingestion of any air-borne chemical.
More hazardous chemicals (HN2, PM, MNNG) were handled within a 
glove box. The glove box was not pressurised during use and was flushed 
with nitrogen, being passed through an ammonia solution (to deactivate 
any alkylating material) before being allowed to vent into a fume 
extractor after use.
All apparatus, including pipette tips, were washed in an ammonia 
solution before disposal or reuse. A solution of sodium thiosulphate 
(2M) was kept near working areas should a skin wash be necessary after an
accidental spillage
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(3) Ozonisation
The ozonisation was carried out in a fume cupboard within the 
"dangerous operations laboratory". The entire apparatus was kept behind 
a screen of armour plate glass due to the explosion hazard of using ozone. 
Rubber tubing was avoided because of the possibility of producing explosive 
ozonides. All ozone was flushed from all apparatus before anyone was 
allowed to enter the cupboard, by flushing with oxygen (by turning off the 
ozoniser) for at least 10 minutes after ozonisation.
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CHAPTER 3
THE ASSAY FOR ALKYLATING ACTIVITY BY THE NBP TEST 
3»1 Introduction
The NBP test (section 2.4) is a useful analytical assay for 
alkylating agents. It may be used to measure the stability of a stored 
alkylating agent and may also help to determine which alkylating agent is 
present in an unknown solution by the different behaviour of an alkylating 
agent in the NBP test before and after acid hydrolysis.
Because of their high reactivities HN2 and nor-HN2 have been used as 
standards by many workers in this field.
3.2 Results and Discussion
The optical densities of the NBP complexes with various alkylating 
agents are shown in Table 3»‘'i together with HN2 equivalents as determined 
from the standard curve, Fig. 2.5B. The alkylation index was determined 
by expressing the direct reading as a percentage of the acid-hydrolysis 
reading (Direct/Acid-hydrolysis X 100).
Acid hydrolysis of CP derivatives is considered to cleave the 
molecule at the P-N bond (exocyclic) thus releasing nor-HN2 and explains 
the dramatic increase in alkylating activity observed in the NBP test for 
such compounds after acid hydrolysis (Table 3«1)»
As can be seen from these results, only phosphoramide mustard and 
4-hydroperoxy-CP yield values in HN2 equivalents after acid-hydrolysis, 
which are directly related to their true concentrations. All other 
compounds tested gave a much lower reading than might at first be expected.

112
This can be explained partly by each complex possessing a slightly 
different molar absorbance and partly by inter-molecular P-N bond cleavage 
as postulated by Freidman et al. (143)*
The wavelength of maximum absorbance (X ) was measured (Table 3*1)
rn s ix
and found to vary according to the compound used, from 540 nm (HN2) to 
554 am (PM). This could have introduced a maximum error of 1.54% as the 
absorbance of PM measured at 540 nm (which was used for all regular 
alkylating assays) was found to be 98.46% of that at its m^ax*
CP hydrolysis at high temperatures, even in strong acid, involves 
competition between P-N bond cleavage leading to relase of nor-HN2 and 
internal alkylation leading to a series of products from which nor-HN2 
cannot be released. This competition would account for the observed loss 
of recoverable nor-HN2 and explains the less than theoretical extent of 
alkylation observed when phosphoramide mustards are allowed to react with 
NBP. However, nothing like the reported extent could be observed.
Freidman e_t al. have reported that only 40% of the theoretical amount 
of nor-HN2 can be observed for CP after acid hydrolysis. This is clearly 
not the case. Morita et al. (228) have reported a value of 90% using 
this method of assay and as can be seen from Table 3»I» I have obtained 
a value of 84% relative to HN2, for CP.
This discrepancy between the measured concentration after acid 
hydrolysis and the true concentration in the sample would make it difficult 
to determine the concentrations of alkylating agents in unknown solutions 
accurately. This difficulty could be overcome by plotting a standard curve 
for each compound or by applying a correction factor, calculated from 
these results. However, the alkylating agent would have to be identified first 
and for this the direct reading is required. The direct reading is an
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indication of how reactive the alkylating agent actually is, and therefore 
(as an analytical probe) which alkylating agent it may be. To determine 
this precisely, the concentration of the sample would have to be 
determined and the appropriate correction factor for absorbance applied.
This apparent paradox can be overcome by the use of an "alkylation 
index", which by dividing the direct by the acid-hydrolysis reading, applies 
the appropriate correction factor, and, hence, the precise concentration of 
alkylating agent in a solution need not be determined in order to identify 
it. As can be seen from Table 3-1t the values for the alkylation index 
correlate well with values of alkylating activity reported by Brock (172) 
although it was not explained how he arrived at these values. It has been 
assumed that they were calculated similarly to the alkylation index 
presented here.
It has been observed in these experiments that the initially blue 
alkylating agent - NBP complex formed in the aqueous layer does not always 
extract fully into the organic phase. The extent of extraction appears to 
be dependent upon the compound used. This phenomenon has been observed 
previously (170). The blue (aqueous phase) complex was found to have a 
^max ®nd a small peak was observed, separate from the major
absorbance maximum at 540 nra, in the extracted organic phase. The nature 
of this and its effect on the estimation of alkylating activity by NBP 
test was not determined.
An interesting effect was the different alkylation indices measured 
with HP, depending upon the solvent used to dissolve it prior to its 
estimation. When dissolved in acetone and assayed with no waiting period 
whilst added to aqueous solutions (section 2.4(2)iii) the alkylation 
index measured corresponded to the reported alkylating activity of HP.
If, however, the sample of HP was first dissolved in water by gentle warming,
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the alkylation index corresponded to the alkylating activity reported for 
OHCP. This was found to occur immediately and the alkylation index 
remained unchanged for up to 30 minutes during the incubation of aqueous 
HP solution in an ice bath. The spontaneous production of OHCP from HP 
in aqueous solution was suggested by Fenselau (2k3) and a postulated 
mechanism has been published. This was, therefore a very convenient method 
for the production of OHCP from HP and has been discussed in more detail in 
Chapter 10.
It should be pointed out that although the NBP test has been shown 
to be a useful tool for the determination of alkylating agents in solution, 
the results obtained may not reflect the alkylating activity of alkylating 
agents under physiological conditions, such as those found in _in vitro 
assay systems for enzymic activity and ¿n vivo.
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CHAPTER if
THE OZONISATION OF CYCLOPHOSPHAMIDE :
THE PRODUCTION OF if-HYDROPEROXY-CP (HP) AND if-KETO-CP (XP) 
if .1 Introduction
After many initial difficulties, the ozonisation of CP was found to 
be the most successful of the methods tried to produce an 'activated' 
derivative of CP. As an additional "bonus" the reaction also yields KP, 
the isolation of which proved to be very simple compared with that of HP. 
The method has been described in detail in section 2.5»
RESULTS AND DISCUSSION
if . 2  T h e  T im e  C o u r s e  O f  T h e  O z o n isa tio n
The ozonisation was "scaled down" from the reported procedure (5 g 
rather than 30 g) and it was not known whether the time required for 
ozonisation would have to be reduced in order to produce the maximum amount 
of HP. For this reason, the ozonisation was carried out for 6 hours (as 
reported originally by Peter et al. (233)) and samples were taken every 
30 minutes for analysis. These samples were subjected to thin layer 
chromatography (TLC) after drying under air (in an ice bath) and re­
dissolving in the TLC system solvent (ethyl acetate). This was done 
primarily to remove water which markedly affects the performance of CP and 
derivatives in the TLC systems leading to spurious RF values (23*f) . The 
results of the TLC are shown in Fig. <f.1. As well as Rf values, the 
relative intensity of the spots was also recorded. For reasons discussed 
in Chapter 3 the intensity of the blue complexes formed with NBP cannot
Fis;, ii.1  TLC R e s u lts  of Samóles Taken Purine: Tho Ozonisation of GP
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be used to distinguish the relative concentrations between different 
compounds. It should also be noted that a positive reaction to NBP on 
silica gel does not correspond to alkylating activity in solution (161). 
However, this method may be used to estimate the relative concentrations 
of the same alkylating agent in different samples. Standards were run also 
and were the only method employed to distinguish the relevant CP 
derivatives as Rf values differed greatly from those published by Peter 
et al. (233)* The HP standard yielded two spots : since the CP molecule 
can have the hydroperoxy group attached to it in two positions on the 0!+ 
atom, this carbon atom becomes a chiral centre and two diastereoisomers 
of HP are produced.
The TLC shows that ozonisation was quite rapid : many alkylating 
agents were produced within the first 30 minutes. The number and type 
of alkylating agent produced appears to remain constant after 2 hours, 
and no change in Rf values or the number of spots was observed after 
this time. There was, however, a change in the relative concentrations 
of the compounds of interest. CP appeared to decrease over the period 
of ozonisation but did not disappear completely, even after 6 hours.
A decrease was expected since CP is the precursor of the derivatives 
produced but its persistence was puzzling. KP appeared in quite 
reasonable yield in all samples and toward the latter half of the 
ozonisation procedure was found as a precipitate in the reaction 
mixture. This was confirmed by TLC which showed that KP together 
with some CP was precipitated from the solution after 3 hours ozonisation. 
The concentration of HP, however, could be seen to increase to a 
maximum after 2.3 hours ozonisation after which its concentration 
decreased. This pattern was followed by both stereoisomers. An interesting 
observation, however, was that the relative concentration of the fast­
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running isomer appeared to be less than that of the slow-running one. This 
was also the case with the HP sample supplied by Colvin and which was 
utilised as a standard. The relative concentration was judged by the 
relative intensity of the spots and also by the fact that the slow-running 
isomer produced a much larger spot.
4.3 N3P Test
An NBP assay was also run on the samples taken at 1 hour intervals 
during ozonisation. The results are presented in Table 4.1.
(1) Optical Density (O.D)
The sample size for the acid hydrolysis measurement was smaller than 
that used for the direct measurement. For this reason, a correction factor 
was applied to the O.D for acid hydrolysis and these are therefore larger 
than actually measured spectrophotometrically.
(2) Alkylation Index
It is apparent from these results that the alkylation index is 
approaching that of 4-hydroxy-CP (OHCP) rather than that of HP. The 
reason for this is the conversion of HP to OHCP in aqueous solution during 
the NBP assay. This occurred during the 20 minute period whilst waiting 
for acid hydrolysis to take place in other samples (section 2.4 and 
Chapter 3) and the direct measurement samples were left to stand in an 
ice bath.
(3) Concentration Of Alkylating Agents In The Reaction Mixture
The concentration alkylating agents has been calculated from the acid 
hydrolysis readings. As can be seen from Table CP and OHCP (HP
in aqueous solution) both gave the same value relative to HN2 (and there­
fore their concentration) after acid hydrolysis. KP, however, gave only
TABLE A.1 N3P test on samples taken during the ozonisation of CP
TLMS
(hr)
NBP TEST O.D. 5'*Onm CONCENTRATION
(56)
ALKYLATION
INDEX
%
CONVERSIONDIRECT ACID
0 0.14 2.2 100 6.36 - 0.51
1 0.60 2.2 100 27.20 35.20
2 0.66 2.2 100 30.00 ifO.OO
3 0.80 2.1 95 38.09 51.00
if 0.70 1.3 59 53.80 if 7.60
5 0.73 1.1 50 57.69 if3.70
6 0.79 1.1 50 60.70 L6.30
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90.4% of this value and this effect could not be taken into account in 
these calculations, resulting in a maximum error of 4.7%, as only 50% 
of the starting material was expected to yield KP.
The concentration of alkylating agents in the reaction solution has been 
shown to decrease markedly after 3 hours, due to the precipitation of 
KP and some CP.
(4) % Conversion Of CP to HP
The alkylation indices of CP and KP were virtually identical (Table 
3.1). It has been assumed therefore, for the purposes of this estimation, 
that only two alkylating indices contributed to the index measured in 
samples from the reaction mixture, (i) that of CP and KP and (ii) that 
of HP. The fact that many other unidentified alkylating substances were 
present, as shown by TLC, Fig. 4.1, has been ignored, although these may 
have contributed up to 10% of the reaction mixture composition and their 
effect on the alkylating assay unknown, the values for % conversion should 
therefore be read as a guide rather than in absolute terms.
The following equations were used to calculate conversion : 
let x = concentration of CP (and KP)
y = concentration of HP
A = total concentration
= x + y
N
= [CP] + [KP] + [HP]
= alkylation index
= direct reading___________  x 100
acid hydrolysis reading
(from Table 3.1) N(CP ♦ KP) 
N(HP, H20)
6.66
65
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% conversion of HP from CP :
6.66A
6.66x + 65y
A A
6.66x ♦ 65y
6.66y + 65y
y
= N
= A N
= A N
= A N -  6.66A %
58.34
This equation was used to measure % conversion in Table 4.1, 
substituting values of concentration (A) and alkylating index (N).
A trend can be identified in these estimations and reflects the 
results observed from the TLC system. The conversion increases to a 
maximum after 3 hours ozonisation and then decreases.
4.4 Ozonisation Conditions
From the results presented here, it was decided to use an incuoation 
time of 2.5 hours for the ozonisation of CP. This allowed for the maximum 
production of HP and very little XP was found to be precipitated up to 
this ozonisation time. The production of such a precipitate is thought to 
occur only after the production of maximal amounts of HP, when the 
reaction then goes predominantly toward KP production, probably at the 
expense of HP (234). Such reaction would explain the observed decrease 
in HP concentration during long ozonisation times.
The TLC results of the oily residue after 2.5 hours ozonisation have
been presented in Fig. 4.2
Fig. 4.2 Thin Layer Chromatograms of Ozonisation Reaction Products
Rf - NBP KI
O-B- • 1
t •
O-G- • 1 &
• • ft ft
0-4- •
•
0-2- •
_ « • ft
origin— t —  —  —  —
A B C D  A B C D
TLC system was silica gel 60, ethyl acetate run at -25°C. 
Visualisation was by either NBP spray reagent to identify alkylating 
material or KI spray to identify peroxides.
J \  - ozonisation mixture after 2.5 hours ozonisation
B - cp, C -HP Q -Kp
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4.5 Purification of KP
KP was filtered from the reaction mixture at several stages (section
2.5) . Those samples, which were contaminated least as determined by TLC, 
were combined and recrystallised from boiling chloroform. The major 
contaminant was CP, which crystallised much later and at a lower 
temperature than KP. Substantial quantities of purified KP were obtained 
by filtration of the crystals formed from the recrystallisation system 
when it had reached room temperature.
4.6 Purification of HP
As can be seen from the results presented in Fig. 4.2, more than 
one compound was produced by CP ozonisation which was both alkylating 
(N3P positive) and a peroxide (KI positive). KP could also be seen 
as a contaminant. HP was identified by employing a standard.
This extract was applied to a flash chromatography column (section
2.5) and the 10 ml fractions collected were reduced in volume by 
evaporation of solvent and applied to TLC plates which were run in the 
same solvent system as those in Fig. 4.2. Because there were so many 
samples, the TLC plates were run over the short dimension of 2". The 
results have been presented in Fig. 4.3.
It can be seen from these results that a good separation was achieved 
using this method and all samples containing only HP were pooled together 
(samples 13 to 21, Fig. 4.3) and the solvent removed by rotary evaporation 
under ice cooling. The remaining solid was stored at -25°C and further 
characterised by various techniques and shown to be HP.
Fig. k.J> Thin Layer Chromatograms of Ozonisation Products After 'Flash'
Chromatography
0-9^ o o  © o  o  o
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0-3-
OO 0 0 oooo 0
o
origins
1 2 3 4  5 6 7  8 9 1 0  11 12 13 14 15 16 17 181920  
FRACTION NO
AB
The TLC system was silica gel 60, ethyl acetate run at -25°C. 
Visualisation was by NBP spray, incubated for 20 minutes. Each 
fraction number represents a collected 10 ml. fraction off the 
'flash' chromatography column which had been further concentrated 
by evaporation of solvent before application to the TLC plate. 
A- CP, B -  HP, C-KP
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CHAPTER 5
THE CHARACTERISATION OF CP AND ITS DERIVATIVES 
5-1 Introduction
Before their use in enzyme assay systems, it was felt necessary to 
test the purity of all derivatives, particularly those produced by 
ozonisation, the nature of which had to be confirmed. Several physical 
techniques were used as well as a chemical test (Chapter 3) which also 
supplied evidence as to the identity of the compounds.
5.2 Melting Point Determination
Table 5»'' shows the measured melting points of various compounds 
together with reported values from the literature. It can be seen that 
there is good agreement between measured and reported values.
Two of the latter melting points, however, differ significantly from 
all others, both reported and determined. The melting point for CP 
reported by Garcia-Bianco e_t £l. (2A5) is quite low. This corresponds 
to the value for [^H^q]CP reported by Cox et al. (185) and also to values 
obtained with early preparations of CP (1^4).
The other value to differ is that of HP determined by Struck et_ al.
{2b7). In this case, the difference in M.P. reported is due to the unstable 
character of HP. On heating, HP darkens and then explosively decomposes. 
Struck e_t al^ . have noted that the recorded melting point can be manipulated 
by regulating the rate of heating the sample. Other values thus obtained 
include 108.1°C at 10°/min, 93»i*°C at 2°/min and 71.i»°C at 0.2°C/min.
This lowering of the melting point is most probably due to the premature
TABLE 5.1 Melting points of CP and derivatives
COMPOUND MEASURED 
M.P. (°C)
REPORTED 
M.P. (°C) Ref.
CP monohydrate
OO-Î-1IN 47 - 49 (144)
40 - 41 (245)
KP 148 - 149 148 - 149 (164)
HP 106 - 107 —k 1 —X 0 00 (231)
102 - 103 (246)
131 - 133 (247)
HI 103 - 107 106 - 107 (248)
cyclohexylammonium
salt
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decomposition of HP before the melting point has been reached. No such 
difficulties were encountered under the conditions used for these 
determinations.
5.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
(1) [1H]NHR
Proton NMR spectra have been presented in Fig. 5*1* together with the 
structures of the compounds tested. The assignment of peaks is shown in 
Table 5-2, together with integrals. Assignment was made for CP using the 
data of Egan et_ al. (2**9) and for HP using the data of Takamizawa et_ al. 
(231) Struck et al. (2<+ 7) and Van der Steen et al. (2^6). The NMR spectra 
are in good agreement with the literature values.
Confirmation of the HP peak produced by the hydroperoxy group (OOH) 
was made by observation of its disappearance after the sample was shaken 
with a few drops of deuterium oxide (D2O).
Assignment of peaks for KP was made by comparison with the other 
spectra. Only the peak due to the C^ protons is significantly different 
from the other peak assignments (cf CP or HP) and this is brought about 
by the highly electronegative keto oxygen atom at the C^  position, causing 
a downfield shift in the C^ proton signal.
The spectrum of PM was complicated by the cyclohexylamraonium moiety 
in the upfield region, but the peaks characteristic of the chloroethyl 
groups were easily identified.
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TABLE 5.2 Assignment of peaks for [ H]NMR
CHEMICAL SHIFT (t)
GROUP CP HP KP
00H - 1.6A,s,(1H)
NH A.58 - A . 85 (1H)
C. H 5.10 - 5.39 (1H)
C6H2 5 M  - 5-70 (2H) 5.58 - 6.00 (2H) 5-59 - 5.63 (2H)
Cßß’H2 6.23,t, (AH) 6.2A,t,(AH) 6.2A,t,(AH)
Caa'H2 6.A3 - 6.52 (AH) 6.28 - 6.58 (AH) 6.A5 - 6.6A (AH)
S H2 6.52 - 6.8O (2H)
C5H2 7.96 - 8.21 (2H) 7.76 - 8.00 (2H) 7.28 - 7.65 (2H)
Except where stated otherwise, all peaks were multiplets (s = singlet,
t = triplet). Figures in brackets are the integrals for the peaks.
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(2) [1?C]NMfl
The data obtained and the assignment of peaks for [1^ C]NMR has been 
presented in Table 5-3* These are in agreement with the published data 
of Egan and Zon (2^ 9) and Struck at al. (2^7). Splitting of some peaks 
was observed due to the phosphorus atom of the oxazaphosphorinane ring.
5 A  Infrared Spectroscopy
IR spectroscopy of KP (Mull) revealed a strong band at 1695 cm , which 
is indicative of an amide carbonyl group and is in agreement with the 
findings of Hill et al. (16**). This band was not observed in the IR 
spectrum of CP. No other IR spectra were recorded.
5«5 Mass Spectrometry (MS)
(1) Introduction
Field desorption MS has been used most widely for the study of CP 
and its derivatives (250). This method was not, however, available and 
electron-impact MS was utilised to gather as much information as possible.
The interpretation of the spectra was simplified by the fact that the
35 37isotopic chlorine atoms Cl and Cl differ in their abundance by a 
factor of 3:1.
(2) Phosphoramide Mustard
The spectrum of PM (Fig. 5*2) showed only traces of ion3 around its 
molecular weight of 220. A characteristic fragmentation pattern of 
nitrogen mustard compounds is the loss of a CH^Cl group and this was 
observed by the presence of a small peak at m/e 171« Nor-nitrogen mustard 
may be observed as the small peak at m/e 11*1 and the rest of the spectrum 
consisted basically of that observed for nitrogen mustards, including the
TABLE 5-3 Assignment of peaks for r 13C]NMR spectroscopy
COMPOUND C4
CHEMICA
C5
L SHIFT (6 
C6
)
C(3p* Coa'
cpV ¿♦1.00 25.28 69-57 ¿♦2.18 k ? . %
^pacetone-dg 170.¿f2 33.79 62.85 ¿♦2.57 ¿♦9.39
ypacetone-dg 86.65 27.77 63.12 ¿♦1.67 ¿♦9.05
Fift. 5.2 Mass Spectra of CP and Derivatives
12k
characteristic fragmentation pattern m/e 92, 63/65, 56 (250). The peak 
observed at m/e 99 was probably due to the cyclohexylamine moiety.
(3) Cyclophosphamide
The largest mass observed in the spectrum of CP was due to the 
monohydrate, molecular weight 279. A very small peak was seen at m/e 265 
due to the formation of an (M + 1)+ molecular ion which is unusual in 
electron impact MS. The loss of the CH^Cl group resulted in the peak at 
m/e 211/213 (2:1). All other peaks were not relevant to the determination 
of CP.
(It) ¿t-ketocyclophosphamide
The molecular ion peak (M+) for KP could be observed at m/e 27k but 
it was the characteristic loss of CH^Cl which produced the spectrum's base 
peak at m/e 225/227 (2:1) (1&t). The fragmentation pattern characteristic 
of nitrogen mustard was also present.
(5) ¿t-hydroperoxycyclophosphamide
HP has a low chemical stability and this was demonstrated by the 
difficulty encountered in obtaining a good electron impact MS spectrum. 
Conditions were optimised to prevent the decomposition of HP whilst the 
mass spectrum was taken. The decomposition of HP was observed by its 
decolouration.
Among other fragmentation pathways, the loss of H^O and to
yield KP and CP respectively has been observed in field desorption MS to 
give peaks at m/e 27k and 258 by Przybylski et al. (250).
In the spectrum recorded (Fig. 5*2) no molecular ion peaks could be 
seen except at very high amplitude when many other random peaks also 
appeared. The loss of H-0 to yield KP and subsequent loss of CH2CI
125
resulted in the observed peak at m/e 225/227 (3:1) which is 
characteristic of KP. Most abundant fragment ions were unspecific with 
regard to the structural determination of this compound.
5-6 High Performance Liquid Chromatography (HPLC)
Table 5*i* shows the retention times obtained for compounds using 
HPLC (section 2.1 (5)). Although conditions were different, these recorded 
times are in agreement with reported data, with regard to relative 
retention times.
CP and KP gave single peaks whereas HP was found to give two peaks.
The sample of HP supplied by Colvin (section 2.1) and also produced by ozo- 
nisation, was also found to exhibit this effect. It was expected that HP 
would do so on the basis of its performance on TLC (Chapter k ) . However, 
the peak which has been tentatively attributed to the HP diastereomer did 
not appear with the longer retention time than CP as suggested by the 
reported data (230. This peak coincided with that found for KP which was 
confirmed by co-chromatography of the HP and KP samples. Measurements 
indicated that the purified HP sample was composed of 2% of this material, 
as was the supplied sample. This estimation was made only after a linear 
relationship between peak areas and concentration of sample was confirmed, 
using CP as standard (linearity was found betwen 6 and 60 pg. CP and 
areas were reproducible to - 2%).
TABLE 5*4 Retention times of compounds by HPLC
RETENTION TIMES (minutes)
FLOW RATE (ml/min) 1 2*
COMPOUND
KP 3.58 -  0 .11 2.70
HP 4.11 - 0.23 3.64
(diastereomer) (3.58) (6.57)
CP 4.80 - 0.12 4.86
Reverse phase column with MeOH/H^O (2:3 v/v) eluant, refractometric
detection was used in both cases. 4> Measured using data supplied by
Peter (234).
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CHAPTER 6
MICROSOMAL HYDROXYLATION OF CYCLOPHOSPHAMIDE
6.1 Introduction
The incubation of CP with rat liver microsomes was investigated as 
a method for obtaining ^-hydroxycyclophosphamide (OHCP). The method of 
Connors et_ al. (151) was followed closely, and produces a more stable 
derivative of OHCP, ^-ethoxy-CP, by the addition of ethanol to OHCP in 
aqueous solution. The formation of alkylating material during the 
incubation was followed by the application of the NBP test (section 2 . b  
and Chapter 3).
RESULTS AND DISCUSSION
6.2 Incubation
Several experiments were performed to investigate the formation of 
OHCP from CP in the microsomal system (section 2.6). A representative 
experiment has been presented here.
Table 6.1 shows the results of the NBP test before and after the 
incubation period, and an increase in the direct reading can be seen, 
leading to an increase in the alkylation index (see Chapter 3).
If it is assumed that only CP and OHCP contribute to the measured 
alkylating activity after incubation, then the conversion of CP to OHCP 
can be calculated (see section *f.3)» Using the values reported in 
Table 6.1, the calculated conversion is 35.10# (substituting A = 100 in 
the equation presented in section k . J>(k) ) . This was found to vary from 
30 to 60% and no two experiments gave the same result. The only variable
TABLE 6.1 NBP test results from a typical microsomal incubation of
cyclophosphamide
NBP test (HN2 equivalent.3)
DIRECT READING ACID HYDROLYSIS ALKYLATION
READING INDEX
BEFORE INCUBATION 0.75 - 0.05 12.0 - 1.0 6.25
AFTER INCUBATION 3.80 -  0.05 11+.0 - 2.0 27.1*»
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between such experiments was the microsomal preparations from rat liver 
(section 2.12). One experiment was performed using microsomes which had 
been stored in liquid nitrogen previously and were found to show very 
little activity, whereas the same preparation when used immediately after 
its preparation had produced the results shown in Table 6.1. For this 
reason microsomes were prepared prior to each experiment and used 
immediately. It must be concluded that variations in the performance of 
microsomes was due either to the preparation procedure or to variations 
in the animals used. The preparation of microsomes was carried out under 
identical conditions each time and so the latter possibility would seem 
the most likely. This is particularly likely when it is considered that 
no control was imposed on the dose of phénobarbital received by each 
animal via its drinking water. Phénobarbital was used because it has 
been shown to increase the activity of the microsomal fraction of rat 
liver towards CP activation, by induction of liver microsomal enzymes, 
by as much as 5“fold (146). Better reproducibility may have been attained 
by strict control over the dosage of phénobarbital to each animal, i.e. 
by administration by intra-peritoneal injection.
Using the results from Table 6.1, the increase in total alkylating 
activity can be calculated (146):
Total alkylating activity = DIRECT NBP, (HN2 equiv.) total nmoles of
nmoles of CP used in the CP in the
NBP test. incubation.
BEFORE INCUBATION = 0.75 IO787.5 = 480.15
16.85
X
AFTER INCUBATION = 3-80 x 10787.5 = 2432.70
6.85
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INCREASE IN ACTIVITY = 1952.63 nmoles HN2 eq./3g.liverA5 min.
= 0.86 pinoles HN2 eq./ g.liver/hr.
In an experiment where 30% conversion was calculated, an increase 
in alkylating activity of 0.68 pinoles HN2 eq./ g.liver/hr. was found. 
Similarly, for the experiment where the highest conversion of 60% was 
calculated, an increase in alkylating activity of 1.32 pinoles HN2 eq./ 
g. liver/hr. was found.
These results are in good agreement with that of Cohen and Jao 
(1it6), who have found an increase of 0.60 pinoles HN2 eq./ g.liver/hr. using 
slightly different incubation conditions and different rat species. Cohen 
and Jao have reported a sex difference in the ability of rat liver 
microsomes to activate CP, by as much as 3-fold. For this reason, male 
rats were used. It is possible that species differences also occur. 
Furthermore, these workers have also shown that the concentration of 
NADPH in the incubation medium can effect the activity of the microsomes. 
They have reported a 10-fold change in activity (0.18 to 1.95 pinoles HN2 
eq./ g.liver/hr.) due to a 10-fold difference in NADPH concentration 
(0.3 to 3*0 mM). In these experiments, NADP and an NADPH-regenerating 
system were used.
6.3 Extraction of The Metabolites
After extraction of the microsomal incubation medium (section 2.6) 
the extract was subjected to TLC and the results are shown in Table 6.2. 
This TLC system was used by Connors et al. (151) who utilised radio- 
labelled CP and found four radioactive areas on the TLC plate after
TABLE 6.2 TLC of CP and microsomal incubation extraction material
Rf values
CP CU6
EXTRACT 0.00, O.f+6, 0.98
TLC was on silica gel 60 in a chloroform/ethanol (19s1 v/v)
solvent system at k°C;. Visualisation was by NBP spray
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incubation, with different Rf values to these findings. This is 
probably due to water vapour (section 4.2) (234). By running a CP 
standard, it was possible to identify the area on the plate in the extract 
chromatogram corresponding to this compound (Rf = 0.46). By comparing 
these results to those of Connors et al. (15*0 it is possible to assign 
the compound at Rf = O.98 as the "fast-running" isomer of the 4-ethoxy-CP 
derivative. The "slow-running" isomer coincides with the spot due to CP. 
NBP-positive substances at the origin of the chromatogram probably 
consist of breakdown products such as monochloroethyl-CP and PM.
6.4 Instability of Products
Attempts to isolate the product at Rf = O.98 by 'flash' chromato­
graphy (section 2.5(5)) were hampered by the unexpected instability of the 
extracted metabolites. Yellowing of activated CP derivatives has been 
used previously as an index of their decomposition (143) and this was 
observed in the chloroform extracts. Although it was found quite 
possible to isolate the product of Rf = O.98, it was found impossible to 
concentrate it by reduction of the volume (ice cooling, rotary 
evaporator) before yellowing of the sample was observed.
CHAPTER 7
THE EFFECT OF CYCLOPHOSPHAMIDE AND ITS DERIVATIVES ON ADENYLATE CYCLASE 
ACTIVITY
7.1 Introduction
The effects of alkylating agents on the activity of enzymes involved 
in cyclic AMP degradation and expression of biological activity have 
been noted (section 1.11). Cyclic AMP phosphodiesterase is inhibited (11*1) 
and cyclic AMP-dependent protein kinase is activated (131*) by such agents. 
The effect of the alkylating agent cyclophosphamide on the cyclic AMP- 
synthesising enzyme has been studied.
7.2 Plasma Membrane Characterisation
Plasma membranes were first produced by the method of Neville (21*0) 
modified by Pohl et_al. (80). This preparation was found to have low 
activity with respect to (i) 5'-nucleotidase, a marker enzyme for plasma 
membranes, and (ii) adenylate cyclase (Table 7.1). Furthermore, it was 
found that although phosphodiesterase activity was not detectable in this 
preparation by using the assay method of Butcher and Sutherland (section 
2.7) addition of the potent phosphodiesterase inhibitor, theophylline, 
greatly enhanced the apparent activity of adenylate cyclase (Fig. 7.1A).
Due to the low enzyme activities associated with this preparation, 
it was abandoned in favour of a technique using the combined methods of 
Emmelot et_ £l. and Neville (section 2.10). The initial low speed 
centrifugations and plasma membrane separation were carried out according 
to the method of Emmelot et al. (21*1) and the final discontinuous sucrose
TABLE 7.1 Enzyme activities associated with various fractions isolated
during the production of plasma membranes
5'-Nucleotidase Adenylate cyclase
U(mg protein)^ pmoles/15 min/mg protein
Plasma membranes
(1) Neville 0.160 40.85 - 6.48
(2) Neville/Emmelot 0.540 253.96 -  10.93
(a) Whole homogenate 0.062 36.92 - 6.91
(b) Cell debris 0.130 76.27 - 10.42
(c) Membrane pellet 0.004 48.33 - 9.83
5 1-nucleotidase activity was measured by the method of Widnell and
Unkless (251 ) and expressed as ymoles of inorganic phosphate formed
per minute (U). Phosphate was measured by the method of Ames e^t al.
(252).
(a) Whole homogenate was prepared from step 4, section 2.10.
(b) Cell debris was prepared from step 5* section 2.10.
(c) Membrane pellet was prepared from step 13* section 2.10.
Fig. 7.1 The Effect of Phosphodiesterase lrmioitors un Adenylate
Cyclase Activity
preparation of N e v ille  (see text)
B The e ffe ct of theophylline
C The e ffe ct of SQ20009
Error bare represent the d ifference between d up licates in  one experiment
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density gradient separation of "crude plasma membranes" was carried out 
according to the method of Neville (21+0). This preparation showed greatly 
increased enzyme activities (Table 7.1) and was used for the following 
studies on adenylate cyclase.
7.3 The Effect of Phosphodiesterase Inhibitors On Adenylate Cyclase Activity
Since theophylline was found to increase the measured activity of 
adenylate cyclase in crude plasma membranes prepared by the method of 
Neville (Fig. 7-1A) its effects were investigated using the improved plasma 
membrane preparation. Fig. 7.1B shows the inhibitory effect that was 
observed.
Although this was an unexpected result considering the previous 
results obtained with theophylline, it is very similar to the effects 
observed by Sheppard (253)» Measuring adenylate cyclase activity in rat 
erythrocyte ghosts, Sheppard observed between 21+ and 1+2# inhibition by 20 
mM theophylline. This effect was only apparent when phosphodiesterase 
was not a contributory factor in the measurement of adenylate cyclase 
activity.
The effect of another potent phosphodiesterase inhibitor, SQ20009, 
was also investigated. As can be seen from Fig. 7.1C, SQ20009 increased 
the measured activity of adenylate cyclase in concentrations up to 1+.0 mM. 
After this concentration was reached, a precipitate was found to form when 
SQ20009 and Tris buffer were present in the assay medium. This may explain 
the drop in measured adenylate cyclase activity above 1+.0 mM SQ20009 
(Fig. 7.1C).
Because of the effects observed with phosphodiesterase inhibitors 
it was decided not to include them in the assay system for routine adenylate
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cyclase assays. According to the reasoning of Sheppard (253) such 
inhibitors are not necessary and the 'cold trap' arrangement first 
developed and used by Weiss and Costa (25^) seems perfectly adequate to 
deal with any reduction in cyclic AMP due to phosphodiesterase activity.
It has not been considered necessary to include phosphodiesterase 
inhibitors when this arrangement is used (216).
7 .k Characterisation of The Adenylate Cyclase Assay
The assay of adenylate cyclase in rat liver plasma membranes has 
been well characterised in the past (15) and for this reason there seemed 
to be no necessity to characterise the system with respect to Mg^+ ions, 
pH and ATP concentration, these being taken from the data of Pohl ejt al. 
(80).
Table 7.2 shows the effects of EDTA, BGTA and calcium ions on the 
activity of adenylate cyclase. It has been shown that in the presence 
of Mg^+ ions, Ca^* ions are inhibitory in concentrations above 0.1 mM (80). 
This has been corroborated and may explain the effect of the chelating 
agents EDTA and EGTA in the assay system. EDTA was first introduced into 
the adenylate cyclase assay system by Pohl e£ al. (80) and has been used 
since as a 'standard' addition by many workers.
If the effects observed with the chelating agents is due to the 
chelation of endogenous Ca^+ ions then the increased effectiveness of 
EGTA over EDTA can be explained, since EGTA has a greater specificity for 
Ca^+ ions than does EDTA. EGTA was therefore included in the assay medium
for all routine assays
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cyclase assays. According to the reasoning of Sheppard (253) such 
inhibitors are not necessary and the 'cold trap' arrangement first 
developed and used by Weiss and Costa (254) seems perfectly adequate to 
deal with any reduction in cyclic AiMP due to phosphodiesterase activity.
It has not been considered necessary to include phosphodiesterase 
inhibitors when this arrangement is used (216).
7-4 Characterisation of The Adenylate Cyclase Assay
The assay of adenylate cyclase in rat liver plasma membranes has 
been well characterised in the past (15) and for this reason there seemed 
to be no necessity to characterise the system with respect to Mg^+ ions, 
pH and ATP concentration, these being taken from the data of Pohl e_t al. 
(80).
Table 7*2 shows the effects of EDTA, EGTA and calcium ions on the 
activity of adenylate cyclase. It has been shown that in the presence 
of Mg^+ ions, Ca^+ ions are inhibitory in concentrations above 0.1 mM (80). 
This has been corroborated and may explain the effect of the chelating 
agents EDTA and EGTA in the assay system. EDTA was first introduced into 
the adenylate cyclase assay system by Pohl et^  aT. (80) and has been used 
since as a 'standard' addition by many workers.
If the effects observed with the chelating agents is due to the 
chelation of endogenous Ca^+ ions then the increased effectiveness of 
BGTA over EDTA can be explained, since EGTA has a greater specificity for 
Ca^+ ions than does EDTA. EGTA was therefore included in the assay medium
for all routine assays
TABLE 7.2 The effect of calcium ions and chelating agents on
adenylate cyclase activity
ADDITION ADENYLATE CYCLASE ACTIVITY
cyclic AMP formed : pmol/15 min/mg protein
none 256.41 - 32
EGTA (1 mM) 440.31 - 8
EDTA (1 mM) 371.62 - 20
CaCl2 (1 mM) 47.69 - 6
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7.5 Linearity of The Assay
Before further experiments were performed, it was felt necessary to 
demonstrate the linearity of the adenylate cyclase assay with respect to 
time and protein concentration. It was necessary to perform all routine 
assays under conditions which corresponded to the linear portions of such 
curves. Fig. 7.2 shows the results of time course and protein 
concentration studies in the absence or presence of EGTA (1 mM). It can 
be seen that the assay was linear for up to 20 minutes when 15 pg of 
protein were used and linear for up to 20 pg of protein when assayed for 
15 minutes. It can also be seen that although EGTA increased the measured 
activity, no effect on linearity with respect to time or protein was 
observed.
Loss of linearity may have been due to the fact that liver plasma 
membrane contains a potent ATPase (255) and this may effect the assay 
even in the presence of the creatine phosphate-creatine phosphokinase 
ATP-regenerating system.
7.6 The Effect of CP And Its Derivatives On Basal Adenylate Cyclase Activity
The effect of CP and its derivatives on basal adenylate cyclase
activity in the presence or absence of EGTA is shown in Table 7.3« Of 
those compounds tested in the absence of EGTA, only the metabolite extract 
from a microsomal incubation of CP had any significant effect.
The microsomal incubation and extraction of metabolites was performed 
on the same day as the adenylate cyclase assay due to the observed 
instability of the activated compound (Chapter 6). The alkylation index 
for this extract was 1*0.58 which corresponds to a 59*3# conversion of 
CP to OHCP (section 1*.3(1*)). It has been calculated, using the data from 
the NBP test, that the chloroform extract, totalling 18 ml contained 6.21
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■pinoles of OHCP, assuming that only CP and OHCP (or its ethoxy derivative) 
were present in the solution. 4.0 ml of this extract was evaporated to 
dryness (rotary evaporator under ice cooling) and the residue redissolved 
in water (200 pi). An aliquot (20 pi) of this was used per assay tube in 
the adenylate cyclase assay. For a final assay volume of 50 pi, this 
corresponded to a concentration of 2-76 mM for OHCP.
CP was also present in this sample at a concentration of 1.89 mM.
CP, however, had no effect on adenylate cyclase activity alone (Table 7.3) 
and the result must be regarded as being solely due to the presence of 
OHCP.
This result was confirmed by the behaviour of HP in the assay system. 
In solution HP spontaneously forms OHCP and the inhibition observed for 
both metabolites and HP is therefore due to the same compound, OHCP.
In the presence of EGTA, HP was the only derivative tested to show any 
significant effect on adenylate cyclase activity (Table 7.3)- Furthermore, 
a dose-response relationship was also observed (Table 7.4, Fig. 7-5) 
between HP concentration and inhibition of activity. None of the other 
compounds tested showed any significant effect on basal activity at 
concentrations up to 15 mM. HP produced an inhibition of approximately 
50# at 5*0 mM concentration (Table 7.4).
7.7 The Effect of CP And Its Derivatives On Stimulated Adenylate Cyclase
Activity
Table 7»5 shows the effects of glucagon (3 nM) and fluoride (3 mM) 
on adenylate cyclase activity. This concentration of glucagon corresponds 
to a saturating level (of glucagon receptors) as demonstrated by the 
dose-response curve for glucagon, Fig. 7«3B. Although this represents
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B Glucagon activation in the presence or absence of
4-hydroperoxycyclophosphamide (HP)
Error bars represent the standard deviation of quadruplicate measurements 
from two separate experiments ________
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maximal stimulation of the enzyme, the observed effect, a 2 . 9 5 - f o l d  
increase over the basal enzyme activity, is low compared with that 
reported by some laboratories. Pohl et_ al. (80) for example, have reported 
an 11.1-fold increase using 5•7'' pM glucagon. This group have also 
reported that half-maximal stimulation with glucagon occurred at k nM.
Fluoride (3 mM) represents a non-saturating concentration (Fig. 7.*»B). 
Again, however, these findings disagree with those reported by Pohl et^  al. 
and others.
Fluoride (3 mM) causes a 2.68-fold increase over the basal level and 
10 mM fluoride has been found to increase basal activity by 3*69-fold.
Pohl et al. (80) have reported a 6.1*-fold increase for 10 mM fluoride 
but only a 1.6-fold increase at 3 mM fluoride. However, Marinetti et al. 
(256) have reported inhibition by fluoride, activation by calcium ions 
and inhibition by insulin as well as a much reduced sensitivity to glucagon, 
in rat liver plasma membranes.
(1) Effect On Glucagon-Stimulated Activity
Table 7*5 shows that, of the compounds tested, only HP showed any 
significant effect on adenylate cyclase activity when stimulated by 
glucagon. The resultant, inhibited, activity is not significantly different 
from the HP inhibited basal activity reported in Table 7 . k .
Fig. 7*3 shows the effect of varying the glucagon concentration in 
the absence or presence of HP (5 mM). In the absence of HP, it 
demonstrates the characteristic 'saturation' effect and the association 
constant, Ka, of glucagon for its receptor can be calculated from the 
intercept of the double reciprocal plot, after basal activity has been 
subtracted, Fig. 7-3A, and was found to be 0.92 nM. In the presence of 
HP (5 mM, Fig. 7.3B) all sensitivity for glucagon was lost, with no 
significant difference between any of the points shown.
Fig. 7.4 Fluoride Stimulation of Adenylate Cyclase Activity In The
4 -
oo
X
c
> a>
K o
> Cl
h-
o !
< C
£
UJ IT)
(A \
< __;_l O
O E
>- a
o
UJ
l-
<
i
1
_i
> o
z CLUJ
D
<
5
<
o
o
S'
6 -
TH 1— 1— ' Z  ^
1/ fluoride ( -a.',;)
B
A + HP (5rxM)
fluoride ( nM)
A Double reciprocal plot
B Direct plot
Error bara represent the standard deviation between duplicate measurements 
from three separate experiments
TABLE 7.5 The effect of CP and its derivatives on glucagon and 
fluoride stimulated adenylate cyclase activity
ADENYLATE CYCLASE ACTIVITY
ADDITIONS cyclic AMP formed : pmo1/15 min/mg protein
(5 mM) + GLUCAGON (3 nM) + FLUORIDE (3 mM)
none 1309*06 - 28 (1 .00) 1191.67 - 50 (1.00)
CP 1222.50 -  27 (0.93) 1185.00 - 10 (0.99)
KP 1315.24 - 55 (1 .00) -
HP 27^.51 - 63 (0.21 )* 852.61 - 20 (0.72)*
[P<0.05] [P<0.1]
PM 1322.12 -  53 (1 .01) 1217.50 - 32 (1 .02)
*Figures show a significant difference from the control in the 
Student's t test. Figures in brackets represent the ratio of 
activity in the assay to the control. All figures represent 
duplicates from one experiment.
136
(2) Effects On Fluoride-Stimulated Activity
As for glucagon-stimulated activity, Table 7.5 shows that of the 
compounds tested, only HP showed any significant effect on fluoride- 
stimulated activity. The inhibition observed, however, still represents 
an increase over the basal activity of the enzyme.
Fig. 7.4B shows the effect of varying fluoride ion concentration on 
adenylate cyclase activity in the absence or presence of HP (5 mM). It 
can be seen that although HP inhibits the activity of the stimulated 
enzyme, fluoride ion still evokes response in a dose-dependent manner in 
the presence of HP. The association constants, Ka, of fluoride for its 
receptor have been calculated from the intercepts of the double-reciprocal 
plots in Fig. 7.4A (after subtraction of basal activity). The Ka for 
fluoride in the absence of HP was found to be 4.69 mM and this is almost 
halved in the presence of 5 mM HP to 2.65 mM. Behaviour such as this 
is often regarded as evidence of 'uncompetitive' inhibition. However, 
because of the complexity of the adenylate cyclase enzyme system, one 
must be cautious in such analyses.
7.8 Effect of 4-hydroperoxy-CP On Adenylate Cyclase Activity
Fig. 7-5 shows the effect of HP on basal, glucagon and fluoride 
stimulated adenylate cyclase activity. Although very few data points are 
present, it can be seen that a dose-response relationship exists between 
between cyclase activity and HP concentration in all circumstances.
Whereas the response appears to be linear for both basal and fluoride- 
stimulated activity, HP has a much more 'pronounced' effect on glucagon- 
stimulated activity at low concentrations, resulting in a non-linear 
dose-response relationship. At a concentration of 5 mM HP, the glucagon- 
stimulated activity coincides with that of HP inhibited basal activity as 
shown in Fig. 7.3B for different concentrations of glucagon.
Adenylate Cyclase Activity In The Presence Or Absence 
Of Glucagon Or Fluoride
Fig. 7.5 The Effect of ¿»-hydroperoxycyclophosphamide (HP) On
Error bars represent the standard deviation between duplicate 
measurements from two separate experiments
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CHAPTER 8
THE EFFECT OF CYCLOPHOSPHAMIDE AND ITS DERIVATIVES ON GUANYLATE 
CYCLASE ACTIVITY
8.1 Introduction
Alkylating agents have been reported to produce a small elevation in 
intracellular cyclic GMP levels (257) and the inhibitory effects of 
many anti-tumour agents, including alkylating agents, on carcinogen- 
stimulated guanylate cyclase activity have been noted (section 1.11). CP 
has been shown to depress the stimulation induced by NNPG (121).
The effects of activated CP derivatives on both basal and carcinogen 
(MNNG)-stimulated guanylate cyclase activity have been studied.
8.2 Linearity of The Guanylate Cyclase Assay
Fig. 8.1 shows the linearity of guanylate cyclase activity with 
respect to time (at a constant protein concentration) and to protein 
concentration (at a constant incubation time). As can be seen, no deviation 
from linearity was observed for up to at least 150 pg protein (using a 15 
minute incubation time) and for up to at least 30 minutes (using 102 V£ 
protein). Routinely, 102 pg protein and an incubation time of 15 minutes 
were used for each assay. This produced a basal activity of 253*22 -  5*0 
pmol cyclic GMP formed/15 minutes/mg protein.
Fig. 8.1 Guanylate Cyclase Activity
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8-3 Effect of MNNG On Guanylate Cyclase Activity
MNNG is the most potent guanylate cyclase activator known and the 
dose-response relationship is shown in Fig. 8.1B.
DeRubertis and Craven (73) have reported a 36-fold increase in 
guanylate cyclase activity using 1 mM MNNG in the presence of 1-methyl- 
3-isobutylxanthine a powerful inhibitor of phosphodiesterase. In these 
studies 100 pM MNNG has been observed to stimulate cyclase activity by 
28-fold.
For studies on the effects of CP and its derivatives on MNNG- 
stimulated activity, 40 pM MNNG was selected. Although this concentration 
is not quite maximal with regard to enzyme stimulation (and the enzyme is 
not, therefore, fully 'saturated') the activity does not fall on the 
steep part of the sigmoidal curve, Fig. 8.1B.
8.4 The Effect Of CP And Its Derivatives On Basal Guanylate Cyclase
Activity
Table 8.1 shows the effects of CP and its derivatives on basal 
guanylate cyclase activity. This represents the activity of the enzyme 
in the presence of Mn^+ ions. The only effects observed were evoked by 
HP and PM. HP was found to inhibit cyclase activity by nearly 50# at a 
concentration of 30 mM. PM was .found to stimulate the enzyme by up to 
40# at 30 inM concentration but this effect was not observed in the pre­
incubation studies, discussed in the following paragraphs. It should be 
noted, therefore, that during these experiments the alkylating agents were 
present in the assay cocktail for no longer than five minutes before the 
start of the assay by addition of enzyme solution (liver cytosol).
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None of the other compounds tested showed any significant effect on 
basal cyclase activity. This corroborates the results of Vesely and 
Levey (121) who found no action of CP on basal guanylate cyclase activity 
at concentrations of up to 53 mM.
Table 8.2 shows the results of pre-incubation studies on basal cyclase 
activity.
The first column (a) in Table 8.2 was derived similarly to results 
presented in Table 8.1, except that the test compounds were pre-incubated 
in the assay cocktail for 30 minutes. The final concentration of test 
compounds was 10 mM, hence the concentration during incubation was 33*33 
mM. Apart from the fact that basal enzyme activity was apparently reduced 
(although this is not a significant difference from previously measured 
activity as determined by the Student's t test) two major differences were 
observed. Firstly, PM did not appear to stimulate the cyclase enzyme and 
secondly, the inhibitory effect of HP was more pronounced, being 31% 
compared with 12% reported in Table 8.1.
The fact that PM did not appear to stimulate the enzyme may have been 
due to its removal from the cocktail solution by reaction with assay cock­
tail constituents or by its breakdown in aqueous solution (Chapter 9).
The increased effectiveness of HP as an inhibitor may have been due 
to similar reasons. The breakdown of HP, however, produces PM which would 
be expected to stimulate the enzyme (Table 8.1). The formation of OHCP 
from HP has been discussed in Chapters 9 and 10, and is considered to have 
been complete before the addition of HP to the cocktail. Enhancement of 
inhibition may therefore have been due to the unique binding properties 
of OHCP thiol or alcohol groups of compounds present in the assay cocktail. 
It is unclear how this might affect the assay to increase the observed
inhibition.
TABLE 8.2 The effect of CP and its derivatives on basal guanylate
cyclase activity. II
GUANYLATE CYCLASE ACTIVITY
cyclic GMP formed : pmol/15 min/mg protein
ADDITION to cocktail (a) to enzyme (b)
none 216.88 - 5 (1.00)
CP 202.60 - 24 (0.93) 198.65 - 1 (0.92)
KF 254.50 - 11 (1.17) 213.95 1 7 (0.99)
PM 158.25 - 18 (0.73) 175.79 -  3 
[P<0.1]
O O
O
 
—
1 e^-
HP 149.50 -  4 (0.69)* 50.88 -  6 (0.23)*
[P <0.05] [P< 0.05]
HN2 223.29 - 8 (1.03) 206.52 - 6 (0.95)
Compounds were added to either cocktail or enzyme solutions to yield 
a 10 mM final concentration in the assay, (a) compounds in the cocktail 
were incubated for 30 minutes at 30°C. (b) compounds in the enzyme
solution were incubated for 30 minutes at 4°C. ^Figures show a 
significant difference from the control in the Student's t test. Figures 
in brackets represent ratio of test:control. Results from one 
experiment only.
TABLE 8.2 The effect of CP and its derivatives on basal guanylate
cyclase activity. II
GUANYLATE CYCLASE ACTIVITY
cyclic GMP formed : pmol/15 min/mg protein
ADDITION to cocktail (a) to enzyme (b)
none 216.88 - 5 (1.00)
CP 202.60 -  Zb (0.93) 198.65 - 1 (0.92)
KP 25**.50 - 11 (1.17) 213.95 1 7 (0.99)
PM 158.25 - 18 (0.73) 175-79 1 3 
[P<0.1]
O C
O
HP 149.50 - b (0.69 )* 50.88 - 6 (0.23)*
[P <0.05] [P< 0.05]
HN2 223.29 - 8 (1.03) 206.52 - 6 (0.95)
Compounds were added to either cocktail or enzyme solutions to yield 
a 10 mM final concentration in the assay, (a) compounds in the cocktail 
were incubated for 30 minutes at 30°C. (b) compounds in the enzyme
solution were incubated for 30 minutes at 4°C. ^Figures show a 
significant difference from the control in the Student's t test. Figures 
in brackets represent ratio of test:control. Results from one 
experiment only.
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The second column (b) of Table 8.2 shows the effect of pre-incubating 
the test compounds with enzyme. Since the final concentration was 10 mM, 
the concentration of compounds during pre-incubation was kO mM. The 
enzyme and test compounds were pre-incubated for 30 minutes at k°C before 
their addition to the assay cocktail to start the reaction. Again, there 
are two important differences to be noted. Firstly, PM appeared to 
inhibit the enzyme by 19% and secondly, the inhibition produced by HP was 
increased to 77%.
The effects observed for PM are contradictory to those presented in 
Table 8.1. It is unlikely that under incubation conditions at lf°C for 30 
minutes, fW would break down and therefore it may be assumed that the 
enzyme pre-incubation study reflects the 'true' action of PM upon the 
enzyme. However, the recorded results were the results from only one 
experiment in the case of the pre-incubation studies. It can be seen that 
the inhibition observed by PM during pre-incubation with enzyme (column 
(b), Table 8.2) was apparently a higher specific activity than that 
recorded for PM pre-incubated with assay cocktail (column (a), Table 8.2). 
Application of the Student's t test to these results suggested that 
although the assay cocktail pre-incubation results for PM appeared to 
reflect a higher inhibition of enzyme activity than pre-incubation with 
enzyme, they were not of statistical significance. This result may shed 
some doubt on the findings for pre-incubation of PM with enzyme. More 
data would have to be obtained to clarify the situation regarding pre­
incubation of PM.
The increased effectiveness of HP to inhibit the enzyme probably 
reflects an action of HP directly upon the enzyme. Therefore, the 
inhibition was increased due to both an increase in time and concentration.
1if1
8.5 The Effect of CP And Its Derivatives On MNNG-stimulated Guanylate
Cyclase Activity
The effect of MNNG on guanylate cyclase activity has been presented 
in Fig. 8.1B. Fig. 8.2 shows the inhibitory effects of CP and its 
derivatives on this activity. The dose-response curve demonstrate a non­
linear relationship which is very similar to that reported by Vesely and 
Levey (121) whose data have been redrawn in Fig. 8.2F for CP and iso- 
phosphamide inhibition of NNPG-stimulated guanylate cyclase activity.
It is apparent from these results that HP was the most effective and 
HN2 the least effective agent used, in inhibiting MNNG-stimulated activity. 
CP, KP and Hi all showed very similar curves intermediary between HP and 
HN2. Some indication of their relative effectiveness may be given by the 
concentration required to reduce the stimulated activity by half. Such 
values are presented below :
CP 18.20 mM
PM 16.72 mM
KP 17.70 mM
HP 1.97 mM
HN2 >30 mM
These figures have been deduced from the data shown in Fig. 8.2 but 
it should be noted that the curves are not linear and, therefore, 
calculations relying on the extrapolation of data must be considered 
approximations only. However, it can be clearly seen that HP is between 
8 to 9 times more effective than either CP, KP or PM.
Fig. 8.2 Effect of Cyclophosphamide And Derivatives On MNNG-stimulated
Guanylate Cyclase Activity
A to E : In the presence of 40 pM MNNG. Test compounds were present 
in the assay cocktail, MNNG was pre-incubated with enzyme.
F : Redrawn using data from ref. (121). Stimulation is with 
NNPG (1 mM) and enzyme assayed for 10 min at 37°C.
Error bars represent standard deviation of results from two separate 
experiments performed in duplicate.
Table 8.3 shows the results of pre-incubation studies on MNNG- 
stimulated activity. To produce the results presented in Fig. 8.2 MNNG 
was pre-incubated with enzyme (4°C for J>0 minutes) before its addition to 
the assay cocktail containing the test compounds. Column (c) (Table 8.3) 
was produced similarly but the test compounds were pre-incubated in the 
assay cocktail (30 minutes at 30°C). No differences between these results 
and those in Fig. 8.2 can be seen. This is in contrast to the
results observed on basal enzyme activity (section 8.4).
A difference was observed, however, if the MNNG was incubated together 
with the test compound in the assay cocktail (30 minutes at 30°C) as seen 
in column (a) (Table 8.3)* HP was found to be 4 times more effective and 
both CP and KP approximately 1.5 times more effective. Differences in 
activity observed could have been due to reactions of nitrogen mustards 
with MNNG or cocktail constituents. It is possible that HP, CP or KP may 
have also prevented the production of nitric oxide from MNNG or the 
interaction of this compound with the enzyme. These three compounds, of 
those tested, are the only ones which possess an oxazaphosphorinane ring.
When pre-incubated with the enzyme first (column (b)) a significant 
difference was observed for HP. This was similar to the effect observed 
on basal activity (section 8.4) HP inhibited the enzyme to a much greater 
extent. This can only reflect a direct action of HP on the enzyme. The 
greatest effect observed occurred when both MNNG and the test compounds 
were incubated with the enzyme column (d). All alkylating agents used, 
with the exception of HN2 showed a significantly increased effectiveness 
under these conditions compared to pre-incubation in assay cocktail alone, 
column (c). HP produced a 28-fold decrease in activity and PM a 5-fold 
decrease in activity under these conditions.
TABLE 8.3 The effect of CP and its derivatives on MNNG stimulated
guanylate cyclase activity
ADDITION
GUANYLATE CYC 
cyclic GMP formed : pmol
(a) to MNNG in cocktail
USE ACTIVITY 
/15 min/mg protein
(b) to enzyme solution
none 5254.11 -  239 (1.00)
CP 2762.14 - 75 (0.55) 5884.00 -  320 (1.16)
KP 2433.84 - 5 (0.48) 3205.30 - 670 (0.63)
PM 3824.41 - 212 (0.76) 3890.74 -  125 (0.77)
HP 115-54 1 3 (0.02) 26.63 - 1 (0.005)
HN2 4376.71 -  365 (0.87) 4442.11 t  200 (0.88)
(c) to assay cocktail (d) to enzyme in MNNG
none 5234.24 - 103 (1.00)
CP 4237.13 - 106 (0.81) 1355.85 1 31 (0.26)
KP 4130.50 - 23 (0.79) 2610.40 - 231 (0.50)
PM 3588.85 - 215 (0.69) 609.16 - 129 (0.12)
HP 508.19 - 127 (0.10) 18.70 -  1.7 (0.003)
HN2 4565.27 - 384 (0.87) 4324.01 -  228 (0.83)
Test compounds were added to yield a final concentration of 10 mM,
MNNG was added to yield a final concentration of 40 pM.
Results represent data from only one experiment performed in duplicate.
The most likely explanation of these results is (i) a direct effect 
of alkylating agent with enzyme, or (ii) a reaction of alkylating agent 
with MNNG, probably with nitric oxide produced from MNNG.
Pre-incubation studies, therefore, have suggested that CP and KP 
may act by an action with MNNG, possibly acting as centres or reaction 
with nitric oxide, and that HP apparently acts by a direct effect upon the 
enzyme. Several effects have been observed by pre-incubation;
(1) There was no significant difference in inhibition of MNNG-stimulated 
activity when the alkylating agents were pre-incubated with the assay 
cocktail.
(2) HN2 showed no significant difference in its effectiveness, whether
it was pre-incubated with enzyme, MNNG or both enzyme and MNNG. Inhibition 
observed with this compound was 13-75 - 2.2%.
(3) All other compounds were most effective when pre-incubated with both 
enzyme and MNNG. This may suggest that the inhibitory effects are brought 
about by a mechanism preventing MNNG stimulation.
(*♦) PM did not increase in effectiveness in any pre-incubation system 
other than with both enzyme and MNNG. Inhibition by PM was effectively 
increased from 26 - it.3% to 88 - 2.5%.
(5) Although the results for CP were quite inconsistent (no inhibition 
observed in one set of data) this compound and KP appeared to be most 
effective when pre-incubated with MNNG.
(6) HP appeared to be more effective when pre-incubated with enzyme. 
Inhibition increased from 90 to 98% on pre-incubation with MNNG, to 
99% on pre-incubation with enzyme and to 99*7% when pre-incubated with
both MNNG and enzyme
1Í*Í*
CHAPTER 9
THE BEHAVIOUR OF CYCLOPHOSPHAMIDE AND ITS DERIVATIVES HI SOLUTION :
EFFECTS OF THIOL-CONTAINING COMPOUNDS ON ALKYLATING ACTIVITY
9*1 Introduction
The reaction of I*-hydroxycyclophosphamide (OHCP) with thiol (SH) 
groups has been noted (section 1.8) and has been studied previously by 
measurement of the decrease in titratable SH groups during incubation with 
thiol-containing compounds (169) and of the stabilising effect of such 
compounds on its alkylating activity. In this chapter, an account has 
been given of the behaviour of CP and its derivatives in solution.
9.2 Effect of Alkylating Agents On Measureable Thiol Groups
The results of incubation studies of CP and its derivatives with 
cysteine (section 2.9) are shown in Fig. 9*1* Within the time course of 
the experiment, neither CP nor KP had any effect on the concentration of 
free thiol groups in buffered solution. PM, however, produced a decrease 
in the concentration of free thiols, in a time-dependent manner. HP was 
found to exhibit the greatest effect, reducing the concentration by 50% 
in approximately 1+ minutes at 30°C. The rate of this observed reduction 
in free thiol groups was shown to be reduced by either (i) decreasing the 
temperature of incubation (ii) decreasing the molar ratio of HP : cysteine. 
At a molar ratio of 1 : 10 the rate appeared to be reduced to zero, 
equalling that measured for CP, KP or cysteine alone. The data presented 
for HP appear to have little in common with the published data for OHCP
Fig. 9-1 Decrease in Titratable SH Groups By CP Derivatives
<OD4i2nm)
Except where stated otherwise, 
cysteine (10 mM) was incubated 
with test compound (10 mM) in 
phosphate buffer (0.1 M, pH7»0) at 
30°C.
EFFECT OF :
X CYSTEINE ALONE 
X CYCLOPHOSPHAMIDE (CP) or 
X k-KETOCYCLOPHOSPHAMIDE (KP)
A PHOSPHORAMIDE MUSTARD (PM)
U-HYDROPEROXY-CP (HP) :
O  37°C
• 30°C
■ i*° C
D 30°C, 1 mM
Data for ^-HYDROXY CYCLOPHOSPH AM IDE, 
from ref.(169).
Results are from one experiment in  each case, performed in  t r ip lic a t e
(Fig. 9.1). The observed reaction of HP with cysteine was both faster 
and more pronounced, than the published data suggest for OHCP and cysteine.
9*3 Behaviour of Alkylating Agents In Buffered Solution
By using the NBP test (section 2.¿4) the alkylating activity (both 
before and after acid hydrolysis) was determined. No detectable difference 
in this activity was observed for CP or KP during a two hour incubation 
in phosphate-buffered solution, Fig. 9.2. PM showed a decrease in both 
direct and acid hydrolysed alkylating activity. Although both curves 
(Fig. 9-2) show a sigmoidal relationship of activity with respect to time, 
they are not apparently proportional to each other. This had the effect 
of increasing the alkylation index (the ratio of direct : acid hydrolysed 
activity) which reached a maximum after approximately 70 minutes 
incubation. After this time the two curves appear to diverge (thus 
decreasing the alkylation index). A similar effect has been observed for 
HP, Fig. 9.2. The total or acid-hydrolysed activity decreased gradually, 
following approximately the decrease in alkylating activity reported for 
OHCP (169) (Fig. 9-2). The direct activity, however, increased to a 
maximum after 50 to 60 minutes incubation and then declined. The effect of 
this is an increase in the alkylation index from 65»3 (measured 5 minutes 
after addition of HP to buffer) to 86.6 after 54 minutes incubation.
There are a number of chemical transformations which may take place 
during incubation of PM or HP in buffered solution. For PM the most 
likely is hydroxylation of the chloroethyl groups by replacement of the 
chlorine atoms. This process is quite probably responsible for the 
observed decreases in alkylating activity of both PM and HP. HP may be 
capable of various other transformations. The observed initial alkylation
Fig. 9 .2 Effect of Time On Alkylating Activity During Incubation In Buffer. 
od540
Incubation in phosphate buffer (0.1 M, pH7.0) at 30°C. Open figures 
represent readings before and closed figures readings after acid 
hydrolysis.
O PHOSPHORAMIDE MUSTARD (PM).
□ /«-HYDROPEROXY CYCLOPHOSPHAMIDE (HP)
A it-HYDROXYCYCLOPHOSPHAMIDE (OHCP) Plotted from data
obtained from ref. (169)
All compounds used at a concentration of 2 mM. 100 nmoles assayed for 
alkylating activity by the NBP test, section 2.<t. Results are from one 
experiment performed in triplicate. CP and KP showed constant activities 
(indicated) from 5 min to 2 hr curves omitted for clarity.
Fig. 9.2 Effect of Time On Alkylating; Activity During Incubation in Buffer. 
od540
Incubation in phosphate buffer (0.1 M, pH7.0) at 30°C. Open figures 
represent readings before and closed figures readings after acid 
hydrolysis.
O PHOSPHORAMIDE MUSTARD (PM).
□ k-HYDROPEROXYCYC LOPHOSPHAMIDE (HP)
A It-HYDROXYCYCLOPHOSPHAMIDE (OHCP) Plotted from data
obtained from ref. (169)
All compounds used at a concentration of 2 mM. 100 nmoles assayed for 
alkylating activity by the NBP test, section 2.1*. Results are from one 
experiment performed in triplicate. CP and KP showed constant activities 
(indicated) from 5 min to 2 hr curves omitted for clarity.
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index supports the hypothesis that HP spontaneously produces OHCP in 
aqueous solution and the close similarity of the decrease in acid 
hydrolysed activity for HP to OHCP (Fig. 9 .2 ) provides further evidence. 
OHCP is capable of further degradation to more reactive intermediates 
(section 1 .14) and this may account for the observed increase in directly 
measured alkylating activity.
9 .k Effect of Thiol Groups On Alkylating Activity
Table 9-'' shows the effect of incubating CP and its derivatives with 
cysteine on their alkylating activity. Although PM is the only compound 
to show a significant difference in alkylating activity after incubation, 
it must be borne in mind that section 9*3 described the effect on 
alkylating activity of incubation of these compounds under identical 
conditions but in the absence of cysteine. The results presented in Fig.
9.2 must, therefore, be used as the control for this experiment. It can 
be seen from the results that CP and KP showed no significant change in 
alkylating activity when incubated either with or without cysteine. 
Although PM lost alkylating activity after 2 hours incubation in phosphate 
buffer alone (Fig. 9 .2 ) the loss of activity observed in the presence of 
cysteine appeared much greater (Table 9*'')« This may be explained by the 
fact that PM is the only active alkylating agent tested, under the 
conditions of the incubation, and that alkylation of the thiol compound, 
cysteine, may be responsible for this loss in activity. This is further 
supported by the observed loss of thiol groups during such incubation 
(section 9.2).
TABLE 9--1 The effect of incubation with cysteine on alkylating activity
ALKYLATING ACTIVITY
COMPOUND BEFORE INCUBATION AFTER INCUBATION
DIRECT ACID DIRECT ACID
CP 0.032 0.510 0.027 0.500
KP 0.025 0.1*70 0 .02k 0.465
HP 0.345 0.530 0.320 0.510
PM 0.495 O.58O 0.052 0.080
Alkylators were incubated at equimolar concentration with cysteine 
(2 mM) in phosphate buffer (0.1 M, pH7.0) for 2 hours at 30°C. 
Alkylating activity was measured by NBP test (section 2.A) before 
(DIRECT) and after (ACID) acid hydrosysis, and expressed in O.D. 
units measured at 5**0 nra. Triplicate measurements were made and 
errors were within 5%.
U*7
Although HP showed no significant difference in alkylating activity 
during incubation with cysteine (Table 9»'') comparison with Fig. 9.2 
shows that the alkylating activity has been stabilised in the presence of 
cysteine, a finding reported previously for OHCP (169). This effect 
correlates well with the observed disappearance of thiol groups during 
incubation (section 9.I).
v*&
CHAPTER 10 
DISCUSSION
10.1 The Production of An 'Activated' Derivative of Cyclophosphamide 
For studies of the mechanism of action of CP, especially those 
studies involving tissue or cell homogenates, it is essential to use an 
active form of CP unless the homogenate contains the necessary enzymes 
required for the conversion of CP to the 'primary' hydroxylated metabolite. 
Three methods of synthesis of such activated species were investigated. All 
methods involved the use of CP as starting material, which was available in 
abundance. Of these three methods, ozonisation of CP was the most 
successful.
(1) The Photooxidation Of CP (section 2.13)
The liver microsomal system which hydroxylates CP _in vivo has been
1 1shown to generate singlet oxygen ( C^) (258). Furthermore, 0^ is
thought to be formed in the reaction mixture of CP ozonisation and there
is some evidence for this species forming HP upon reaction with CP (233)»
1Photooxidation was attempted as a method of producing 0^ in the presence 
of CP, in the hope that a hydroxylated or hydroperoxylated derivative might 
be formed. The results were extremely disappointing. No change in the 
composition of the reaction mixture could be detected by NBP test (a 
measurement of alkylating activity), TLC or HPLC. The CP remained completely 
unchanged throughout the incubation procedure for up to 6 hours. Alteration 
in composition of the reaction mixture or in temperature had no effect.
Interestingly, the Rf value of CP obtained on TLC (silica gel 60, 
ethyl acetate, -25°C) wa6 found to be dependent upon the solvent of
v* 9
application. When applied in acetone, a high Rf value (0.92) was 
obtained and when applied in i^O a low value (0.35) was observed. This 
was probably due to the presence of H^O on the TLC plate when an aqueous 
application solvent was used. Thorough drying of the sample after 
application to the TLC plate might have prevented this effect but the risk 
of causing thermal decomposition of the sample was considered to be too 
great.
(2) Microsomal Activation of CP (section 2.6 And Chapter 6)
The microsomal hydroxylation of CP by the mixed function oxidase 
system of rat liver was rather more successful. This method has been 
used in the past (1^6) (1^ 8) (15 1) and information from these sources was 
used (a) to produce microsomes of the highest activity (using male rats fed 
with phénobarbital before utilising their livers for the production of 
microsomes) and (b) to produce a more stable derivative of CP than OHCP, 
by ’trapping' the OHCP produced as its ethoxy derivative. This was 
achieved simultaneously with deproteinisation upon the addition of ethanol 
to the reaction mixture (section 6.2).
It was found possible to identify both CP and the 'fast-running' 
diastereoisomer (151) of ¿*-ethoxy-CP by TLC. Other, possibly decomposition 
products, i.e. PM, were also observed. The presence of such compounds 
made it important that purification was carried out before use in enzyme 
studies.
It was possible to isolate the fast-running product relatively easily 
by flash chromatography. However, its instability proved to be too great 
for effective purification, concentration and subsequent characterisation 
by this route.
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(3) Ozonisation of CP (section 2.5 and Chapter 4)
Ozonisation of CP was the most successful of the methods tried, many 
initial difficulties being overcome. Although many products are formed 
(Fig. b . Z ) the eventual availability and use of a sample of HP as a 
standard, made identification of product by TLC quite simple. It was 
not possible to identify HP unequivocally by published Rf values because 
of the inconsistency of these. Variation is thought to be due to the 
presence of water vapour (234) and the effect of application solvent upon 
Rf value bears this out (section (1), above).
Of the many products formed during ozonisation most were shown to be 
alkylating agents (by visualisation with NBP spray) and some of these were 
also shown to be peroxides (by visualisation with KI). Although there were 
so many products, the subsequent isolation of HP after prior removal of most 
KP, was successfully achieved by the application of flash chromatography. 
Some success has been reported by the use of fractional crystallisation but 
this is exceptionally difficult even when the process of 'seeding' with 
crystals of HP is employed. The technique currently employed by other 
workers in this field for purification of products is preparative HPLC 
(234). Silica gel column chromatography has been previously reported for 
the isolation of HP from reaction mixtures, after the Fenton oxidation of 
CP, containing CP, KP, HP and the 4-hydroperoxy-CP-anhydrodioer (247) but 
the use of pressure columns in particular has not. The major advantage 
of this technique in this context is one of time-saving. This is 
particularly important in view of the instability of the product at 
temperatures above -25°C. Once the flash chromatography column had been 
characterised and the elution profile for HP known, chromatography took 
less than 30 minutes at 4°C. Concentration of the product by solvent 
evaporation in vacuo at 0°C did not affect the physico-chemical properties
of the product
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Peter et al. (233) have suggested the following reactions for the 
formation of products during ozonisation (reaction 18) but this does not
( 1 ) CP + ° 3  -— >  4 - k e t o - C P  + 1 o 2
( 1 8 )
( 2 ) CP +
V -
— 5»  i t -h y d r o p e r o x y - C P
correlate with the observation that increased ozonisation reaction time 
results in a greater yield of KP at the expense of HP (23*t).
(4) Characterisation (Chapter 5)
Using various physical techniques (and the NBP test, Chapter 3) it 
was possible to show that various parameters measured agreed with the 
published data and that the samples of CP, KP and were chemically pure. 
The use of a standard sample of HP was essential due to certain dis­
crepancies found between measured and reported properties. This has been 
found, particularly, for the material present in both supplied (by Colvin) 
and synthesised samples which has been assumed to be the diastereoisomer 
of HP (Fig. 1.13). NMR and melting point data suggest that the sample 
synthesised is indeed HP. Contamination of the sample may have appeared 
in the NMR spectra and would probably have reduced the melting point from 
that observed. TLC and HPLC both revealed two products in this sample, 
however. Peter et al. (233) have reported that one of the diastereoisomers 
produced is less «table than the other and this may result in a lower 
yield of this product. This has allowed the discrimination between the 
isomers in the chromatographic systems. By HPLC, the fast-running isomer 
has been measured to comprise only 2% of the total sample (section 5*6).
By TLC, the fast running isomer has been estimated to be in lower
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concentration than the other, by colour intensity and spot size when 
visualised with NBP spray (Fig. i».1). Although the HPLC system was unable 
to resolve KP from the fast-running HP isomer, it was possible to easily 
differentiate between these compounds by TLC.
The chromatographic data reported by Peter e_t al^ . (233) (23^) suggests 
a larger difference in the physico-chemical properties of HP and its 
diastereoisomer than has been observed. This would not, perhaps be 
expected where no large groups are involved in the structure of the 
compound (Fig. 1.13)« The sample donated by Colvin (see section 2.1(1)) 
was produced in his laboratory by ozonisation of CP as reported here. The 
sample produced in our laboratory was found to be identical to that of 
Colvin's, by melting point, TLC, HPLC, mass spectroscopy and alkylating 
activity. The performance of the less stable diastereoisomer in these 
samples in TLC and HPLC systems does not agree with reported data which 
suggests much larger differences between isomers than has been observed.
10.2 The Conversion of HP to OHCP
The NBP assay for alkylating activity has been shown to be capable 
of differentiating between certain alkylating agents by their activity in 
the assay before and after acid hydrolysis and the reasons for this have 
been discussed (Chapter 3)* Brock (172) has provided data which shows that 
it is possible to discriminate between HP and OHCP using this method. No 
details of his method were given, however, and it has been assumed, there­
fore, that the quantity he has termed alkylating activity" was derived 
in the same way as that which I have termed the "alkylation index"
(section 3-2).
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Using this method, evidence for the spontaneous conversion of HP to 
OHCP has been presented (Chapter 3)» This evidence has been provided by 
the different alkylation indices observed for HP dependent upon the solvent 
in which the sample had been dissolved. In non-aqueous, organic solvent,
i.e. acetone, a lower activity (Alkylation Index = 39.85) was recorded than 
when HP was dissolved in aqueous solution (Alkylation Index = 66.3). These 
values correlate well with those reported by Brock for HP (40$) and OHCP 
(65$) respectively. This result has been interpreted as the deoxygenation 
of HP in aqueous solvent, yielding OHCP. A possible mechanism for this 
reaction has been published by Benckhuysen et^al. (244) and involves the 
production of hydroxyl radicals from HP (reaction 19)- The involvement of 
one molecule of water per molecule of HP explains why this reaction does 
not occur in non-aqueous solvent systems.
Further evidence for this conversion has been provided by the behaviour 
of HP in solution (Chapter 9)- It has been shown that the decrease in 
alkylating activity (after acid hydrolysis) observed over two hours
CP-O-OH CP-0 + -OH
CP-0 ♦ h20 CP-OH ♦ OH (19)
CP-O-OH CP-OH ♦ OH
in aqueous solution (buffered) for HP follows closely the reported rate 
for OHCP (Fig. 9.2). Furthermore, the stabilisation of HP alkylating 
activity by equimolar cysteine in buffered solution also agrees with data 
for OHCP (Table 9.1). This effect is brought about by the 
derivitisation to sulphido-corapound of OHCP via the postulated imino—
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phosphamide intermediate (section 1.18). Evidence for this reaction is 
further supported by the observed reduction in the amount of free thiol 
groups in the presence of HP (Fig. 9-1)» This latter observation also 
provides 6ome conflicting evidence. The extent of sulphydryl "removal" 
and the rate of reaction does not agree with the published data for OHCP 
(Fig. 9*1) (169). The observed effect of HP was more rapid and effective 
(i.e. removed more free thiol groups from solution) than that reported for 
OHCP. It may well be that there is some involvement of hydroxyl radicals 
in this behaviour of HP towards thiol-containing compounds, as these would 
not be present in solutions of OHCP produced by other means. Triphenyl- 
phosphine in equimolar concentration to HP has been extensively used as 
a method for converting HP to OHCP (154) and has been reported to give 
OHCP in only 4C# yield. However, the spontaneous conversion in aqueous 
solution reported here is now generally accepted and has been used in 
previously published experiments (154) (157) (199) (243).
Given the formation of OHCP from HP, there is no reason to suppose 
that further conversions will not occur. Tautomérisation of OHCP to AP 
followed by g-elimination of acrolein to yield PM is quite possible, 
considering the instability of OHCP (154). The production of PM from HP 
in solution has been suggested (199) to explain the observed similarity 
of action of these two compounds in long time course (48 hr) experiments. 
The observed increase in alkylation index of HP in solution (Fig. 9.2) 
may be evidence for the existence of derivatives formed from OHCP. At the 
maximum value recorded, the alkylation index reached 84.78 after 46 
minutes incubation in phosphate buffer. This compares favourably with the 
alkylation index observed for PM (83*60).
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10.3 Behaviour of The Alkylating Agents In Solution (Chapter 9)
Whereas CP and KP were shown to undergo no changes in buffered aqueous 
solution, both PM and HP have been found to exhibit different alkylating 
activities during incubation. The possibility of conversion of HP to other 
derivatives with higher alkylating activity has been discussed and this may 
be responsible for the observed rise in activity with time. Decreases 
observed in alkylating activity were most probably due to hydrolysis of 
the compounds. In the presence of thiol-containing compounds the measured 
decrease in PM alkylating activity is most probably attributable to both 
hydrolytic products and alkylation of the thiol (section 9»^). It has been 
observed that the direct and acid-hydrolysed alkylating activity do not 
vary in direct proportion. This may be explained by the formation of new 
compounds, possibly by hydrolysis, which have different alkylating indices. 
Hydrolysis would be expected to decrease the total alkylating and potential 
alkylating material (as measured after acid hydrolysis) and would also 
decrease the ’true' or direct alkylating activity.
During the time of incubation with enzyme in such studies (15 
minutes) very little change in alkylating properties can be seen to have 
occurred. Greater changes may be expected for longer incubation times such 
as those used in the pre-incubation studies with guanylate cyclase activity. 
Voelcker et al. (157) have also shown that the spontaneous 0-elimination 
of acrolein from OHCP (and therefore the production of PM) is reduced by 
7056 in the presence of Mg2+ or Ca2+ ions. This effect is relevant to 
the incubation conditions used for enzyme studies.
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10. k Adenylate Cyclase (Section 2.2 and Chapter 7)
(1) Characterisation
The observed activity of adenylate cyclase in rat liver plasma 
membranes was slightly lower than reported levels (approximately 90# 
compared to recorded activity (80)). Difficulties were encountered with 
preparing the membranes from rat liver and the method of preparation may 
be responsible for this discrepancy (section 2.2). Stimulated enzyme 
activity using either sodium fluoride or glucagon was also slightly 
less than reported values, however, the fact that stimulation did occur 
suggested that the adenylate cyclase system was intact within the membranes. 
The specific activity observed would be a function of the purity of the 
membrane preparation, and a low cyclase : protein ratio could be obtained 
if membranes were contaminated with other proteins. A second possibility 
is loss of or inactivation of some cyclase during membrane preparation.
The assay for the standard 'marker' enzyme for plasma membranes, 
5-nucleotides, indicated that the subcellular fractionation technique 
employed, did in fact isolate plasma membranes, as the specific activity 
for this enzyme was equal to reported values (Table 7.1). However, the 
effects of the phosphodiesterase inhibitor SQ20009 on adenylate cyclase 
activity may demonstrate that the preparation was contaminated with small 
amounts of phosphodiesterase, although another inhibitor of this enzyme, 
theophylline, did not corroborate this and it was not considered necessary 
to include such a compound in the routine assay (Fig. 7.1). Purification 
of the membranes by sucrose density gradient centrifugation has been 
reported (2*f0) but highly purified membranes have been shown to possess 
low specific activity of adenylate cyclase (80) and this procedure was not, 
therefore, carried out.
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(2) The Effect of Cyclophosphamide And Its Derivatives On Adenylate
Cyclase Activity (Chapter 7)
Of the derivatives tested (CP, KP, HN2, PM and HP) only HP was found 
to evoke any response on the adenylate cyclase activity. No effects were 
observed on basal or stimulated (sodium fluoride or glucagon) activity in 
the presence of the other four compounds. Although CP and KP are 
chemically unreactive, PM and HN2 may be considered to be active alkylating 
agents under the cyclase assay conditions. It is important to note, there­
fore, that alkylating activity per se does not determine the effectiveness 
or activity of CP derivatives in the cyclase assay. HP, it has been noted, 
produces OHCP, the 'primary' metabolite of microsomal activation, under 
appropriate conditions, and it is considered that the latter compound is 
present in the enzyme assay incubation. Both HP and OHCP are inactive 
alkylating agents under the conditions of the assay, and the effects 
observed are not, therefore, considered to be due to the alkylating activity 
of these compounds.
(3) Effects of HP On Basal Adenylate Cyclase Activity
HP was shown to inhibit basal (Mg2+) adenylate cyclase activity by 
50# at approximately 5 mM concentration. This inhibition of activity 
exhibited a linear dose-response relationship with respect to the 
concentration of HP (Fig. 7.5)« Although the inhibition observed at 1 mM 
HP was quite small (18%) it was shown to be a significant difference by 
the Student's t test (Table 7*3).
Although microsomal activation in vitro and subsequent metabolite 
extraction was found to be difficult (Chapter 6 and section 10.1) a 
freshly prepared extract was employed in this assay. Information from 
the NBP test on this sample suggested that it contained OHCP at a
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concentration of 2.76 mM (the 4-ethoxy-CP derivative of OHCP produced 
during extraction by this method yields OHCP spontaneously in aqueous 
solution in a similar fashion to HP). The same sample was also shown to 
inhibit basal cyclase activity by approximately 36%. Although the 
estimation of OHCP concentration may be subject to error due to certain 
assumptions made in the calculation (section 4.3) it can be seen that these 
values of concentration and enzyme activity (or inhibition) correlate quite 
well with the inhibition observed with HP (Fig. 7.5)* Further, 
discrepancy between these values in comparison to the results obtained for 
HP may be accounted for by the fact that EGTA was not included in the 
reaction cocktail when the microsomal extract was used (Table 7*3)•
Inhibition of basal activity implies that OHCP interacts with, in some 
way, the catalytic component itself, and may involve the Mg^+-binding 
(probably the N) component also (section 1.4). Reaction by alkylation must 
be ruled out, but OHCP possesses chemical reactivity of an unusual type 
(section 1.18). This reactivity is unique to OHCP (although similar binding 
can occur with AP). OHCP has the ability to bind reversibly to thiol or 
alcohol-containing compounds via an irainophosphamide intermediate, with 
which it is in equilibrium. Apart from this reaction, the only other 
possible interaction for OHCP involves its suggested structural similarity 
to cyclic AMP (137)* Physico-chemical effects such as membrane permeation 
may also be involved (see section 10.4(6)).
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(4) Affects of HP On Sodium Fluoride-Stimulated Adenylate Cyclase Activity
HP inhibits the sodium fluoride-stimulated activity of adenylate 
cyclase (Fig. 7.4). Inhibition is only partial (as is inhibition of basal 
activity) and sodium fluoride is therefore still an effective activator in 
the presence of HP, although the degree of activation is proportionately 
lower. Increasing HP (inhibitor) concentration decreased the enzyme activity 
in the presence of sodium fluoride (activator) (Fig. 7.5) in a linear dose- 
response relationship similar to that observed for HP and basal activity.
F ion activation is mediated by the N (nucleotide binding) component 
of adenylate cyclase which then associates more closely with the 
catalytic unit and by an unknown mechanism this stimulates cyclase activity 
(Fig. 1.6). During inhibition by HP this mechanism still appears to be 
operating since sodium fluoride is still effective as an activator ligand. 
This may be seen as evidence that HP does not exert its effect by action on 
the N-coraponent, but on the catalytic unit. At least, HP cannot be acting 
at the level of F ion binding or N-C component coupling.
From a kinetic point of view, analysis of the observed data is 
extremely difficult due to several factors : (1) The adenylate cyclase 
enzyme is a complex unit of functional sub-components (2) Two activator 
ligands are present in this experiment (Mg^+ ion and F ion) (3) Enzyme 
activity is absent without Mg^+ ion but is still present without F ion 
(at a lower velocity) (4) The inhibition observed with HP is only 
partial. Many models of Enzyme-Activator(s)-Substrate-Inhibitor inter­
actions seem to satisfy the sparse evidence for such modelling presented 
in Fig. 7.4. Of the apparently more probable cases, those involving the 
binding of inhibitor to an enzyme-activator and/or enzyme-activator-
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substrate complex appear to be consistent with the results. To ascertain 
more precisely the mechanism of action of HP, studies should be made with 
varying substrate concentrations, in the presence or absence of HP and/or 
activators. This would enable one to discriminate between sites of action 
for HP. Because of considerations of time and expense, this could not be 
done.
(5) Effect of HP On Glucagon-Stimulated Adenylate Cyclase Activity
The stimulation of cyclase activity evoked by glucagon was completely 
abolished by HP at 5 nM concentration (Fig. 7.3). Increasing HP 
concentration decreased the enzyme activity in the presence of glucagon 
rapidly, and in a non-linear dose-response relationship (Fig. 7.5)*
At 5 fflM concentration, the inhibited adenylate cyclase activity in 
the presence of glucagon was not significantly different from the HP 
inhibited basal activity. Several possible sites of HP-cyclase inter­
action may be postulated. Glucagon acts by binding to the receptor (R) 
component (section 1.4) and the stimulatory action on the catalytic unit 
is mediated by the nucleotide binding protein (N component) which must bind 
GTP to exert any effect on the C unit during glucagon stimulation (Fig. 
1 . 4 ) .
If HP were to act on the catalytic unit alone, as suggested for basal 
and fluoride-stimulated cyclase inhibition, it would be difficult to 
explain the observed effects of HP on glucagon-stimulated activity. In 
this case, HP probably acts at a second site also. HP may act at the level 
of glucagon binding, R-N interaction, GTP binding to N or RC-N interaction. 
The latter case is unlikely in view of the results for fluoride 
stimulation in the presence of HP, unless the N-C interaction is somehow 
different during glucagon stimulation.
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Further experiments would be necessary to determine the site of action 
of HP during glucagon stimulation. Binding studies of glucagon and GTP 
have been used to investigate adenylate cyclase component interactions (15) 
and similar studies in the presence of HP would help to elucidate and 
discriminate between proposed mechanisms of action.
(6) Postulated Mechanisms of Action of HP
In view of the fact that only HP of all the alkylating agents tested 
had any effect on adenylate cyclase activity, it may be assumed that its 
inhibitory actions were brought about by a property unique to this compound. 
In this respect, the further conversion of HP to chemically reactive 
compounds may be important.
The conversion of HP to OHCP has been discussed (section 10.2) and it 
is considered that the latter compound is present in enzyme incubations.
The production of free radicals during this process is one possible 
mechanism for HP action due to the high reactivity of such species. Both 
CP-0* and *0H radicals are thought to be produced (244) (reaction 19) and 
either of these could conceivably attack either enzyme molecules or assay 
cocktail constituents. This mechanism seems unlikely due to the pre­
incubation of HP before its addition to the assay (4°C, H^O) and the usually 
short half life of free radicals.
OHCP exhibits both structural and functional properties which may 
be involved in its (and, therefore HP) action. Tisdale (137) has suggested 
a structural similarity between cyclic phosphate moieties of cyclic AMP 
and cyclophosphamide (section 1.11) Fig. 10.1. This evidence does not 
appear entirely convincing, especially since the proposed structural 
congruity is shared between all CP derivatives which possess an intact 
oxazaphosphorinane ring (these include CP, KP, HP, OHCP and related
Fig. 10.1 Bond Distances And Angles Of The Cyclic Phosphate Moiety 
Of Cyclic AMP And ¿»-Hydroxycyclophoanhamide
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sulphido-derivatives of OHCP). Because this property is not unique to the 
active species (the OHCP derivative) it cannot, alone explain the observed 
effects specific to HP or OHCP. However, recognition of this portion of 
the molecule by the active site of an enzyme may serve to bring the 
derivatives into close proximity with the enzyme molecule, where other 
properties of the derivative might act to alter the activity of the enzyme.
The functional, thiol (sulphydryl group) and alcohol (hydroxyl 
group) binding property of OHCP have been discussed and this is a highly 
probable mechanism for HP action. Binding to protein thiol or alcohol 
groups could well interfere with the further binding of ligands (glucagon, 
GTP, F ion, Mg^+ion, ATP in the case of adenylate cyclase) or interfere 
with component interactions. Binding of OHCP to thiols may also be a method 
for bringing the molecule into close proximity to the enzyme. Although OHCP 
is not an active alkylating agent, and appears to be unreactive when bound 
as a sulphido derivative, it may be possible that under the right 
conditions, release of active PM would occur from OHCP in the close 
proximity of the enzyme. The alkylating properties of PM would in this 
case be responsible for the inhibitory effects of HP. Such a hypothesis 
must also explain why PM itself is ineffective. It may be postulated that 
the site of alkylation of the enzyme which leads to its inhibition is some­
how inaccessible to PM. Binding of OHCP to enzyme, by whatever mechanism, 
would thus serve to introduce alkylating material into the immediate 
neighbourhood of the enzyme.
Although it seems likely that OHCP exerts its tumour-specificity 
through selective permeation of cancer cells (section 1.18) and that this 
may be achieved via a carrier mechanism, permeation of OHCP into the liver 
plasma membrane may be of importance to its action on adenylate cyclase 
activity.
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Further conversion of OHCP is very likely. Tautomerisation to AP is 
reported to result in an equilibrium favouring OHCP (157). This tautomer­
isation may be important as AP has been shown to be a thiol-reactive 
compound, producing semi-mercaptal derivatives which may be capable of 
cyclisation to mercapto derivatives of OHCP (157) (233). ^-elimination 
of acrolein from AP yields PM. The formation of PM may not be responsible 
for the effects of HP, since PM alone has no effect on cyclase activity.
10.5 Guanylate Cyclase (Section 2.3 And Chapter 8)
(1) Effect of CP And Its Derivatives On Basal Activity
Guanylate cyclase basal (Mn^+) activity was found to be close to 
reported values. Different CP derivatives were found to affect basal 
activity in different ways; (1) HP was found to inhibit basal activity by 
nearly 50% at 30 mM concentration (50% inhibition was estimated to occur 
at approximately 32 mM concentration) (2) PM was found to stimulate basal 
activity by nearly kCfji at 30 mM concentration (50% stimulation was 
estimated to occur at approximately 36 mM concentration). None of the 
other compounds tested (CP, KP or HN2) had any significant effect on 
guanylate cyclase activity (Table 8.1).
The inhibitory effectiveness of HP was increased when it was pre­
incubated with assay cocktail before addition of enzyme, the observed 
inhibition increased from 12 to 31% at a concentration of 10 mM HP (Table 
8.2). Several explanations are possible. For example, the effect could 
be due to reaction of OHCP with assay constituents which contain thiol or 
hydroxyl groups. Presuming that HP itself is not inhibitory and that 
inhibition of cyclase activity is dependent upon the conversion of HP to 
OHCP, pre-incubation may conceivably increase conversion of HP to OHCP
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or even favour tautomérisation of OHCP to AP. This explanation assumes 
that conversion of HP to OHCP was not complete before addition to the 
assay cocktail or that formation of AP from OHCP enhances the inhibitory 
effect. An explanation of the mechanism of action of HP on guanylate 
cyclase may be as follows: guanylate cyclase has been shown to possess 
and require vicinal thiol groups for full expression of its activity 
(section 1.8(iii)),(70) binding of OHCP or AP to these groups would most 
likely inhibit the enzyme.
A third possible mechanism is that some other product of HP incubation 
in assay cocktail produces the enhanced inhibition (Chapter 9). One 
possibility here is that HP (OHCP or AP) may "remove" necessary compounds 
from the assay cocktail or that the products of such reactions are them­
selves inhibitory but this seems unlikely in view of the nature of the 
cocktail constituents (Table 2.4).
Pre-incubation of HP with enzyme solution showed that inhibition does 
not apparently involve assay constituents since inhibition under these 
conditions was greatly enhanced. Inhibition increased to 77% (Table 8.2) 
when HP was pre-incubated with enzyme. This is probably due to a combined 
effect of time and concentration. By extrapolation of previous data 
(Table 8.1) increasing concentration to 40 mM would not be expected to 
produce the observed inhibition. The favoured mechanism of action on basal 
cyclase activity is the reaction of OHCP or AP with protein thiol groups. 
Increased incubation time would allow more thiols to be bound to OHCP or AP 
if the reaction equilibrium was reached only slowly.
When PM was pre-incubated with assay cocktail, the stimulation observed 
originally was abolished (Table 8.2). Incubation of PM under such 
conditions reduces its alkylating activity by hydrolytic reactions (Chapter
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9) but alkylating activity per se is not apparently a prerequisite for 
effecting activity (as in the case of adenylate cyclase activity) since 
HN2 had no effect. Reaction of PM with assay cocktail constituents is a 
possibility. Pre-incubation of PM with enzyme produced an inhibition of 
cyclase activity, in complete contradiction of previous results. There 
would appear to be two possible explanations for this result. The first 
is that low concentrations of PM are stimulatory whereas high concentrations 
are inhibitory. The loss of any action after pre-incubation in assay 
cocktail would therefore be due to hydrolysis of PM with a resultant loss 
of alkylating activity. In view of the results presented in Table 8.1 
this explanation seems very unlikely since the action of PM would have 
to change from stimulatory (1.39-fold) at 30 mM to inhibitory (0.81-fold) 
at k0 mM (as used for enzyme incubation studies to yield a final 
concentration of 10 mM). The second explanation assumes that the hydrolysis 
product of PM is inhibitory whereas PM itself is. stimulatory. However, 
since pre-incubation with assay cocktail would be expected to produce 
more of the hydrolysis product due to the raised temperature (30°C cf. 4°C 
during enzyme pre-incubation) this explanation does not fit the results. 
Inhibition of the enzyme by a PM hydrolysis product would not explain all 
of the observed effects, although inhibition by an intermediate of PM 
hydrolysis might. Such an intermediate could be the product of hydrolysis 
of just one chloroethyl group. Why there should be such variation in the 
effects of PM depending on the assay conditions is completely unknown.
(2) Effect of CP And Its Derivatives On MNNG-Stimulated Guanylate Cyclase
Activity
MNNG stimulated guanylate cyclase activity by a maximum of 28-fold 
at 100 pM concentration (Fig. 8.1B) and exhibited a sigmoidal dose-response
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relationship. It is considered that this compound acts on the cyclase 
enzyme via the spontaneous formation of nitric oxide radical which is a 
potent stimulator (71 )f the mechanism of action of which may involve the 
free thiol groups of the enzyme (section 1.8(vi)). All of the alkylating 
agents tested were shown to inhibit MNNG-stimulated activity. The extent 
of inhibition varied between compounds, relative effectiveness being in 
the order : HN2 CP KP PM HP (Fig. 8.3)» HP was nearly 10 times as 
effective as either, CP, KP or PM. The dose-response relationship for these 
compounds was found to be non-linear and very similar to that reported for 
CP and isophosphamide inhibition of NNPG-stimulated activity (Fig. 8.3F) 
( 1 2 1 ).
The mechanism of the inhibition observed cannot be related to the 
alkylating activity of the derivatives; both reactive and unreactive 
compounds showed an inhibitory effect. The superior effectiveness of HP 
may have been due to the action of OHCP or AP on enzyme thiol groups 
especially in view of this compounds effects on basal activity.
Pre-incubation studies (Table 8.3) suggest that CP and KP may exert 
their effects by interaction with MNNG and that HP exerts its effects on 
the enzyme molecule predominantly. PM was shown to exert greater inhibition 
when pre-incubated with both MNNG and enzyme, whereas HN2 was found to 
show no difference in the level of inhibition whether it was pre- 
incubated or not.
Inhibition of MNNG-stimulated activity may be produced by interaction 
with NO-(nitric oxide radical), and its action on the enzyme. It may be 
possible that the CP derivatives used are preferential substrates for NO- 
attack, thus preventing its reaction with enzyme. The only objection to 
this hypothesis is the difference between the concentration of MNNG (and
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therefore NO- ) and nitrogen mustard derivatives required for inhibition 
of its effects. MNNG was present in only kO pM concentration whereas 
partial inhibition (50$) required approximately 17 mM concentration (CP,
KP, PM) a difference of over i+00-fold in favour of CP derivatives.
(3) Radicals
The results of HP with guanylate cyclase activity may reflect the fact 
that conversion of HP to OHCP has already been completed before addition 
of HP solution to the enzyme assay. The generation of OHCP is thought to 
generate hydroxyl radicals. Hydroxyl radicals have been shown to be a potent 
stimulator of guanylate cyclase activity (section 1.8(vii)). Since HP 
produced inhibition of the enzyme either (i) OHCP is in competition with 
stimulatory hydroxyl radicals or (ii) no hydroxyl radicals are present and 
OHCP only is affecting the enzyme.
10.6 Relevance To Cyclophosphamide Therapy
The physiological concentrations of CP and its derivatives in CP- 
treated patients have not yet been fully determined. Fig. 10.2 shows the 
changes in concentration of CP, PM and nor-HN2 in the plasma of a patient 
receiving CP chemotherapy.
The maximum plasma concentration of CP reached is 0.5 mM, nor-HN2 
0.3 mM and PM 0.1 mM. Jardine et al. (17**) have reported a large 
variation in these levels between patients. In some cases the levels of 
nor-HN2 peaked at 0.5 to 0.6 mM, similar to that of CP. PM plasma 
concentration, however, has not been reported above 0.1 mM.
Quantitative estimation of CP metabolites possess several problems 
but some attempts have been made. Successful attempts to measure the
Fig. 10.2 Plasma Levels of CP (0) PM (A) And Nor-HN2 (□) For A Patient 
Receiving A 1 Hour Infusion of Cyclophosphamide (75 mg/kg).
From Ref (17^)
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primary activated metabolite OHCP or AP have been reported. Conversion 
of OHCP to l*-(S-benzyl)mercapto-CP by reaction with benzyl 
mercaptan followed by separation of this derivative by thin layer chromato­
graphy was shown to be possible (259)» Fenselau et al. (155) have 
characterised AP by its derivatisation to the cyanohydrin derivative 
followed by gas chromatography-mass spectrometry. The authors of these 
papers suggest that these techniques could be used to quantitate OHCP and 
AP levels in plasma but, unfortunately, no results of such studies have 
been presented.
The concentration of these metabolites is possibly increased in urine. 
Averaged results for urine collected over k hour periods from patients 
receiving CP treatment, suggest that CP has a maximum concentration of 2.5 
mM (8 to 12 hours after start of CP infusion) and nor-HN2 peaks at 3«97 mM 
(12 to 16 hours after start of infusion) (17**). PM concentration 
apparently remains low in urine, peak concentration being 0.21 mM (12 to 
16 hours after start of infusion). Its higher reactivity at acid pH values 
would make this compound a very reactive metabolite in urine (Table 1.6) 
which may possibly prevent its detection.
The plasma concentration of OHCP may be equivalent to that of PM.
Cells are not likely to experience concentrations higher than 0.1 mM unless 
metabolites were selectively concentrated. This may well be the case for 
OHCP since the oncostatic specificity of CP is considered to be exerted 
at least in part by the specific permeation of tumour cells by OHCP. The 
concentration of OHCP within such cells has not been measured and is 
difficult to estimate.
It must be remembered that the effects observed on the cyclase enzymes 
were exhibited by normal tissue. There is no reason at present to assume 
that cyclase enzymes of tumour cells would respond differently.
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10.7 Concluding Remarks
Although the rautogenic, carcinogenic and (probably) anti-tumour 
effects of cyclophosphamide metabolites are undoubtedly the manifestation 
of some effect of these agents on the cell nucleus (damage to DNA in 
particular) the fact that possibly active compounds must first reach the 
nucleus will of necessity bring them into contact with cytoplasmic 
constituents. Binding of CP derivatives has been observed to be quite 
indiscriminate and involves the binding of DNA, RNA and protein, cross- 
linking of these has also been reported (196) (204) (195)» Alkylating 
agents have been shown to effect cytoplasmic proteins (Chapter 1) and of 
particular interest here are the effects observed on phosphodiesterase, 
protein kinase and cyclic nucleotide binding protein (section 1.11). 
Guanylate cyclase is a predominantly cytoplasmic protein (section 1.8(ii)) 
and it may, therefore, be considered inevitable that during CP chemo­
therapy this enzyme would be subjected to contact with low concentrations 
of CP metabolites.
Increased binding to cytoplasmic constituents has been observed for 
OHCP and is thought to occur because of sulphydryl binding (180) and this 
fact may be of particular relevance to guanylate cyclase, since free 
sulphydryls are required for full expression of activity (section 1.8(iii)) 
(10.5).
Even before CP metabolites can reach the cell cytoplasm, they must 
come into contact with the outer cell membrane. Metabolites are probably 
in contact with the cell surface at concentrations not dissimilar from 
the reported plasma levels (section 10.6). On penetration of the membrane 
(whether carrier-dependent or not) and upon entering the cell, the 
metabolites undoubtedly must come into contact with membrane-bound proteins.
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The fact that activated CP metabolites can affect membrane-bound proteins 
has been demonstrated by the denaturation of cytochrome P-^50 by acrolein 
and OHCP (260). Effects of alkylating agents on outer membrane protein 
components has also been demonstrated. The trifunctional nitrogen mustard, 
HN3, has been shown to cross-link many of the membrane proteins of the 
human erythrocyte as well as cytoplasmic constituents (261). HN2 has also 
been shown to exert effect on membrane-bound ATPase and is a potent 
inhibitor at extremely low concentrations (262). These results demonstrate 
the inevitability of adenylate cyclase, a membrane-bound enzyme, coming 
into contact with CP metabolites.
To produce a significant difference in the activity of the cyclase 
enzymes (say 50%) it has been found that relatively high concentrations 
of CP metabolites are required. Only HP affected adenylate cyclase and 
a concentration of 5 bH was required for a significant difference in its 
activity to be affected (50% inhibition). Guanylate cyclase was inhibited 
by HP only at very high concentrations (30 mM) and stimulated by PM to a 
lesser extent. It is unlikely, therefore, that these effects would be of 
any significance to the anti-tumour action of CP. Unless selectively 
concentrated, OHCP would be present in concentrations 50-fold less than 
that required to inhibit adenylate cyclase and 300-fold less than that 
required to effect guanylate cyclase in this way. This assumes that OHCP 
does not exceed the maximum concentration observed for PM in plasma (0.1 
mM). Cyclic nucleotide metabolism is not therefore likely to be altered 
by a change in the synthesis of nucleotides during CP chemotherapy. Cyclic 
nucleotide metabolism is most likely going to be altered by changes in the 
degradation of cyclic AMP, while synthesis remains unaffected.
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Guanylate cyclase is stimulated by many chemical carcinogens (section 
1.8) and under such stimulated conditions is inhibited by all CP 
derivatives tested at lower concentrations than those required to inhibit 
basal activity. Of these, HP was found to be most effective and produced 
50% inhibition at approximately 2 mM, the difference between this and 
possible physiological concentrations of OHCP being 20-fold. It seems 
unlikely, therefore, that cyclic GMP metabolism would be altered 
significantly by changes in the activity of this enzyme during CP therapy.
Concentrations of metabolites may be increased during treatment of 
nonlymphocytic leukaemia before bone-marrow transplantation, when large 
doses of CP are given (1^ 3)» PM has been used in clinical trials alone, 
and would presumably therefore be present in quite high concentration.
Local perfusion of organs by active CP metabolites has been suggested but 
clinical use of HP has not been forthcoming due to the effects of hydroxyl 
radicals which would be formed during production of OHCP from this compound. 
If local perfusion was carried out with HP, high concentrations would 
presumably be used and the effects upon the cyclase enzymes observed here, 
particularly on adenylate cyclase, may become significant.
Of the CP derivatives tested, OHCP (generated from HP) appears to 
have a uniquely high reactivity with both adenylate and guanylate cyclase.
In further studies on potential targets for activated CP derivatives, there 
must be included comparisons of OHCP and PM action on the target system 
examined. Although PM is now considered the active alkylating metabolite 
of CP, the ultimately therapeutically important form of CP may well turn
out to be OHCP
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APPENDIX I
THE STUDENT'S t TEST
(1) Definition of symbols used
X = value of each datum
N = number of data
X = mean
lx2 - IX2 - (£X)2
N
df = degrees of freedom
= (N1 + N2 - 2) when N1 = N2
= N-1 when N1 = N2
(2) Calculation of S ^  (standard error of difference between the means)
When N^ " N2
SDX "
When N1 " N2
SDX *
Calculation of t
N
_ 2 _ 2 Ix1 + I x2
r
1+
U N2
ixi; *
N(N-1)
x 1 -  x2
DX
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Calculation of t
N
2
Zx1 + Z x22
( '  ‘
+ N2 - 2 ■T* 
I zT
Zxn2 ♦ IX22
N(N-1)
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(if) The t table is used to find the t value for a given degree of
freedom. Reading across the t values for a given degree of freedom, 
the value next lowest to that calculated (above) will give the 
probability of significant difference from the column heading of the
table
Table of t values for use in the t test
df .1 .05 .01 .001
1 6.314 12.706 63.657 636.619
2 2.920 4.303 9.925 31.598
3 2.353 3.182 5-841 12.941
4 2.132 2.776 4.604 8.610
5 2.015 2.571 4.032 6.859
6 1.943 2.447 3.707 5-959
7 1.895 2.365 3-499 5.405
8 1.860 2.306 3.355 5.041
9 1.833 2.26 2 3.250 4.781
10 1.812 2.228 3.169 4.587
11 1.796 2.201 3.IO6 4.437
12 1.782 2.179 3.O55 4.318
13 1.771 2.160 3.012 4.221
14 1.761 2.145 2.977 4.140
15 1.753 2.131 2.947 4.073
16 1.746 2.120 2.921 4.015
17 1.740 2.110 2.898 3.965
18 1.734 2.101 2.878 3.922
19 1.729 2.093 2.861 3.883
20 1.725 2.O86 2.845 3.850
Table Continued
df .1 .05 .01 .001
21 1.721 2.080 2.831 3.819
22 1.717 2.074 2.819 3-792
23 1.714 2.069 2.807 3-767
24 1.711 2.064 2.797 3.745
25 1.708 2.060 2.787 3.725
26 1.706 2.056 2.779 3.707
27 1.703 2.052 2.771 3-690
28 1.701 2.048 2.763 3-674
29 1.699 2.045 2.756 3-659
30 1.697 2.042 2.750 3-646
40 1.684 2.021 2.704 3.551
60 1.671 2.000 2.660 3.460
120 1.658 1.980 2.617 3-373
00 1.645 1.960 2.576 3.291
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APPENDIX II
LINEAR REGRESSION
( 1 )  D e f i n i t i o n  o f  s y m b o l s  u s e d
X x  d a t a  c o o r d i n a t e
Y y  d a t a  c o o r d i n a t e
X o r  Y = mean v a l u e s
o  = s t a n d a r d  d e v i a t i o n
( 2 )  C a l c u l a t i o n  o f  t h e  g r a d i e n t  (m)
n
r  X. Y .
• 1 1  1  Y V1=1__________  -  XY
n
rX2
( 3 )  C a l c u l a t i o n  o f  t h e  i n t e r c e p t  ( b )  
b = Y - raX
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